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Abstract
This thesis focuses on the synthesis of a variety of heterocycles and carbocycles such as
pyrrolidines, dihydrofurans, dihydropyrroles, cyclopentenes, and 2,5-dihydrooxepines.
Traditional synthetic methods are discussed first, followed by the manipulation of donoracceptor cyclopropanes towards the above-mentioned compounds. This leads to a discussion
about an important pyrrolidine-containing natural product known as kainic acid. Kainic acid
has been studied in the neuroscience field for its biological properties which have led to a
better understanding of common human neurological disorders like epilepsy, Huntington’s
disease and the after-effects of strokes.
Chapter two focuses on a common rearrangement of donor-acceptor cyclopropanes known as
the Cloke-Wilson reaction. Without isolating the desired cyclopropane, two modes of
reactivity were observed which depended solely on the choice of starting reagent. The first
was the traditional Cloke-Wilson rearrangement generating dihydrofurans and the second
was a vinylogous variant forming 2,5-dihydrooxepines. It was discovered that with careful
choice of Lewis acid or transition metal catalysts, each of the obtained compounds can be
manipulated to other dihydrofuran derivatives or dihydropyrrole heterocycles. One of the
dihydropyrrole compounds obtained was deemed as a viable synthetic precursor towards
kainic acid.
Chapter three describes the synthetic efforts towards kainic acid utilizing the methodology
from chapter two. The difficulties towards this natural molecule will be presented with the
major issue resulting from stereochemical constraints. This resulted in the successful
synthesis of β-allokainic acid which is one of the less active isomers of naturally occurring
kainic acid.
Chapter four discloses a single-step manipulation of the dihydrofurans synthesized via
Cloke-Wilson rearrangement to their corresponding cyclopentenes. Extensive screening of
Lewis acids and solvents provided insights into the possible mechanism of this reaction.
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Lay Audience Abstract
This thesis describes the synthesis of molecules known as carbocycles and heterocycles.
These types of compounds are abundant in products obtained from natural sources and are
highly sought in the pharmaceutical industry. Finding new ways of synthesizing carbocycles
and heterocycles is always in high demand. Common synthetic procedures are discussed,
followed by how cyclopropanes can be utilized towards the mentioned compounds. This
leads to a discussion about a heterocycle-containing natural product known as kainic acid.
The biological properties of this compound were studied which lead to a better understanding
of common human neurological disorders such as epilepsy, Huntington’s disease and the
after-effects of strokes.
Chapter two focuses on a common reaction involving cyclopropanes and their rearrangement
to heterocycles of value. The reaction proceeds by a famous transformation known as the
Cloke-Wilson rearrangement. It was discovered that with a careful choice of catalyst, each of
the compounds can be manipulated to other heterocycles that are seen in desired
pharmaceuticals and natural products. We determined one of the compounds to be a useful
starting reagent towards the synthesis of kainic acid.
Chapter three describes the synthetic efforts towards kainic acid. Initial synthetic problems
are discussed with the most significant issue arising once the relative three-dimensional
arrangement of atoms on a specific intermediate was determined, also known as
stereochemistry. Attempts at obtaining the correct stereochemistry failed which resulted in
the synthesis of one of the isomers of kainic acid known as β-allokainic acid.
Chapter four discloses the rearrangement of products obtained in chapter two to their
corresponding cyclopentene derivatives. An extensive testing of catalysts and solvents were
preformed which helped obtain the cyclopentenes in high yields and provided insights into
the possible mechanism of the rearrangement.
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Chapter 1
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The Importance of Heterocycles and Carbocycles in
Life and Synthesis

Structures that are studied for their important biological properties, whether isolated from
natural sources or synthesized in the lab, typically have one or more cyclic motifs either
fused together or connected by a small linker chain1–3. Due to the rigidity of cyclic
structures, better interactions with the binding sites are typically obtained since the active
conformation is locked in place. Acyclic systems however, contain multiple rotating
bonds resulting in many different conformations, only one of which results in the desired
binding interaction3. Therefore, ideal pharmaceutical candidates contain heterocyclic or
carbocyclic structures.
Cyclic compounds are extremely important for normal life functions 1,2,4. DNA, which
contains the genetic information of all life forms on our planet, is made of heterocyclic
compounds, nucleic acids and carbohydrates (Figure 1-1a). Amino acids, which are the
building blocks of proteins also contain several cyclic motifs (Figure 1-1b). Important
porphyrins, which are heterocyclic macrocycles, such as chlorophyll-a and heme are vital
compounds for photosynthesis and the transfer of oxygen to body tissues respectively
(Figure 1-1c). Drugs that many people take on a regular basis to maintain a healthy
lifestyle like vitamins are all composed of heterocyclic systems (Figure 1-1d).
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Figure 1-1. Important biological compounds. [a] Nucleic acids and carbohydrate segment of DNA.
[b] Amino acids. [c] Heterocyclic macrocycles responsible for photosynthesis and transfer of oxygen
to blood. [d] Vitamins

Since cyclic structures are so important in life and highly desirable in the pharmaceutical
industry, ways of synthesizing hetero- and carbocycles is one of the most explored fields
of organic chemistry. New methodologies are published on a regular basis that can
provide easy access to complex cyclic motifs towards natural product synthesis or for
pharmaceutical studies. From the vast array of hetero- and carbocycles, only a select few
are discussed in this dissertation. This includes five-membered carbo- and heterocyclic
rings and seven-membered oxacycles (Figure 1-2). Examples of such structures in natural
products and pharmaceuticals will be presented.

Figure 1-2. The hetero- and carbocycles of interest
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1.1 Synthesis of Five-Membered Carbocycles and
Heterocycles
1.1.1

Synthesis of Pyrrolidines

Pyrrolidines are among the most important heterocyclic compounds that are featured in a
wide array of naturally occurring and synthesized compounds that contain many
biological properties.5–7 (Figure 1-3a). Paraherquamide A8 (1-10) is a potent anthelmintic
agent with activity against drug resistant intestinal parasites. γ-Carboxyglutamic
derivatives9 (1-11) have been shown to be useful towards the synthesis of neuroprotective
agents. Kainic acid10 (1-12) possesses important neuroexcitatory properties that will be
discussed in greater detail in the upcoming sections. Enantiomerically pure pyrrolidines
(1-13 to 1-15) also have a dominant role as organocatalysts11,12 (Figure 1-3b).

Figure 1-3. [a] Select examples of naturally occurring and synthetically made compounds with
biological properties. [b] Examples of organocatalysts.

Thus, discovering ways of synthesizing pyrrolidines can have a great impact in synthetic
and pharmaceutical communities. The most common synthetic strategy of forming the
pyrrolidine core is by [3+2]-cycloaddition and annulation chemistry.11–19
Recently, Singh and co-workers showed a synthesis of pyrrolidines rings (1-18) by a
[3+2]-cycloaddition between α,β-unsaturated pyrazolamide (1-16) and azomethine ylides
(1-17) using a Ag(I) catalyst and chiral ligand (1-19) (Scheme 1-1).20
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Scheme 1-1. Diastereo- and enantioselective synthesis of highly substituted pyrrolidines using a chiral
Ag(I) catalyst

The pyrrolidines synthesized contained four contiguous stereogenic centers and were
produced in excellent diastereoselectivity, high yields, and enantioselectivities. The group
also showcased transformations of the pyrrolidine products to various synthetically useful
advanced intermediates.
Since the first introduction of Pd-trimethylenemethane (Pd-TMM) complexes by Trost
and Chan21, their utility as three-carbon synthons for [3+2]-cycloaddition chemistry has
grown significantly with the formation of a variety of carbo- and heterocycles of various
ring sizes.16,17,22,23 Trost et al. recently published an enantioselective synthesis of
pyrrolidines (1-22) containing a quaternary center with the first use of disubstituted
donors (1-20) in a Pd-TMM cycloaddition with imines (1-21).24 The reaction was made
possible with the use of diamidophosphite ligands (1-23 and 1-24) (Scheme 1-2).

Scheme 1-2. Pd-TMM cycloaddition with disubstituted TMM-donors and imines forming
enantioselective pyrrolidines containing quaternary centers
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Continuing with the synthesis of pyrrolidines containing quaternary centers, Chandra Pan
and co-workers utilized an organocatalyzed double Michael addition/annulation
chemistry towards highly enantioselective pyrrolidines.25 Using a cinchonidine derived
bifunctional amino-squaramide catalyst (1-28), both N-tosyl amino-methyl enones (1-25)
and trans-α-cyano-α,β-unsaturated ketones (1-26) were activated simultaneously towards
a double Michael addition reaction to form pyrrolidines (1-27) (Scheme 1-3).

Scheme 1-3. Organocatalyzed enantioselective double Michael addition towards highly substituted
pyrrolidines

Although not enantioselective, Kang and co-workers were able to show the conversion of
2,3-dihydroisoxazoles (1-29) to fully substituted pyrrolidines (1-31) through an iridiumcomplex catalyzed N-O bond cleavage/rearrangement/cyclization of (1-29) with various
alkenes (1-30)26 (Scheme 1-4).

Scheme 1-4. Single step transformation of 1,3-dihydroisoxazoles to pyrrolidines

The reaction was found to work with a variety of substrates bearing aromatic
substituents; however, any alkyl substituents except for (R3) resulted in no observed
product. The iridium catalyst used could be recycled up to seven times with only a slight
drop in yield which can be advantageous in industrial-scale reactions.
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1.1.2

Synthesis of Dihydropyrroles

Similar to pyrrolidines, except with an extra unit of unsaturation, dihydropyrroles are
another class of five-membered heterocycles that have a prominent role in natural
products and pharmaceuticals (Figure 1-4). Anthramycin (1-32) has been shown to
interact in the minor groove of DNA to form covalent bonds with guanine bases. This
interrupts biological processes that involve transcription factors and RNA polymerase
which can aid in the treatment of various cancers.27 Dihydropyrrole (1-33) has been
proven to inhibit protein geranylgeranyltransferase type I which is an enzyme that is
important for the regulation of many protein functions.28,29 Dihydropyrrole (1-34) is an
example of nonpeptide peptidomimetics which are an important class of compounds that
mimic natural peptide strands and overcome the limitations of these peptides in
therapeutic interventions.30

Figure 1-4. Natural and synthetic dihydropyrroles with important biological properties

Dihydropyrroles are commonly synthesized through cycloaddition and annulation
chemistry. However, cycloisomerization reactions are also prevalent. Wender et al. were
able to showcase the formation of dihydropyrroles (1-37) by treating aziridines (1-35)
with silver or Bronsted acid catalysts. This resulted in the formation of 1,3-dipoles which
reacted with a variety of alkynes (1-36) in a formal [3+2]-cycloaddition.31 The reaction
was shown to be highly regioselective (Scheme 1-5).

Scheme 1-5. Highly regioselective formation of dihydropyrroles through a formal [3+2]-cycloaddition
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Asymmetric formal cycloadditions towards dihydropyrrole derivatives are also possible.
Recently, Guo and co-workers performed a Ph3P catalyzed [3+2]-cycloaddition with
sulfamate derived cyclic imines (1-38) and allenoates (1-39) forming sulfamate fused
dihydropyrroles (1-40) in high yields.32 Using a phosphine chiral catalyst (1-41), an
asymmetric version was developed forming the desired products in high enantiomeric
purity (1-42) (Scheme 1-6). Sulfamate fused dihydropyrroles are interesting heterocycles
that could potentially be used in the pharmaceutical industry.33

Scheme 1-6. Phosphine catalyzed [3+2]-cycloaddition of sulfamate derived cyclic imines with
allenoates

As mentioned above, cycloisomerizations are another common technique used towards
dihydropyrrole synthesis. Ye and co-workers performed a gold catalyzed
cycloisomerization of chiral homopropargyl sulfonamides (1-43) forming enantiopure
dihydropyrroles (1-44)34 (Scheme 1-7). The reaction proceeded through an antiMarkovnikov addition. With careful examination of reaction conditions, the authors
determined that adding a catalytic amount of base suppressed an undesirable dimerization
reaction.35

Scheme 1-7. Cycloisomerization reaction producing enantiopure dihydropyrroles

Multicomponent reactions (MCRs) are useful techniques that involve the reaction of
three or more reactants in a single reaction vessel to produce a single product containing
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majority of the reactants.36 MCRs are a great way to form a variety of complex
heterocycles and carbocycles since the reaction is highly chemo- and regioselective, atom
economical, and step efficient.36 Miranda et al. were able to show a four component Ugi
reaction forming a propargyl-Ugi product (1-49). This was then treated with a strong base
forming a Ugi-allenamide intermediate (1-50) that underwent a cycloisomerization to
form dihydropyrrole derivatives (1-51)37 (Scheme 1-8).

Scheme 1-8. Four component Ugi reaction followed by base mediated cycloisomerization towards
dihydropyrrole derivatives

The utility of this transformation has been expanded by synthesizing advanced
intermediates in a single step (Scheme 1-9). Using dihydropyrrole (1-52), the group was
able to form a bicyclic structure (1-53) by performing a Heck cross-coupling reaction. 2arylpyrrolidine (1-54) was formed through a reduction using triethylsilane hydride which
are pharmacologically important compounds.38

Scheme 1-9. Subsequent transformations of dihydropyrroles

Another interesting MCR was developed by Gong et al. resulting in the first catalytic
asymmetric formal [3+2] cycloaddition of electron deficient alkynes and azomethine
ylides under chiral phosphoric acid conditions.39 The use of various aldehydes (1-56) and
α-amino esters (1-57) generated the desired azomethine ylide in-situ which reacted with
various alkynes (1-55) forming dihydropyrrole (1-58) derivatives in high yields and high
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enantioselectivities (Scheme 1-10). Compound (1-59) showed to have potential
bioactivities in vitro against mammary carcinoma cell line, MCF7.

Scheme 1-10. First catalytic asymmetric formal [3+2]-cycloaddition using electron deficient alkynes
and azomethine ylides to form dihydropyrroles

DFT studies showed that the chiral phosphoric acid has a duel role in the reaction: it
behaves as a Bronsted acid and Lewis base (Scheme 1-11). The alkyne becomes more
electron deficient once the carbonyl oxygen interacted with the OH group on the
phosphorus through H-bonding. Simultaneously, the anion of the azomethine ylide
became more reactive through H-bonding between the N-H of the ylide and the Lewis
basic phosphoryl oxygen (1-60). This resulted in a conjugate addition of the azomethine
ylide to the alkyne followed by a Mannich-type cyclization (1-61) forming
dihydropyrrole (1-62).

Scheme 1-11. Proposed mechanism towards dihydropyrrole formation showcasing the dual role of
the chiral phosphoric acid

1.1.3

Synthesis of Dihydrofurans

Dihydrofurans are found in numerous natural products and pharmaceuticals but also
serve as precursors in an array of organic transformations.40,41 Radical-induced
cyclizations between 1,3-dicarbonyl species or similar variants and alkenes is a common
way of synthesizing dihydrofurans. Nishino and co-workers reported an oxidative radical

10

cyclization of a variety of 1,3-dicarbonyl compounds (1-63) and 1,1-diarylethene (1-64)
promoted by Mn(OAc)3 in an AcOH-HCO2H media forming dihydrofurans containing a
quaternary center (1-65) (Scheme 1-12).42

Scheme 1-12. Oxidative radical cyclization forming dihydrofuran derivatives

The addition of formic acid results in increased reaction rates and yields. The explanation
of the rate enhancement with the addition of a secondary strong acid was explained by
Kochi (Scheme 1-13).43 Under typical reaction conditions involving acetic acid (AcOH),
complex A is thought to undergo ligand exchange with the 1,3-dicarbonyl species
generating Mn(III)-enolate complex, which was found to be the rate-limiting step.
However, with the introduction of formic acid, ligand exchange between complex A
occurs forming complex C. Due to the production of both ion-pair and cationic Mn(III)
species, the reactivity of the intermediate is increased resulting in a rate-enhancement for
the 1,3-dicarbonyl ligand exchange forming complex D. This is followed by two SET
additions that resulted in carbocation G which underwent cyclization forming the final
product H.
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Scheme 1-13. Rate-enhancement of the oxidative radical cyclization with the introduction of formic
acid

In a similar reaction, Yilmaz and co-workers performed an oxidative radical cyclization
between 3-oxopropanenitriles (1-66) and various alkenes (1-67) induced by Mn(OAc)3
which furnished a variety of 3-cyanodihydrofuran derivatives (1-68) (Scheme 1-14).44

Scheme 1-14. Formation of 3-cyanodihydrofuran derivatives via oxidative radical cyclization

Biological studies were conducted with the compounds synthesized against a variety of
Gram-positive and Gram-negative bacteria. The results obtained showed that all 3cyanodihydrofuran derivatives had stronger antimicrobial activity against the bacteria
studied when comparing to more traditional antibiotics such as the β-lactams or
tetracyclines.
The main limitation of performing these and similar reactions is the need to use large
excess of transition metal oxidants, which upon scale-up can be costly. With recent
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reports of iodine serving as an alternative catalyst to transition metals in many
reactions45, the group of Lei wanted to see if they could substitute the typical transition
metals used in oxidative radical cyclizations between 1,3-dicarbonyls (1-69) and alkenes
(1-70) with iodine to form various dihydrofuran compounds (1-71).46 After screening
many conditions, it was found that I2 and tert-butyl peroxybenzoate (TBPB), with
NaOAc as an additive, furnished dihydrofurans in good yields (Scheme 1-15).

Scheme 1-15. The use of iodine towards an oxidative radical cyclization

1.1.4

Synthesis of Cyclopentenes

Although heterocyclic compounds have a greater presence in the pharmaceutical
industries than their carbocyclic counterparts, cyclopentane and cyclopentene motifs have
been utilized as the main scaffold in several medicinally active compounds.47–49 The five
membered carbocycle is also present in many naturally occurring compounds each with
their own unique biological properties.47,49–51 Many of these compounds contain highly
substituted cyclo-pentane or -pentene cores, thus synthetic efforts for synthesizing
complex five membered carbocycles gained considerable interest in the chemical
community. There are a number of different ways that five-membered carbocycles can be
synthesized: cycloaddition reactions, electrocyclizations, transition metal mediated
cyclizations, rearrangements, and Aldol-type reactions.51
The presence of functionalized cyclopentenes in natural products or pharmaceuticals is
limited compared to its saturated counterpart; however, the ability to synthesize
cyclopentene cores can serve as key intermediates towards cyclopentane motifs. An
important example is the synthesis of vicinal 2-arylated cyclopentenylamines.48 The work
by Zhang et al. showcased the formation of such cyclopentenes (1-74) by performing a
Rh(III) catalyzed directing group (DG) assisted C-H functionalization of arenes (1-73)
and desymmetrization of diazabicycles (1-72) (Scheme 1-16).48 The products were
obtained under mild conditions and high yields.
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Scheme 1-16. Rh(III)-catalyzed C-H activation/desymmetrization of diazabicycles with arenes
towards the synthesis of functionalized cyclopentenes

Recently, the Lopez group reported the synthesis of functionalized cyclopentenes (1-77)
by reacting vinylazides (1-76) with alkenyldiazo compounds (1-75) in the presence of a
copper catalyst in a formal [3+2]-cycloaddition/allylic azide rearrangement (Scheme 117)52.

Scheme 1-17. [3+2]-cycloaddition/allylic azide rearrangement towards cyclopentenes

The first step in the proposed mechanism involves generation of a copper carbene
complex (1-79) (Scheme 1-18). The vinylazide (1-80) reacted with the carbene complex
as an enamine-type nucleophile forming intermediate (1-81) followed by cyclization
generating cycloadduct (1-82). This cycloadduct underwent a [3+3]-sigmatropic
isomerization forming the final product (1-83).
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Scheme 1-18. Proposed mechanism towards cyclopentene formation

Due to the retention of the azide functionality, further chemical manipulations were
studied. Under Staudinger conditions, the azide (1-84) was reduced to the amino
derivative (1-85). An azide-click reaction was also performed forming triazole derivative
(1-86) and this reaction was efficiently executed in a one-pot fashion (Scheme 1-19).

Scheme 1-19. Manipulations of the azide functionality to amino and triazole derivatives

Cycloadditions involving metal-free conditions can provide easy access to complex
products in a cost-effective process. Recently, Li and co-workers were able to show the
synthesis of highly substituted cyclopentenes (1-87) or indenes (1-88) via a metal-free
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oxidative decarbonylative [3+2]-annulation of terminal alkynes (1-89) with tertiary alkyl
aldehydes (1-90a,b) (Scheme 1-20)53.

Scheme 1-20. Metal free oxidative decarbonylation, [3+2]-annulation between tertiary aldehydes and
terminal alkynes towards functionalized cyclopentenes and indenes

The reactions worked well with a variety of (hetero)aryl and alkyl alkynes, as well as
with a variety of alkyl aldehydes. Secondary alkyl aldehydes failed to provide any desired
products and the reaction temperature seemed to play an important role as small
deviations from 100 °C resulted in irreproducible results.

1.2 Synthesis of Seven-Membered Oxacycles
Compounds containing a seven membered oxacycle are found in numerous natural
products that were found to possess antiviral (1-91)54, inhibition of histamine release
from mast cells (1-92)55, and anti-inflammatory properties (1-93)56 (Figure 1-5).

Figure 1-5. Bioactive natural products containing a seven-membered oxacycle

The structural complexity and biological properties of these seven-membered oxacycles
resulted in considerable synthetic efforts.54,57,58 Nicolaou et al. showed a mild three step
sequence towards the synthesis of a variety of 4,5-dihydrooxepines59. Beginning with an
array of cyclohexenones (1-94), a regioselective Baeyer-Villiger oxidation was achieved
forming enol lactone (1-96) in good yields. The enol lactone was then converted to an
enol phosphate (1-97) that was either reduced under palladium catalysis and a suitable
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reducing agent or various C-C bond forming reactions were done furnishing the desired
dihydrooxepines (1-98a,b) (Scheme 1-21).

Scheme 1-21. Three step sequence towards dihydrooxepines

The complex structure of epidithiodiketopiperazines (ETP) such as (1-92) (Figure 1-5)
has attracted many research groups towards its total synthesis. Liang and co-workers
recently reported the synthesis of dihydrooxepines (1-101) through a radical [2+2+3]annulation of 1,6-enynes (1-99) with α-bromo-1,3-dicarbonyl compounds (1-100)
(Scheme 1-22).60 The products were formed in good yields and were identified as
important scaffolds for the ETP class of natural products.

Scheme 1-22. Radical annulation towards dihydrooxepines

Benzooxepines such as (1-93) (Figure 1-5) are another common structural scaffold found
in numerous natural products and pharmaceuticals. Recently, Kotha et al. devised a
simple synthetic method towards benzooxepines.61 Under basic conditions, a variety of
cyclic 1,3-diones (1-102) were reacted with 1,2,4,5-tetrakis(bromomethylbenzene) (1103) providing benzooxepines (1-104) in moderate yields (Scheme 1-23). With the
functional handles presented, subsequent steps were performed in high yields providing
an array of polycyclic benzooxepines (105a,b,c).
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Scheme 1-23. Synthesis of benzooxepines and subsequent steps towards polycyclic benzooxepines

The work by Du and co-workers showed the synthesis of spirocyclic benzooxepines (1108) bearing oxindole scaffolds in good to excellent yields and good
diastereoselectivities.62 This was accomplished by a Lewis base catalyzed [4+3]annulation of o-Quinone methides (o-QMs) (1-106) and Morita-Baylis-Hillman (MBH)
carbonates (1-107) (Scheme 1-24). The reaction worked regardless of variation in the
substitution pattern. Only a slight decrease in yields were seen when larger ester groups
were present in (1-107).

Scheme 1-24. [4+3]-annulation between o-QMs and MBH carbonates under Lewis basic conditions
towards spirocyclic benzooxepines

The Lecourt group showcased the synthesis of highly functionalized benzooxepines (1111) containing a quaternary center through a ring expansion of chromene derivatives (1109) with donor-acceptor diazo compounds (1-110)63 (Scheme 1-25a).
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Scheme 1-25. [a] Synthesis of benzooxepines through the ring expansion of chromene derivatives. [b]
Proposed mechanism of the reaction.

Treating chromene derivatives (1-109) under a Lewis acid formed benzopyrylium (1-112)
followed by addition of the diazo species (1-110) forming (1-113). A 1,2-migration of the
endocyclic C-C bond resulted in the oxocarbenium ion (1-114) with the extrusion of
nitrogen gas. Trapping (1-114) with the initially generated TMSOMe formed (1-115) and
in the same pot, treating (1-115) with TiCl4 reformed the oxocarbenium ion (1-114)
which was trapped with various nucleophiles forming (1-111) (Scheme 1-25b).
Structures containing pyrrolidines, dihydropyrroles, dihydrofurans, cyclopentenes, and
dihydrooxepines in their scaffolds have numerous biological applications and are found
in many natural products. Thus, the discovery of new synthetic methodologies towards
these highly desirable structural motifs is a major focus in the synthetic community and
pharmaceutical research. An area of research providing several advancements in
methodologies towards the abovementioned structures is the use of donor-acceptor (DA)
cyclopropanes.
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1.3 Reactivity of Donor-Acceptor Cyclopropanes and Their
Uses in the Formation of Hetero- and Carbo-cycles
Cyclopropanes have emerged to be useful synthetic building blocks in organic chemistry
because of its highly strained three-membered ring.64–73 Cyclopropanes that contain
donor (D) and acceptor (A) groups located vicinally to one another are termed DA
cyclopropanes (1-116).74 The presence of the DA groups amplifies the reactivity of the
cyclopropane ring due to a synergistic electron “push-pull” effect which greatly weakens
the vicinal C-C bond (Scheme 1-26a). Typically, moieties with electron-rich aryl groups,
heteroatoms, alkyl or alkenyl serve as the donor group and electron withdrawing moieties
such as carbonyl, sulfonyl, and nitro serve as the acceptor group.72 Upon treatment with a
Lewis acid, the DA cyclopropane is proposed to undergo ring opening forming a 1,3dipole (1-117) and depending on the reaction conditions, many different products can be
obtained (Scheme 1-26b).66,71,72 A high regioselectivity is observed within these reactions
due to the added stability of the positive and negative charges imparted by the D and A
groups.

Scheme 1-26. [a] DA cyclopropane showing the weakened vicinal C-C bond due to the push-pull
effect. [b] Reactivity of DA cyclopropanes.

Of interest, are annulation and rearrangement reactions involving DA cyclopropanes as
this readily allows the formation of a variety of carbo- and heterocycles of various ring
sizes.
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1.3.1

Annulation reactions involving DA-Cyclopropanes

Annulation reactions of DA-cyclopropanes with dipolarophiles, 1,3-dipoles, and dienes
have been reported to highlight the formation of carbo- and heterocycles in
pharmaceuticals or target oriented synthesis. The utilization of these transformations will
be featured towards the formation of cyclopentenes, pyrrolidines and dihydropyrroles.

1.3.1.1

Synthesis of Cyclopentenes

Unlike the formation of heterocycles, the formation of carbocycles is much less prevalent
since the cyclopropane ring-opening event is less favorable with carbon nucleophiles.71
Nevertheless, DA cyclopropanes have been shown to react with a variety of carbon-based
dipolarophiles in [3+2]-annulation chemistry to make cyclopentene rings.67,75 Yadav was
able to take advantage of this reactivity by using aryl acetylene nucleophiles (1-123) and
a stoichiometric amount of Lewis acid generating substituted cyclopentenes (1-124) in
moderate to good yields and cis selectivity up to 95:5 (Scheme 1-27a).76 Intramolecular
variants were also subjected to the reaction conditions which formed polycyclic (1-126)
and spirocyclic motifs (1-129), the latter of which are found in many natural compounds
(Scheme 1-27b).77

Scheme 1-27. [a] Synthesis of cyclopentenes through a [3+2]-annulation of DA cyclopropanes and
acetylenes. [b] Intramolecular variants.
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Budynina expanded these examples with doubly-substituted alkynes (1-131) and DA
cyclopropanes (1-130) in a [3+2]-annulation initiated using a Lewis acid or Bronsted acid
towards the formation of indenes (1-132). These classes of compounds are important for
their bioactivities and fluorescent properties (Scheme 1-28).

Scheme 1-28. [3+2] annulation between DA cyclopropane and alkynes forming indenes

The proposed mechanism involved formation of the 1,3-dipole equivalent (1-134) upon
treating the cyclopropane (1-133) with a Lewis acid or Bronsted acid. Nucleophilic attack
by the alkyne formed vinyl cation intermediate (1-135) which underwent an
intramolecular Friedel-Crafts reaction onto the vinyl cation affording the final indene
product (1-136) (Scheme 1-29).78

Scheme 1-29. Proposed mechanism for indene formation

Recently, Wang et al. was able to showcase the formation of highly functionalized
cyclopenta[b]furans (1-139) through a DBU promoted cascade annulation of
nitroarylcyclopropane-1,1-dicarbonitriles (1-137) and 3-aryl-2-cyanoacrylates (1-138)79
(Scheme 1-30). For cyclopropane derivatives (1-137), only o- or p-nitro groups were
tolerated since the negative charge from deprotonation of the α-proton was stabilized by
the strong inductive and conjugative effects of the nitro group which was not seen for mnitro positions.
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Scheme 1-30. Highly stereoselective formation of cyclopenta[b]furan rings from DA cyclopropanes

Johnson et al. were able to react a variety of DA cyclopropanes (1-140) and ynamides (1141) in a [3+2]-annulation in the presence of a Lewis acid forming highly substituted
cyclopentene sulfonamides (1-142) (Scheme 1-31a).80 With the use of enantiopure
cyclopropanes, complete inversion of stereochemistry was observed at the donor site of
the cyclopropane. These cyclopentene sulfonamides were efficiently converted to their
cyclopentanone counterparts (1-144) as a single diastereomer via two-step sequence of
tosyl removal followed by enamine hydrolysis with concurrent decarboxylations (Scheme
1-31b).

Scheme 1-31. [a] [3+2]-annulation between DA cyclopropanes and ynamides. [b] conversion of
cyclopentene sulfonamides to cyclopentanones.

The work by Yoshikai and co-workers showed the first reported example of an
intermolecular coupling between cyclopropanols (1-145) and unfunctionalized alkynes
(1-131) producing cyclopentenols (1-146) (Scheme 1-32).81
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Scheme 1-32. Reaction between cyclopropanols and unfunctionalized alkynes to furnish
cyclopentenols

The proposed catalytic cycle began with the generation of the active Co(I) species (1147) from the Co(II) pre-catalyst and Zn. Deprotonation with DABCO formed a cobalt
cyclopropoxide species (1-148) that underwent ring-opening which resulted in a cobalt
homoenolate complex (1-149). Insertion of the alkyne gave an alkenylcobalt species (1150) which underwent an intramolecular carbonyl addition (1-151) followed by
protodemetallation affording the final product (1-146) (Scheme 1-33).

Scheme 1-33. Proposed catalytic cycle for the formation of cyclopentenols

1.3.1.2

Formation of Five-Membered Heterocycles

The ability to find new ways of forming heterocycles constitutes one of the largest areas
of research in organic chemistry. The unique reactivity of DA cyclopropane derivatives
has been exploited throughout the years towards the synthesis of compounds that may be
of interest from structural or biological standpoints.
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As mentioned earlier, pyrrolidines are an important class of heterocycles due to their
presence in natural products and pharmaceuticals. It is not surprising that the reactivity of
DA cyclopropanes has been exploited towards pyrrolidine synthesis. The Werz group
showed the synthesis of pyrrolidines (1-155) by reacting DA cyclopropanes (1-152) with
a formaldimine surrogate (1-154), 1,3,5-triazinanes (1-153), under Lewis acid catalysis
(Scheme 1-34a).82 A variety of alkyl and (hetero)aryl cyclopropanes were tolerated and
various 1,3,5-triazinanes worked as well. When using enantiopure cyclopropane under
these reaction conditions, complete retention of stereochemistry was observed indicating
a double SN2-type mechanism (Scheme 1-34b).

Scheme 1-34. [a] Synthesis of pyrrolidines via the reaction of DA cyclopropanes and 1,3,5triazinanes. [b] Proposed double SN2-type mechanism.

In a similar reaction involving aldimines as the dipolarophile in a [3+2]-annulation, the
Kerr group showcased a highly diastereoselective synthesis of 2,5-cis-pyrrolidines (1164) through the ring-opening of DA cyclopropanes (1-163). This was accomplished with
in-situ generated aldimines (1-162) under Lewis acid catalysis (Scheme 1-35).83 Aryl or
heteroaryl aldehydes (1-160) provided the best results whereas both primary alkylamines

25

and anilines (1-161) were also well tolerated. This research was showcased in the total
synthesis of FR901483.84

Scheme 1-35. Formation of cis-2,5-pyrrolidine rings through ring-opening of DA cyclopropanes with
aldimines

The Kerr group expanded the synthesis of pyrrolidines with the use of DA cyclopropanes
tethered to alkoxyamines (1-165) (Scheme 1-36).85 This intramolecular reaction resulted
in the diastereoselective formation of substituted pyrrolo-isoxazolidines with high
enantiopurity (1-166a,b). Reversing the addition order of catalyst and substrate resulted
in the formation of two discrete diastereomers which were subjected to N-O bond
cleavage providing highly substituted 2,5-trans- (1-167a) or 2,5-cis-pyrrolidines (1-167b)
in a predictable manner. In order to avoid epimerization during the N-O bond cleavage,
methanolic HCl was used which likely suppressed the retro-Mannich isomerization
pathway.
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Scheme 1-36. Highly diastereo- and enantioselective formation of pyrrolidines with the use of
tethered DA cyclopropanes-alkoxyamines

Liu et al. recently showed a formal [3+2]-cycloaddition of vinylcyclopropanes (1-170)
and aldimines (1-168) or isatin-derived ketimines (1-169) under palladium catalysis and
chiral phosphoramidite ligands (1-173, 1-174) towards the formation of highly
functionalized and optically enriched pyrrolidines (1-171) or spiro-[pyrrolidin-3,2’oxindole] derivatives (1-172) (Scheme 1-37).86 This was the first enantioselective
example involving ketimines as the dipolarophile in a formal [3+2]-cycloaddition
involving DA cyclopropanes.
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Scheme 1-37. Formal [3+2]-cycloaddition between DA cyclopropanes and aldimines or ketimines

The reactivity of DA cyclopropanes can also be utilized in annulation reactions towards
dihydropyrroles. The Pagenkopf group utilized glycal-derived DA cyclopropanes (1-175)
and were the first to perform formal [3+2]-cycloadditions with a variety of nitriles
providing complex dihydropyrroles (1-176) in high yields (Scheme 1-38).87

Scheme 1-38. Formal [3+2]-cycloadditions with glycal derived DA cyclopropanes and nitriles towards
dihydropyrroles

More recently, France and co-workers showed a nucleophilic ring-opening of DA
cyclopropanes (1-177) with primary amines (1-178) followed by cyclization forming
dihydropyrroles (1-179) in good to excellent yields (Scheme 1-39).88 However, it can be
argued that imine formation occurs prior to cyclization which would be followed by a
Cloke-Wilson type rearrangement through a zwitterionic intermediate. This process will
be discussed in greater detail in the following section.
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Scheme 1-39. Ring-opening/cyclization of DA cyclopropanes with primary amines

Annulation reactions involving DA cyclopropanes towards the synthesis of various
carbocycles and heterocycles is a vast area of ongoing research with unique scaffolds
being synthesized regularly.

1.3.2

Rearrangements of DA Cyclopropanes

Rearrangements of DA cyclopropanes is another large area of research in organic
chemistry since it allows the formation of various cyclic structures in a quick and atom
economical manner. One of the most famous examples of cyclopropane rearrangements
is the vinylcyclopropane-cyclopentene rearrangement64,65,89–93 (Scheme 1-40).

Scheme 1-40. Vinylcyclopropane-cyclopentene rearrangement

Since the discovery of this reaction, numerous reviews were published which debated its
exact mechanism. Today, the majority of the evidence suggests a diradical mechanism or
through zwitterionic intermediates (Scheme 1-41); however, a concerted [1,3] process is
still argued.94–96
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Scheme 1-41. Vinylcyclopropane-cyclopentene rearrangement. [a] diradical mechanism. [b]
zwitterionic intermediate mechanism.

A much less known variant of this reaction is the heteroatom version known as the
Cloke-Wilson reaction. Cloke discovered the formation of 2-phenylpyrroline
hydrochloride (1-190) when he attempted to distill phenyl cyclopropyl ketimine
hydrochloride (1-189) under vacuum. Wilson separately reported the formation of
dihydrofurans (1-192) from the thermal rearrangement of cyclopropylcarboxaldehyde (1191) (Scheme 1-42).92

Scheme 1-42. Cloke-Wilson rearrangements towards the formation of dihydropyrroles and
dihydrofurans

The vinylcyclopropane-cyclopentene and Cloke-Wilson rearrangements were not widely
applicable due to the extremely high temperatures required to induce the rearrangement.92
However, with the introduction of DA cyclopropanes, these types of rearrangements
could be carried out under much milder conditions. Davies et al. showed a highly
stereoselective formation of cyclopentenes (1-194) using vinyl DA cyclopropane (1-193)
under mild conditions in the presence of an aluminum catalyst (Scheme 1-43).95
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Scheme 1-43. Stereoselective vinylcyclopropane-cyclopentene rearrangement under mild conditions

To explain the high stereoselectivity of the rearrangement, Davies proposed that the
rearrangement underwent a formal [1,3]-sigmatropic rearrangement proceeding
suprafacially with retention of configuration. However, it was also proposed that the DA
cyclopropane underwent ring-opening to the zwitterionic intermediate and re-closed to
the cyclopentene before any bond rotation occurred. This may be possible due to the
extremely low temperature the reaction was performed in.
Recently, Robiette et al. developed a highly diastereo- and enantioselective one-pot
protocol that gave cyclopentenes (1-200) via the vinylcyclopropane-cyclopentene
rearrangement. Chiral sulfur ylides (1-196) underwent a formal [4+1]-annulation with
1,1-bis-activated 1,3-dienes (1-195) to yield in situ vinylcyclopropane (1-197). The
cyclopropane was then treated with MgI2 which resulted in a vinylcyclopropanecyclopentene rearrangement with complete retention of stereochemistry (Scheme 1-44).97
Computational studies were conducted to gain insight into the mechanism and results
suggested that the reaction underwent two SN2 reactions which accounted for the
stereochemistry. Upon coordination of MgI2 onto the EWG of the cyclopropane (1-198),
the displaced iodide opened the cyclopropane in an SN2 fashion (1-199) followed by ring
closure with expulsion of the iodide in a second SN2 reaction to form the cyclopentene
ring (1-200).
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Scheme 1-44. Diastereo- and enantioselective vinylcyclopropane-cyclopentene rearrangement
undergoing a double SN2 displacement

Wenkert was able to utilize the reactivity of DA cyclopropanes and perform the ClokeWilson rearrangement under mild conditions forming various dihydrofurans.98
Ethylformyldiazoacetate (1-201) was reacted with n-butylvinyl ethers (1-202) under
metal carbenoid chemistry forming cyclopropane intermediate (1-203) that underwent the
Cloke-Wilson rearrangement which furnished dihydrofuran (1-204) in good yields
(Scheme 1-45).

Scheme 1-45. Cloke-Wilson rearrangement of DA cyclopropane to dihydrofuran

Recently, the group of Xu showcased a high yielding organocatalytic Cloke-Wilson
rearrangement of cyclopropyl ketones (1-205) to dihydrofurans (1-208) with the use of
DABCO (1-206) (Scheme 1-46).99 The products were obtained in high yields and
mechanistic studies supported a SN1 type (zwitterionic) (1-207) mechanism.
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Scheme 1-46. Proposed mechanism for the organocatalyzed Cloke-Wilson rearrangement

Formation of dihydropyrroles via the Cloke-Wilson rearrangement was employed under
mild conditions upon introduction of DA cyclopropanes. Spirocyclic DA cyclopropanes
(1-209) were reacted with a variety of primary amines (1-210) at room temperature
without any catalyst forming bicyclic dihydropyrroles (1-211) in excellent yields
(Scheme 1-47).100 To show the utility of these transformations, the group transformed a
select example to its corresponding indole derivative (1-212).

Scheme 1-47. Cloke-Wilson rearrangement of DA cyclopropanes to dihydropyrroles

DFT studies were conducted for the Cloke-Wilson rearrangement involving up to 72 DA
cyclopropanes.71,101 It was found that in the absence of a catalyst, the rearrangement
occurred through a concerted process.101,102 The corresponding zwitterionic or biradical
intermediates were shown to have higher activation barriers in all cases.101 An example of
this is shown by Werz and co-workers where they synthesized [n,5]-spiroketals (1-217, 1218) (n = 5 or 6) through the Cloke-Wilson rearrangement of DA cyclopropanes (1214)103 (Scheme 1-48).
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Scheme 1-48. Rearrangement of DA cyclopropanes to spiroketals

When no Lewis acid was used, high diastereoselectivity was observed supporting a
concerted mechanism (1-215). In the presence of a Lewis acid, the yields increased and a
mixture of diastereomers (1-217, 1-218) was observed, supporting a zwitterionic
intermediate (1-216).
Larger ring systems can be formed with the use of divinylcyclopropanes (1-219) which
undergo a Cope rearrangement to furnish cycloheptadiene compounds (1-220)104
(Scheme 1-49).

Scheme 1-49. Divinylcyclopropane-cycloheptadiene rearrangement

The heteroatom version of the divinylcyclopropane-cycloheptadiene rearrangement is
also known and useful for making 7-membered heterocycles. This work was pioneered
by Reissig and Boeckman in the mid 1990s. Boeckman synthesized vinylcyclopropane
(1-221) and after oxidation with DMP he formed the required (hetero)-
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divinylcyclopropane (1-222) which instantly underwent a retro-Claisen rearrangement
furnishing 2,5-dihydrooxepines (1-223) in good to excellent yields (Scheme 1-50).105

Scheme 1-50. Boeckman's (hetero)-divinylcyclopropane rearrangement to 2,5-dihydrooxepines

Similarly, Reissig synthesized vinylcyclopropane (1-224) and after further chemical
transformations he formed the required (hetero)-divinylcyclopropane (1-225). This
intermediate instantly underwent a retro-Claisen rearrangement furnishing 2,5dihydrooxepines (1-226) in moderate to good yields (Scheme 1-51).106

Scheme 1-51. Reissig’s (hetero)-divinylcyclopropane rearrangement to 2,5-dihydrooxepines

An enantioselective version of this transformation was recently reported by the Ryu
group. The required enantiopure DA cyclopropane (1-229) was formed via a Michael
addition initiated cyclopropanation between substituted acroleins (1-227) and
vinyldiazoesters (1-228) under chiral oxazaborolidinium ion (COBI) (1-231) catalyst
(Scheme 1-52).107 The cyclopropane instantly underwent a retro-Claisen rearrangement
generating 2,5-dihydrooxepines (1-230) in high yields and enantioselectivities. This was
the first reported example of a catalytic asymmetric formation of 2,5-dihydrooxepines
through tandem cyclopropanation/retro-Claisen rearrangement.
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Scheme 1-52. First enantioselective formation of dihydrooxepines through a tandem
cyclopropanation/retro-Claisen rearrangement

DA cyclopropanes are synthons whose innate dipole moments are appropriate to produce
carbocyclic and heterocyclic compounds. Rearrangement reactions are important since
they allow the formation of said compounds in an atom economical process. Many of
these examples require only mild conditions without the need of any catalysts. These
types of rearrangements will be the main focus of the upcoming chapters, which
ultimately leads into the work towards pyrrolidine-containing product kainic acid.

1.4 Kainic Acid
1.4.1

Isolation and biological activity

The kainoid amino acids are densely functionalized pyrrolidine motifs that are
structurally related to glutamic acid (1-232h), which is an excitatory neurotransmitter
(Figure 1-6).108–111 The parent of the kainoids, α-kainic acid (1-232a), was first isolated
by Takemoto in 1953 from the Japanese marine algae Digenea simplex along with its C-4
epimer α-allokainic acid (1-232b).108–111 A few years after its isolation, Morimoto was
the first to deduce the relative stereochemistry of the pyrrolidine ring through X-ray
analysis and it was not until the first total synthesis by Oppolzer and Thirring in 1982
where the absolute stereochemistry was confirmed.108–112
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Figure 1-6. Kainoid amino acid family and their resemblance to glutamic acid

Since the initial isolation of kainic acid, the compound received attention from chemists
and biologist due to its neuroexcitatory properties. L-glutamic acid (1-232h), which is the
most abundant excitatory neurotransmitter, interacts with two classes of receptors. The
first are called ionotropic glutamate receptors (iGluRs), which are coupled to ion
channels that control the flux of ions to nerve cells and are capable of millisecond or
faster response times. The second are metabotropic glutamate receptors (mGluRs) which
have slower response times compared to the first, but produce long lasting changes to
nerve cells.109 When L-glutamic acid (1-232h) was administered subcutaneously to
animals, it destroyed neurons of the inner retina which suggested that excessive
activation of iGluRs can cause a cascade of events that leads to cell death.109 When kainic
acid (1-232a) was administered, it was discovered that it behaved as an agonist for the
iGluRs, mediating the effects caused by glutamic acid which helped to elucidate the
neurophysiological role of glutamic acid.109,113 It was later understood that when in direct
contact with neurons, kainic acid induced motor hyperactivity and seizures, as well as
destroyed neurons in specific regions of the brain that contained high concentrations of
the molecule.108,109 It was then realized that these symptoms resembled several human
pathological conditions which resulted in creating model conditions for the better
understanding of epilepsy, stroke and Huntington’s chorea.109,111
With its interesting biological properties, kainic acid became high in demand in the
neuroscience field; however, limited supply from natural sources resulted in a shortage
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and high price (50mg from sigma-aldrich costs $1260.00). Due to this demand, kainic
acid sparked interest in organic chemists, resulting in over 70 published synthetic
routes.114

1.4.2

Total syntheses of Kainic acid

Oppolzer and Thirring’s kainic acid synthesis was instrumental for the determination of
its absolute stereochemistry (Scheme 1-53).112

Scheme 1-53. First total synthesis of kainic acid

Starting from a derivative of L-glutamic acid (1-233), Boc protection of the primary
amine resulted in carboxylic acid (1-234). Reduction of the carboxylic acid with borane
followed by protection of the resulting primary alcohol with TBSCl furnished (1-235) in
52% overall yield. N-alkylation was then performed with (1-236) to provide tertiary
amine (1-237) in good yield. The α,β-unsaturated ester (1-238) was formed by treating
(1-237) under strong basic conditions with an organoselenium reagent, followed by
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Grieco elimination. A key stereocontrolled intramolecular ene reaction was performed by
heating (1-238) in toluene which furnished the desired pyrrolidine core (1-239) with the
correct stereochemistry. Deprotection of the silyl group followed by oxidation to the acid
formed (1-240) in 60% overall yield. Finally, saponification of the ester followed by
cleavage of the Boc group and purification using ion-exchange resin gave the final
product (1-232a) in an overall yield of 5%.
Since the pioneering work by Oppolzer and Thirring112, several highly efficient total
syntheses of kainic acid have been reported. In 2002, Clayden reported an
enantioselective synthesis of kainic acid which featured an asymmetric dearomatizing
cyclization forming isoindolinones as the key substrate115 (Scheme 1-54). Beginning with
a N-benzyl benzamide derivative (1-241), the asymmetric dearomatizing cyclization was
made possible with chiral lithium amide (1-242) generating lithium enolate (1-244). This
intermediate was then protonated (1-245) and hydrolyzed forming isoindolinone (1-246).

Scheme 1-54. Asymmetric dearomatizing cyclization towards enantioenriched isoindolinone

Following the groups previously reported racemic kainic acid synthesis 116 (Scheme 1-55),
the enantioenriched isoindolinone (1-246) was treated with an organocuprate in the
presence of TMSCl which formed an enol ether derivative that was hydrolyzed with
subsequent deprotection forming lactam (1-247). After recrystallization of this
intermediate, the product lactam was obtained in a 48% yield with 98% ee. Lactam (1-
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247) was then Boc protected forming (1-248) followed by an oxidative removal of the
aromatic ring generating a carboxylic acid derivative which was esterified with
diazomethane forming methyl ester (1-249). Baeyer-Villiger oxidation formed lactone (1250) regioselectively which was hydrolyzed and esterified forming dimethyl ester (1251). Grieco dehydration of (1-251) to give isopropenyl (1-252) was achieved in one step
by treating the primary alcohol with an organoselenium reagent which was oxidized to a
selenoxide followed by its elimination. Selective reduction of the lactam with sodium
trimethoxyborohydride formed Boc-protected pyrrolidine (1-253) which was deprotected
with subsequent hydrolysis of the methyl esters using a trifluoroacetic acid/water mixture
forming kainic acid (1-232a) in 11 steps with an overall yield of 4%.

Scheme 1-55. Synthesis of kainic acid utilizing the asymmetric dearomatizing cyclization
methodology

In 2011, Fukuyama reported a multigram total synthesis of kainic acid which featured a
stereoselective alkylation and hydrolysis of a nitrile derivative accompanied by
epimerization117 (Scheme 1-56).
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Scheme 1-56. Fukuyama's multigram synthesis of kainic acid

The synthesis involved epoxidation of (+)-carvone (1-254) to epoxide (1-255) in high
yield. The epoxide was then hydrolyzed under acidic conditions producing a
diastereomeric mixture of diols, which was subjected to oxidative cleavage forming a
1,2-diketone intermediate (1-256). The diketone intermediate was further oxidized to acid
(1-257) followed by cyclization involving iodine and base to produce iodolactone (1258). Treatment of (1-258) under standard Pinnick conditions followed by Curtius
rearrangement formed carbamate (1-259). The stereoselective alkylation was then
performed under basic conditions with tert-butylbromoacetate forming ester (1-260).
Reductive ring-opening of (1-260) with Zn produced a carboxylic acid intermediate that
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underwent cyclization with DEPC to form lactam (1-261). Selectively reducing the
lactam and treating the resulting hemiaminal with methanol and acid formed (1-262) as a
single diastereomer. Treatment of (1-262) with TMSCN and Lewis acid gave, via an
acyliminium ion, aminonitrile (1-263) as a 3:1 mixture of diastereomers. This was not an
issue since epimerization of the unwanted diastereomer occurred during the final
hydrolysis step producing kainic acid (1-232a) in 13 steps with an overall yield of 10%,
providing up to 14.6g of product when beginning with 100g of (+)-carvone.
Lin and co-workers reported the highest overall yield of kainic acid in just seven steps
with the instrumental step being an asymmetric alkenylation of cyclic α,β-unsaturated
carbonyl compounds (Scheme 1-57).118 Beginning with lactam (1-264), the asymmetric
alkenylation was performed forming lactam (1-266) in 82% yield and 99% ee. Next,
alkylation of (1-266) with tert-butylbromoacetate gave trans-3,4-substituted ester (1267). To acquire the syn relationship between C3 and C4 (1-268), a dynamic protonation
process was executed by deprotonating (1-267) at -78 °C followed by protonation with ()-CSA. The next final steps followed a similar procedure to that reported by Fukuyama
providing kainic acid (1-232a) in seven steps with a 40% overall yield.

Scheme 1-57. Lin et al. synthesis of kainic acid with high overall yield
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In 2014, Ohshima et al. reported the shortest synthesis of kainic acid to date with a high
overall yield and the ability to perform the reactions on gram scale without affecting yield
or enantioselectivity119 (Scheme 1-58). The key steps featured sequential platinum
catalyzed direct allylic aminations and a thermal ene cyclization.

Scheme 1-58. Oshima's total synthesis of kainic acid

The synthesis began with the direct amination of allylic alcohol (1-271) and 2,4dimethoxybenzylamine (DMB) (1-272) under platinum catalysis forming allylamine (1273). The enantiopure epoxide (1-276) required for the second platinum allylation was
formed in one-pot beginning with oxidizing epoxide (1-274) with TEMPO followed by a
Wittig olefination with (1-275) to form (1-276) in high yields. With the enantiopure
epoxide in hand, the second platinum catalyzed allylation was accomplished forming
diallylamine (1-277). The ene-cyclization was then performed which constructed the
desired pyrrolidine ring (1-278) with three continuous stereocenters. Upon scale-up, a
catalytic amount of base was added to avoid partial decomposition of the substrate.
Oxidizing the primary alcohol to the carboxylic acid (1-279) under Jones conditions
followed by treatment of the crude material with triethylsilane and TFA resulted in the
deprotection of the DMB and tert-butyl groups forming the final product (1-232a) in six
steps with an overall yield of 34-37%.
Each of the synthetic routes to kainic acid presented have had a great impact in the
synthetic community. With the goal to synthesize the compound in a quick and efficient

43

manner, new synthetic methodologies were discovered which can potentially be useful
for other synthetic targets. The ability to provide this compound in multigram scale and
high overall yields can allow for further biological studies to be conducted.
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Chapter 2

2

The Tandem Cyclopropanation/Vinylogous ClokeWilson Rearrangement for the Synthesis of
Heterocyclic Scaffolds

This chapter was adapted from the following manuscript:
Piotrowski, M. L.; Kerr, M. A. Org. Lett. 2018, 20, 7624-7627

2.1 Introduction
The ring strain inherent in DA cyclopropanes and the weakened vicinal C-C bond due to
the synergistic electron push-pull relationship between the D and A groups has been
exploited for decades. Simple nucleophilic ring-opening of a DA cyclopropane (a homoMichael addition) or electrophilic ring-opening (homo-enolate addition) results in linear
compounds, while reaction with dipolar species can result in hetero- or carbocyclic
products. Rearrangement reactions of DA cyclopropanes represents another class of
reactivity for an expedient method to access complex chemical structures in an atom
economical manner.64–73 Perhaps one of the most well-established processes is the
vinylcyclopropane-cyclopentene rearrangement which results in five membered ring
products.92 A much less studied variant of this reaction is the Cloke-Wilson
rearrangement (Scheme 1-42). In 1929, Cloke reported that treatment of cyclopropyl
phenyl ketone with ammonium chloride resulted in the formation of a dihydropyrrole.120
In 1947 Wilson was able to induce rearrangement of cyclopropane carboxyaldehyde to
dihydrofuran.121 Since these initial discoveries, there have been notable advancements
including organocatalysis (Scheme 1-46)99, DYKAT (Scheme 2-1a)122, silicon promotion
(Scheme 2-1b)123, and transition metal catalysis (Scheme 2-1c).124
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Scheme 2-1. Recent advances in the Cloke-Wilson rearrangement to dihydrofurans

Herein we report a tandem cyclopropanation/Cloke-Wilson rearrangement as well as a
rarer but not unprecedented105,106,125–128 vinylogous variant (a retro-Claisen
rearrangement) to form seven-membered oxacycles.

2.2 Results and Discussion
The discovery of the title reactions came about while exploring a route to kainic acid. The
original plan was to cyclopropanate cyclopentadiene (2-7) with (2-8) to produce (2-9).
The aldehyde would then be converted to aldimine (2-10) and subjected to a ClokeWilson rearrangement to produce (2-11) which we deemed a possible synthetic precursor
to kainic acid (2-12) (Scheme 2-2). When subjecting the reactants under metal-carbenoid
cyclopropanation conditions, the desired cyclopropane was not isolable but formed a new
product in situ which we first assigned to a Cloke-Wilson product such as (2-14a).
Extensive NMR analysis, however showed that the product was in fact a 2,5dihydrooxepine (2-13a), the product of a vinylogous Cloke-Wilson reaction. With this
interesting lead result in hand, we sought to explore the reaction for substrate scope and
mechanistic understanding.
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Scheme 2-2. Vinylogous Cloke-Wilson rearrangement to 2,5-dihydrooxepines

Our study commenced with the treatment of 1,3-cyclohexadiene (2-7b) with 2-formyl
ethyl diazoacetate (2-8) (Table 1). Zero-addition of all reagents in DCM at 40 °C
provided dihydrooxepine (2-13b) in low yield along with an unknown by-product (entry
1). It was later realized that the unknown by-product is the dimerization of (2-8) forming
(2-15) which is a common occurrence in metal carbenoid chemistry (Figure 2-1).129,130

Figure 2-1. Dimerization product of 2-formyl ethyl diazoacetate

With this information in mind, it was decided to add (2-8) over an extended period of
time to minimize this side reaction. Addition of the diazo species over a period of 30
minutes did not show an improved yield (entry 2). Extending the addition time to one
hour (entry 3) and two hours (entry 4) improved the yield slightly; however, the
dimerization was still an issue. A switch in equivalence between cyclopentadiene and
diazo showed an improvement in yield (entry 5). Lowering the reaction temperature to 25
°C with a two-hour addition time drastically improved the yield (entry 6) while extending
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the addition time to ten hours did not improve the results (entry 7). Cooling the reaction
to 0 °C in order to minimize the dimerization even further proved to be effective;
however, the yield did not improve due to a great deal of decomposition (entry 9).
Lowering the amount of catalyst to 1 mol % with an addition time of two hours at 25 °C
proved to be the most effective (entry 8). Other catalysts such as Rh2(OAc)4 provided the
product in lower yields (entry 10) or were ineffective (entry 12-14).
Table 1. Tandem cyclopropanation/vinylogous Cloke-Wilson rearrangement with formyldiazoacetate
and 1,3-cyclohexadiene

Entry

Solvent

Temp

Addition time of

(°C)

diazo (hours)

Catalyst (mol %)

Diene:diazo

Isolated
yield (%)

1

DCM

40

0

Rh2(esp)2 (2)

2:1

22

2

DCM

40

0.5

Rh2(esp)2 (2)

2:1

28

3

DCM

40

1

Rh2(esp)2 (2)

2:1

30

4

DCM

40

2

Rh2(esp)2 (2)

2:1

34

5

DCM

40

2

Rh2(esp)2 (2)

1:2

40

6

DCM

25

2

Rh2(esp)2 (2)

1:2

64

7

DCM

25

10

Rh2(esp)2 (2)

1:2

60

8

DCM

25

2

Rh2(esp)2 (1)

1:2

62

9

DCM

0

2

Rh2(esp)2 (1)

1:2

50
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10

DCM

25

2

Rh2(OAc)4 (1)

1:2

20

11

DCM

25

2

Rh2(esp)2 (1)

4:1

50

12

DCM

25

2

Cu(OTf)2 (5)

1:2

No rxn

13

DCE

85

2

Cu(OTf)2 (5)

1:2

Decomp.

14

DCE

85

2

Cu(OTf)2 (5)

4:1

Decomp.

15

DCM

25

2

Rh2(esp)2 (1)

1:3
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Treating a variety of readily available butadienes (2-7) with 2-formyl ethyl diazoacetate
(2-8) under the conditions shown in entry 8 (Table 1), provided the corresponding 2,5dihydrooxepines in modest but acceptable yields given the rapid formation of molecular
complexity (Figure 2-2).

Figure 2-2. Tandem cyclopropanation/vinylogous Cloke-Wilson rearrangement towards 2,5-dihydrooxepines

The modest yields can be explained by the formation of diastereomers during the
cyclopropanation stage (Scheme 2-3). For the rearrangement to occur, an endo
relationship between the aldehyde and the vinyl group is necessary.104,105,131 While one
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diastereomer (2-16b) would be well positioned to undergo the rearrangement, the other
(2-16a) would not. At this stage, this is merely a hypothesis as we have never been able
to isolate products derived from (2-16a).

Scheme 2-3. Mechanistic hypothesis

We were surprised to see a different reactivity pattern when aryl substituted butadienes
(2-17) were employed. Rather than the vinylogous reaction pathway, a tandem
cyclopropanation/Cloke-Wilson process occurred (Figure 2-3). The most electron rich
butadienes (yielding 2-18b,c) underwent spontaneous rearrangement to the
dihydrofurans, while the others required treatment with a Lewis acid such as Sc(OTf) 3 to
promote the cyclization.

Figure 2-3. Tandem cyclopropanation/Cloke-Wilson rearrangement towards dihydrofurans. [a]
Product obtained as a mixture with cyclopropane; required treatment with 5 mol% Sc(OTf) 3 in
DCM at 40 °C to complete cyclization.
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Interestingly, the dihydrooxepines from (Figure 2-1) underwent rearrangement to their
dihydrofuran counterparts (2-14) upon treatment with a Lewis acid (Figure 2-4), likely
via a 1,3-oxygen migration involving an allyl cation (Scheme 2-4). Several things are
worthy of note. The bicyclic dihydrooxepines underwent this process in exceedingly high
yields, likely due the favorable strain relief in going from a seven-membered ring to a
five-membered ring. When the regioisomeric mixture of (2-13d) and (2-13e) was
subjected to the reaction conditions, only (2-13d) underwent rearrangement. This result
is likely due the fact that (2-13d) may form a 3o carbocation while (2-13e) would require
a higher energy 2o cation.

Figure 2-4. Rearrangement of dihydrooxepines to dihydrofurans

Scheme 2-4. Proposed mechanism for the rearrangement of dihydrooxepines to dihydrofurans

Inspired by a report by the Ma group132, we sought to perform an oxygen to nitrogen
transposition to access aza-heterocycles (2-21). The Ma communication reported only a
single example as a mechanistic study and so this is (to the best of our knowledge) an
unexplored reaction. Using slightly modified conditions, we subjected the dihydrofurans
from (Figures 2-3 and 2-4) and were delighted with the results (Figure 2-5). We limited
this study to the use of benzylamine except for a single case where p-anisidine was
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employed successfully. Ma’s paper provides a reasonable mechanism which involves a πallyl intermediate.

Figure 2-5. Conversion of dihydrofurans to dihydropyrroles

To improve the efficiency of the rearrangements described above, we sought ways to
shorten the number of steps involved (Figure 2-6). When testing a one-pot protocol for
the tandem cyclopropanation/vinylogous Cloke-Wilson rearrangement followed by the
1,3-allylic migration, formation of (2-14a) was achieved, however the overall yield was
inferior. Also, when the oxygen to nitrogen transposition was attempted on
dihydrooxepine (2-13a), rearrangement was concurrent with nitrogen insertion. The
yield for the one-step process was similar to that of the sequential reactions.
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Figure 2-6. [a] One-pot cyclopropanation/vinylogous Cloke-Wilson rearrangement/1,3-allylic
migration. [b] Direct conversion of dihydrooxepine to dihydropyrrole.

2.3 Conclusion
In summary, we have described a tandem cyclopropanation/Cloke-Wilson rearrangement
as well as the associated vinylogous Cloke-Wilson rearrangement to provide access to
2,5-dihydrooxepine and dihydrofuran scaffolds. Moreover, the dihydrofurans were
converted to dihydropyrroles via a relatively unknown palladium-catalyzed oxygen to
nitrogen transposition.
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2.5 Experimental
2.5.1

General Considerations

All reactions were conducted under an atmosphere of argon unless otherwise indicated.
DCM, toluene, DMF, and THF were dried and deoxygenated by passing the nitrogen
purged solvents through activated alumina columns. All other solvents and reagents were
used as purchased from Sigma Aldrich, Alfa Aesar, Caledon, VWR or Oakwood
Chemicals and used as received. Reaction progress was followed by thin layer
chromatography (TLC) (Merck, TLC silica gel 60 F254) visualized with UV light, and
the plates developed with p-anisaldehyde, vanillin, basic potassium permanganate or
DMP stains. Column chromatography was performed using silica gel (230-400 mesh,
Silicycle Chemical Division Inc).
NMR experiments were performed on Varian Mercury 400, Bruker AvIII 400, Inova 400
and Inova 600 MHz instruments with 13C operating frequencies of 100, 100, 100, and 150
MHz respectively. Chemical shifts are reported in ppm relative to the residual solvent
signal; CDCl3, referenced to residual CHCl3 at δ = 7.26 for 1H and δ = 77.1 for 13C.
Coupling constants (J) are reported in Hz, and multiplicities of the signals are described
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using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, quin =
quintet, m = multiplet, br = broad. High resolution mass spectra (HRMS) were obtained
on a Thermo Scientific DFS mass spectrometer using electron impact ionization. Melting
points were determined using a Digimelt MPA160 melting point apparatus from Stanford
Research Systems (SRS). Infrared spectra were obtained using a Bruker Alpha II
Platinum ATR spectrometer or as thin films on NaCl plates using a Bruker Vector 33 FTIR instrument and are reported in frequency of absorption (cm -1).

2.5.2

Experimental procedures and characterization data

General procedure for the synthesis of formyldiazoacetate 2-8

Thionyl chloride (1 equiv, 90 mmol) was added dropwise to anhydrous DMF (1 equiv, 90
mmol) at room temperature. Once added, the reaction mixture was heated to 40˚ C for
three hours. The reaction mixture was placed directly under high vacuum until a
colourless precipitate was formed. The precipitate was dissolved in chloroform (40ml)
and cooled to -20˚ C using an ice/acetone bath. To the cooled solution, ethyl diazoacetate
(2 equiv, 180 mmol) was added dropwise over a period of 30 minutes and the reaction
mixture was stirred at room temperature for an hour. Solvent was removed and the
orange precipitate was washed with cold ether (50ml) followed by vacuum filtration. The
precipitate was washed with 100ml cold ether, collected and dissolved in 10% aqueous
acetic acid (40ml) and stirred overnight at room temperature. The aqueous solution was
extracted with ether and the combined organic layers were washed with aqueous
saturated sodium hydrogen carbonate (40ml), 10% aqueous sulfuric acid solution (40ml),
brine, and dried using MgSO4. The resulting yellow oil was used without further
purification (36%, 4.5940g). Full characterization can be found in the published articlesa. Note: if all the α-chloroethyl acetate by product hasn’t been removed during the

c

vacuum filtration washes with ether, the product obtained after the completed workup can
be passed through a silica plug eluting with ethyl acetate.
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Synthesis of 1,3-dienes
Procedure for the formation of allyltrimethylphosphonium bromide

Trimethylphosphine (1M in THF) (30ml, 30mmol) in dry DCM (30ml) under Argon gas
was cooled to 0 ˚C. Allyl bromide (2.6ml, 30mmol) was added dropwise and the reaction
was stirred at room temperature for 2.5 hours. The solvent was removed under reduced
pressure to yield the desired compound (quant. 5.9g)d, e.
General procedure for the synthesis of 1,3-dienes

Allyltrimethylphosphonium bromide (0.25g, 1.25mmol) under argon gas in 6.25ml THF
was cooled to 0 ˚C. Butyl lithium (2.5M in hexanes) (0.5ml, 1.25mmol) added dropwise
and stirred for 15mins. Aldehyde (0.11g, 1.0mmol) in 1.25ml THF was added dropwise
and stirred for one hour at 0 ˚C followed by stirring at room temperature until reaction
completion monitored by TLC analysis. The reaction mixture was quenched with
saturated NH4Cl and extracted with ether. The combined organic layers were washed
with brine, dried with MgSO4, filtered and the solvent was removed under reduced
pressure. The crude material was filtered through a silica plug eluting with 10%
Et2O/pentane providing the final diene (0.1555g, 0.97mmol)f.
Full characterization of these starting materials can be found in the following references:
a) F. M. Stojanovic, Z. Arnold, Collect. Czechoslov. Chem. Commun. 1967, 32,
2155-2160.
b) L. Jiang, A. Davison, G. Tennant, R. Ramage, Tetrahedron 1998, 54, 1423314254.
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c) J. Linder, T. P. Garner, H. E. L. Williams, M. S. Searle, C. J. Moody, J. Am.
Chem. Soc. 2011, 133, 1044-1051.
d) R. Tamura, K. Saegusa, M. Kakihana, D. Oda, J. Org. Chem. 1988, 53, 27232728.
e) J. McNulty, P. Das, Tetrahedron Lett. 2009, 50, 5737-5740.
f) A. Lishchynskyi, K. Muniz, Chem. Eur. J. 2012, 18, 2212-2216.
General procedure for the formation of dihydrooxepine and dihydrofuran compounds (213 and 2-18)
To a round bottom flask containing a stir bar, Rh2(esp)2 catalyst (1 mol %) was added and
purged with argon gas. DCM (0.35M) was added followed by the addition of the 1,3diene (1 equiv). Formyldiazoacetate 2-8 (2 equiv) in DCM (0.35M) was added at room
temperature via syringe pump over a period of 2 hours. The reaction mixture was stirred
at room temperature until completion monitored by TLC analysis. Solvent was removed
under reduced pressure and the residue was purified by flash chromatography
(EtOAc/Hexanes; unless otherwise indicated) to yield the desired compounds. For
dihydrofurans (2-18a, d-f), additional treatment with Sc(OTf)3 in DCM at 40 °C for one
hour was required to complete the cyclization. The mixture was then filtered through a
silica plug eluting with EtOAc/Hexanes.
Ethyl 2-oxabicyclo[3.2.1]octa-3,6-diene-4-carboxylate 2-13a

Reagents employed: formyldiazoacetate 2-8 (0.2g, 1.4 mmol), cyclopentadiene (0.06ml,
0.7 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3-benzenedipropionic acid)] (5mg, 0.007
mmol), DCM (6ml): yield 60% (0.075g, 0.42 mmol) as a yellow oil; Rf = 0.59, 30%
EtOAc/hexanes; 1H NMR (600 MHz, CDCl3) δ 7.11 (d, J = 1.5 Hz, 1H), 6.51 (dd, J =
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5.3, 2.4 Hz, 1H), 5.55 (dd, J = 5.3, 2.4 Hz, 1H), 5.05 (m, 1H), 4.17 (q, J = 7.0 Hz, 2H),
3.35 (br s, 1H), 2.05 (ddd, J = 11.2, 4.1, 2.9 Hz, 1H), 1.85 (d, J = 11.2 Hz, 1H) 1.27 (t, J =
7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.3, 152.6, 143.4, 121.8, 111.8, 81.6,
59.9, 35.8, 34.8, 14.5; IR (thin film, cm-1) 2981, 1703, 1605, 1249, 1078; HRMS (EI)
calc’d for C10H12O3 180.0786, found 180.0781.
Ethyl 2-oxabicyclo[3.2.2]nona-3,6-diene-4-carboxylate 2-13b

Reagents employed: formyldiazoacetate 2-8 (0.2g, 1.4mmol), 1,3-cyclohexadiene
(0.07ml, 0.7mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3-benzenedipropionic acid)]
(5mg, 0.007mmol), DCM (6ml): yield 62% (0.084g, 0.43 mmol) as a yellow oil; Rf =
0.62, 30% EtOAc/hexanes; 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 1.3 Hz, 1 H) 6.70
(ddd, J = 8.8, 6.4, 1.1 Hz, 1 H) 5.97 (ddd, J = 8.8, 6.4, 1.1 Hz, 1 H) 4.62 (ddt, J = 6.5, 5.2,
1.4 Hz, 1 H) 4.14 (q, J = 7.2 Hz, 2 H) 3.23-3.19 (m, 1 H) 2.51 (dddd, J = 15.4, 9.3, 6.2,
1.4 Hz, 1 H) 2.24-2.17 (m, 1 H) 1.95-1.87 (m, 1 H) 1.77 (dddd, J = 12.9, 11.3, 6.2, 4.0
Hz, 1 H) 1.25 (t, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 168.0, 156.3, 141.7,
123.2, 111.5, 72.5, 60.2, 29.3, 28.6, 27.8, 14.5; IR (thin film, cm-1) 2979, 1697, 1615,
1196, 1063, 891; HRMS (EI) calc’d for C11H14O3 194.0943, found 194.0944.
Ethyl 5,6-dimethyl-4,7-dihydrooxepine-3-carboxylate 2-13c

Reagents employed: formyldiazoacetate 2-8 (0.2g, 1.4 mmol), 2,3-dimethyl-1,3butadiene (0.08ml, 0.7 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3-benzenedipropionic
acid)] (5mg, 0.007 mmol), DCM (6ml): purified with column chromatography using 5%
Et2O/pentane; yield 60% (0.083g, 0.42 mmol) as a yellow oil; Rf = 0.64, 30%
EtOAc/hexanes; 1H NMR (400 MHz, CDCl3) δ = 7.47 (s, 1H), 4.60 (s, 2H), 4.15 (q, J =
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7.1 Hz, 2H), 3.19 (s, 2H), 1.80 (br s, 6H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz,
CDCl3) δ = 168.9, 158.0, 139.0, 126.4, 106.4, 71.9, 60.2, 30.0, 20.8, 18.4, 14.4; IR (thin
film, cm-1) 2981, 1698, 1626, 1251, 1210, 1071; HRMS (EI) calc’d for C11H16O3
196.1099, found 196.1100.
Ethyl 6-methyl-4,7-dihydrooxepine-3-carboxylate 2-13d and 2-13e

Reagents employed: formyldiazoacetate 2-8 (0.43g, 3.0 mmol), isoprene (0.15ml, 1.5
mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3-benzenedipropionic acid)] (0.011g, 0.015
mmol), DCM (13ml): purified with column chromatography using 5% Et 2O/pentane;
yield 46% (0.12g, 0.69 mmol) as an inseparable mixture of isomers (3:1) as a yellow oil;
Rf = 0.68, 30% EtOAc/hexanes; 1H NMR (400 MHz, CDCl3, 2-13d) δ = 7.52 (t, J = 1.0
Hz, 1H), 5.74 (t, J = 7.1 Hz, 1H), 4.57 (d, J = 7.1 Hz, 2H), 4.15 (q, J = 7.1 Hz, 2H), 3.22
(s, 2H), 1.86 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H); 1H NMR (400 MHz, CDCl3, 2-13e) δ =
7.50 (t, J = 1.0 Hz, 1H), 5.93 (tq, J = 6.3, 1.7 Hz, 1H), 4.60 (s, 2H), 4.15 (q, J = 7.1 Hz,
2H), 3.15-3.12 (m, 2H), 1.82 (q, J = 1.5 Hz, 3H); 13C NMR (100 MHz, CDCl3, 2-13d) δ
= 168.8, 158.4, 148.4, 120.0, 105.3, 65.8, 60.3, 29.1, 25.0, 14.5; 13C NMR (100MHz,
CDCl3, 2-13e) δ = 168.8, 158.2, 134.9, 130.0, 107.3, 70.4, 62.4, 41.0, 23.3, 22.4, 14.2; IR
(thin film, cm-1) 2978, 1698, 1625, 1223, 1095, 1065; HRMS (EI) calc’d for C10H14O3
182.0943, found 182.0942.
(E)-ethyl 5-styryl-4,5-dihydrofuran-3-carboxylate 2-18a
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Reagents employed: formyldiazoacetate 2-8 (0.22g, 1.54 mmol), (E)-buta-1,3-dien-1ylbenzene (0.1g, 0.77 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3-benzenedipropionic
acid)] (6mg, 0.0077mmol), DCM (7ml); yield 50% (0.095g, 0.39 mmol) as a mixture of
cyclopropane and dihydrofuran; Rf = 0.61, 30% EtOAc/hexanes; Reagents employed:
Cyclopropane/dihydrofuran mixture (0.095g, 0.39 mmol), Sc(OTf)3 (0.01g, 0.019 mmol),
DCM (3ml): yield 100% (0.095g, 0.39 mmol) as a yellow oil; Rf = 0.61, 30%
EtOAc/hexanes; 1H NMR (400 MHz, CDCl3) δ 7.41-7.38 (m, 2H), 7.35-7.31 (m, 2H),
7.30-7.27 (m, 2H), 6.64 (d, J = 15.9 Hz, 1H), 6.28 (dd, J = 15.8, 7.3 Hz, 1H), 5.39 (dt, J =
9.5, 7.6 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.11 (ddd, J = 14.7, 10.6, 1.9 Hz, 1H), 2.74
(ddd, J = 14.7, 8.0, 1.9 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ
= 165.3, 156.3, 136.0, 132.6, 128.7, 128.3, 127.4, 126.8, 108.9, 85.8, 59.9, 34.2, 14.5; IR
(thin film, cm-1) 2980, 1701, 1624, 1102, 751, 692; HRMS (EI) calc’d for C15H16O3
244.1099, found 244.1098.
(E)-ethyl 5-(4-methoxystyryl)-4,5-dihydrofuran-3-carboxylate 2-18b

Reagents employed: formyldiazoacetate 2-8 (0.26g, 1.88 mmol), (E)-1-(buta-1,3-dien-1yl)-4-methoxybenzene (0.15g, 0.94 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3benzenedipropionic acid)] (7mg, 0.0094 mmol), DCM (8ml): yield 63% (0.16g, 0.59
mmol) as a green/yellowish solid; Rf = 0.45, 30% EtOAc/hexanes; melting point: 64.464.6 °C 1H NMR (400 MHz, CDCl3)  7.35-7.31 (AA’BB’, 2H), 7.27 (t, J = 1.9 Hz,
1H), 6.88-6.84 (AA’BB’, 2H), 6.58 (d, J = 15.6 Hz, 1H), 6.14 (dd, J = 15.8, 7.5 Hz, 1H),
5.36 (dt, J = 10.4, 7.7 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.81 (s, 3H), 3.08 (ddd, J = 14.7,
10.4, 1.9 Hz, 1H), 2.72 (ddd, J = 14.4, 8.0, 1.8 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H); 13C
NMR (100 MHz, CDCl3)  165.3, 159.8, 156.3, 132.4, 128.7, 128.1, 125.2, 114.1,
108.9, 86.2, 59.9, 55.4, 34.2, 14.5; IR (thin film, cm-1) 2980, 1700, 1624, 1512, 1249,
1102, 1032; HRMS (EI) calc’d for C16H18O4 274.1205, found 274.1207.
(E)-ethyl 5-(3,4-dimethoxystyryl)-4,5-dihydrofuran-3-carboxylate 2-18c
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Reagents employed: formyldiazoacetate 2-8 (0.27g, 1.9 mmol), (E)-4-(buta-1,3-dien-1yl)-1,2-dimethoxybenzene (0.18g, 0.97 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3benzenedipropionic acid)] (7mg, 0.0097 mmol), DCM (8ml): yield 43% (0.12g, 0.42
mmol) as a yellow oil; Rf = 0.28, 30% EtOAc/hexanes; 1H NMR (400 MHz, CDCl3) δ
7.28 (t, J = 1.9 Hz, 1H), 6.95-6.92 (m, 2H), 6.82 (d, J = 7.9 Hz, 1H), 6.58 (d, J = 15.7 Hz,
1H), 6.15 (dd, J = 15.7, 7.4 Hz, 1H), 5.37 (dt, J = 9.6, 7.7 Hz, 1H), 4.19 (q, J = 7.1 Hz,
2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.10 (ddd, J = 14.8, 10.5, 1.9 Hz, 1H), 2.74, (ddd, J =
14.8, 7.8, 1.8 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H); 13C NMR (100MHz, CDCl3) δ 165.2,
156.3, 149.4, 149.1, 132.6, 129.0, 125.3, 120.3, 111.1, 108.9, 108.8, 86.1, 59.8, 56.0,
55.9, 34.1, 14.5; IR (thin film, cm-1) 2935, 1698, 1623, 1515, 1265, 1101, 1025; HRMS
(EI) calc’d for C17H20O5 304.1311, found 304.1311.
(E)-ethyl 5-(4-nitrostyryl)-4,5-dihydrofuran-3-carboxylate 2-18d

Reagents employed: formyldiazoacetate 2-8 (0.19g, 1.4 mmol), (E)-1-(buta-1,3-dien-1yl)-4-nitrobenzene (0.054g, 0.31 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3benzenedipropionic acid)] (2mg, 0.0031 mmol), DCM (5ml): yield 29% (0.026g, 0.09
mmol) as a dark orange oil; Rf = 0.41, 20% EtOAc/hexanes; Reagents employed:
cyclopropane/dihydrofuran mixture (0.026g, 0.09 mmol), Sc(OTf)3 (2mg, 0.0045 mmol),
DCM (0.75ml): yield 100% (0.026g, 0.09 mmol) as a dark yellow oil; Rf = 0.41, 20%
EtOAc/hexanes; 1H NMR δ 8.21-8.16 (m, 2H), 7.54-7.51 (m, 2H), 7.28 (brs, 1H), 6.69
(d, J = 15.8 Hz, 1H), 6.44 (dd, J = 15.9, 6.5 Hz, 1H), 5.42 (dt, J = 10.6, 7.1 Hz, 4.19 (q, J
= 7.1 Hz, 2H), 3.15 (ddd, J = 14.7, 10.7, 1.4 Hz, 1H), 2.74 (ddd, J = 14.8, 7.7, 1.5 Hz,
1H), 1.28 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 165.1, 156.1, 147.4, 142.5,
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132.3, 129.8, 127.4, 124.2, 109.0, 84.7, 60.1, 34.2, 14.5; IR (cm-1) 2981, 1698, 1514,
1340, 1097; HRMS (EI) calc’d for C15H15NO5 289.0950, found 289.0963.
(E)-ethyl 5-(2-methylstyryl)-4,5-dihydrofuran-3-carboxylate 2-18e

Reagents employed: formyldiazoacetate 2-8 (0.24g, 1.7 mmol), (E)-1-(buta-1,3-dien-1yl)-2-methylbenzene (0.12g, 0.86 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3benzenedipropionic acid)] (6mg, 0.0086 mmol), DCM (7.4ml): yield 50% (0.11g, 0.43
mmol) as a yellow oil; Rf = 0.5, 20% EtOAc/hexanes; Reagents employed:
cyclopropane/dihydrofuran mixture (0.11g, 0.43 mmol), Sc(OTf)3 (0.01g, 0.022 mmol),
DCM (3ml): yield 100% (0.11g, 0.43 mmol) as a dark yellow oil; Rf = 0.5, 20%
EtOAc/hexanes; 1H NMR (600 MHz, CDCl3) δ 7.46-7.43 (m, 1H), 7.29 (br s, 1H), 7.197.14 (m, 3H), 6.86 (d, J = 15.6 Hz, 1H), 6.17 (dd, J = 15.7, 7.3 Hz, 1H), 5.41 (dt, J = 10.3,
8.1 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.12 (ddd, J = 14.8, 10.5, 1.9 Hz, 1H), 2.75 (ddd, J
= 14.7, 8.1, 1.9 Hz, 1H), 2.36 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz,
CDCl3) δ 165.4, 156.5, 135.8, 135.0, 130.5, 130.4, 128.6, 128.1, 126.2, 125.8, 108.8,
86.1, 59.9, 34.2, 19.8, 14.4; IR (cm-1) 2980, 1699, 1622, 1095, 749; HRMS (EI) calc’d
for C16H18O3 258.1256, found 258.1257.
(E)-ethyl 5-(4-fluorostyryl)-4,5-dihydrofuran-3-carboxylate 2-18f

Reagents employed: formyldiazoacetate 2-8 (0.25g, 1.8 mmol), (E)-1-(buta-1,3-dien-1yl)-4-fluorobenzene (0.13g, 0.88 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3benzenedipropionic acid)] (7mg, 0.0088 mmol), DCM (7.5ml): yield 65% (0.15g, 0.57
mmol) as a yellow oil and mixture of cyclopropane and oxepine; Rf = 0.52, 30%
EtOAc/hexanes; Reagents employed: cyclopropane/dihydrofuran mixture (0.15g, 0.57
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mmol), Sc(OTf)3 (0.014g, 0.028 mmol), DCM (3ml): yield 98% (0.14g, 0.56 mmol) as a
yellow oil; Rf = 0.52, 30% EtOAc/hexanes; 1H NMR (600 MHz, CDCl3) δ 7.37-7.36
(AA’BB’, 2 H), 7.27 (t, J = 1.8 Hz, 1 H), 7.03-7.00 (AA’BB’, 2 H), 6.60 (d, J = 15.8 Hz, 1
H), 6.19 (dd, J = 15.8, 7.2 Hz, 1 H), 5.36 (dt, J = 9.9, 7.5 Hz, 1 H), 4.19 (q, J = 7.1 Hz, 2
H), 3.10 (ddd, J = 14.8, 10.5, 1.8 Hz, 1 H), 2.73 (ddd, J = 14.8, 7.9, 1.8 Hz, 1 H), 1.28 (t,
J = 7.1 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 165.2, 162.7 (d, 1JCF = 247.7 Hz),
156.3, 132.2 (d, 4JCF = 3.4 Hz), 131.4, 128.4 (d, J3C-F = 8.1 Hz), 127.2, 115.7 (d, 2JCF =
21.7 Hz), 108.9, 85.6, 59.9, 34.1, 14.5; 19F NMR (376 MHz, CDCl3) δ -113.42-(113.34); IR (thin film, cm-1) 2982, 1700, 1625, 1509, 1229, 1108, 755; HRMS (EI)
calc’d for C15H15FO3 262.1005, found 262.0996.
General procedure for the conversion of dihydrooxepines to dihydrofurans (2-14)
In a round bottom flask containing the starting dihydrooxepine and stir bar was added
DCM (0.12M) and Sc(OTf)3 (5 mol%) under argon gas. The reaction was heated to reflux
for the allotted time. The reaction was then cooled to room temperature and filtered
through celite eluting with DCM. Solvent was then removed under reduced pressure or
with a stream of nitrogen gas for the more volatile compounds. The compounds either
required no further purification or column chromatography eluting with EtOAc/hexanes
or Et2O/pentane.
Ethyl 4,6a-dihydro-3aH-cyclopenta[b]furan-3-carboxylate 2-14a

Reagents employed: Dihydrooxepine 2-13a (0.11g, 0.63 mmol), Sc(OTf)3 (0.016g,
0.032mmol), DCM (5ml): yield 98% (0.11g, 0.63 mmol) as a dark purple oil with a
reaction time of one hour with no further purification required; Rf = 0.59, 30%
EtOAc/hexanes; 1H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 1.4 Hz, 1H), 6.08-6.05 (m,
1H), 5.81-5.76 (m, 2H), 4.17 (q, J = 7.4 Hz, 2H), 3.79-3.74 (m, 1H), 2.76-2.68 (m, 1H),
2.57-2.50 (m, 1H), 1.25 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 165.5, 155.6,
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136.9, 128.3, 113.1, 95.4, 59.8, 42.2, 39.2, 14.6; IR (thin film, cm-1) 2931, 1702, 1622,
1104, 1028, 775; HRMS (EI) calc’d for C10H12O3 180.0786, found 180.0791.
Ethyl 3a,4,5,7a-tetrahydrobenzofuran-3-carboxylate 2-14b

Reagents employed: Dihydrooxepine 2-13b (0.084g, 0.43 mmol), Sc(OTf)3 (0.011g,
0.022 mmol), DCM (3.6ml): yield 93% (0.078g, 0.4 mmol) as a dark purple oil with a
reaction time of one hour and purified by column chromatography eluting with 15%
EtOAc in hexanes; Rf = 0.61, 30% EtOAc/hexanes; 1H NMR (600 MHz, CDCl3) δ 7.30
(brs, 1H), 6.25-6.21 (m, 1H), 5.98-5.95 (m, 1H), 4.92-4.89 (m, 1H), 4.24-4.19 (m, 2H),
3.10-3.06 (m, 1H), 2.17-2.08 (m, 2H), 1.96-1.89 (m, 1H), 1.38-1.34 (m, 1H), 1.31 (t, J =
7.1 Hz, 3H); 13C NMR δ 165.4, 157.1, 134.8, 123.2, 114.2, 81.0, 59.7, 38.6, 24.8, 23.1,
14.5; IR (thin film, cm-1) 2929, 1708, 1616, 1098, 905, 766; HRMS (EI) calc’d for
C11H14O3 194.0943, found 194.0942.
Ethyl 5-methyl-5-(prop-1-en-2-yl)-4,5-dihydrofuran-3-carboxylate 2-14c

Reagents employed: Dihydrooxepine 2-13c (0.05g, 0.25 mmol), Sc(OTf)3 (6mg, 0.012
mmol), DCM (2ml): yield 74% (0.037g, 0.19 mmol) as a yellow oil with a reaction time
of five hours and purified by column chromatography eluting with 5% Et 2O in pentane
and concentrated with nitrogen gas; Rf = 0.33, 10% EtOAc/hexanes; 1H NMR (400
MHz, CDCl3) δ 7.22 (t, J = 2.0 Hz, 1H), 4.99 (brs, 1H), 4.83 (brs, 1H), 4.17 (q, J = 7.1
Hz, 2H), 2.87, 2.63 (ABq, JAB = 14.6 Hz, 2H; with each signal split into a doublet due to
4

JCH = 1.8 Hz coupling with the methine proton), 1.78 (s, 3H), 1.49 (s, 3H), 1.27 (t, J =

7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 165.6, 155.5, 146.9, 110.2, 107.9, 93.2,
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59.9, 39.5, 26.2, 18.5, 14.6; IR (cm-1) 2978, 1700, 1624, 1101; HRMS (EI) calc’d for
C11H16O3 196.1099, found 196.1102.
Ethyl 5-methyl-5-vinyl-4,5-dihydrofuran-3-carboxylate 2-14d

Reagents employed: Dihydrooxepine (2-13d,e) (0.12g, 0.69 mmol), Sc(OTf)3 (0.017g,
0.034 mmol), DCM (6ml): yield 65% (0.082g, 0.45 mmol) as a yellow oil purified by
column chromatography eluting with 5% Et2O in pentane and concentrated with nitrogen
gas; Rf = 0.54, 10% EtOAc/hexanes; 1H NMR (400 MHz, CDCl3) δ = 7.18 (t, J = 1.8 Hz,
1H), 5.95 (dd, J = 17.2, 10.8 Hz, 1H), 5.21 (d, J = 17.3 Hz, 1H), 5.08 (d, J = 10.8 Hz,
1H), 4.14 (q, J = 7.1 Hz, 2H), 2.81, 2.65 (ABq, JAB = 14.6 Hz, 2H; with each signal split
into a doublet due to 4JCH = 1.8 Hz coupling with the methine proton), 1.46 (s, 3H), 1.25
(t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 165.4, 155.4, 140.9, 113.0, 107.9,
90.8, 59.8, 39.9, 26.4, 14.5; IR (cm-1) 2978, 1700, 1622, 1099; HRMS (EI) calc’d for
C10H14O3 182.0943, found 182.0945.
General procedure for the conversion of dihydrofuran to dihydropyrrole (2-21)
In a microwave vial or sealed tube containing magnetic stir bar and capped with a rubber
septum under argon gas was added the starting dihydrofuran (1 equiv.) followed by dry
toluene (0.12M). In the following order was added benzylamine or p-anisidine (5 equiv.
or 3 equiv. respectively), p-TsOH·H2O (0.25 mol%) and Pd(PPh3)4 (6 mol%) under
argon. The rubber septum was replaced with a microwave vial cap or sealed tube cap and
heated to 100 ˚C overnight. The reaction was cooled to room temperature and
concentrated under reduced pressure. The residue was purified by column
chromatography (EtOAc/Hexanes) to yield the desired compounds (2-21a-j).
Ethyl 1-benzyl-1,3a,4,6a-tetrahydrocyclopenta[b]pyrrole-3-carboxylate 2-21a
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Reagents employed: dihydrofuran 2-14a (0.37g, 2.0 mmol), benzylamine (1.0ml, 10.0
mmol), Tetrakis(triphenylphosphine)palladium(0) (0.14g, 0.12 mmol), p-Toluenesulfonic
acid monohydrate (0.095g, 0.5 mmol), toluene (17ml): yield 75% (0.41g, 1.5 mmol) as an
orange oil; Rf = 0.37, 30% EtOAc/hexanes; 1H NMR (600 MHz, CDCl3) δ 7.38-7.27
(m, 4H), 7.26-7.25 (m, 1H), 7.04 (d, J = 1.0 Hz, 1H), 5.99-5.96 (m, 1H), 5.66-5.63 (m, 1
H), 5.72-5.68 (m, 1 H), 4.36, 4.28 (ABq, JAB = 15.0, 2H), 4.19-4.06 (m, 2 H), 3.88 (dddd,
J = 10.6, 8.3, 2.7, 1.0 Hz, 1 H), 2.81-2.73 (m, 1 H), 2.62-2.55 (m, 1 H), 1.24 (t, J = 7.1
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 166.7, 148.9, 137.0, 135.6, 128.9, 128.1,
127.9, 126.9, 103.9, 73.5, 58.8, 52.6, 43.3, 40.9, 14.8; IR (thin film, cm-1) 2918, 1671,
1582, 1167, 1086, 698; HRMS (EI) calc’d for C17H19NO2 269.1416, found 269.1417.
Ethyl 1-(4-methoxyphenyl)-1,3a,4,6a-tetrahydrocyclopenta[b]pyrrole-3-carboxylate
2-21b

Reagents employed: dihydrofuran (2-14a) (1.32g, 7.4 mmol), 4-methoxyaniline (2.82g,
22.9 mmol), Tetrakis(triphenylphosphine)palladium(0) (0.51g, 0.44 mmol), pToluenesulfonic acid monohydrate (0.35g, 1.8 mmol), toluene (62ml): yield 75% (1.58g,
5.5 mmol) as a pale brown solid; Rf = 0.44, 30% EtOAc/hexanes; melting point: 61.662.0 °C; 1H NMR (600 MHz, CDCl3) δ 7.51 (d, J = 1.2 Hz, 1H), 6.93-6.91 (AA’BB’,
2H), 6.86-6.83 (AA’BB’ m, 2H), 6.03-6.01 (m, 1H), 5.88-5.85 (m, 1H), 5.33=5.30 (m,
1H), 4.22-4.13 (m, 2H), 3.97 (br t, J = 9.1 Hz, 1H), 3.76 (s, 3H), 2.87-2.81 (m, 1H), 2.662.64 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 166.4, 154.6,
140.7, 135.9, 134.9, 126.6, 116.2, 166.0, 115.1, 108.9, 72.8, 59.2, 55.7, 42.9, 40.2, 14.8;
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IR (thin film, cm-1) 2928, 1679, 1596, 1514, 1243, 1211, 1100, 1034, 819; HRMS (EI)
calc’d for C17H19NO3 285.1365, found 285.1367.
Ethyl 1-benzyl-3a,4,5,7a-tetrahydro-1H-indole-3-carboxylate 2-21c

Reagents employed: dihydrofuran (2-14b) (0.078g, 0.4 mmol), benzylamine (0.22ml, 2
mmol), Tetrakis(triphenylphosphine)palladium(0) (0.028g, 0.024 mmol), pToluenesulfonic acid monohydrate (0.019g, 0.1 mmol) toluene (3.3ml): yield 70%
(0.079g, 0.28 mmol) as a yellow oil; Rf = 0.4, 20% EtOAc/hexanes; 1H NMR (600 MHz,
CDCl3) δ 7.36-7.33 (m, 2H), 7.30-7.27 (m, 1H), 7.25-7.23 (m, 2H), 7.13 (s, 1H), 6.106.07 (m, 1H), 5.79-5.76 (m, 1H), 4.35 (ABq, JAB = 15.0 Hz, 1H), 4.18-4.09 (overlapped
of quartet with ABq, 3H), 3.77-3.74 (m, 1H), 2.99 (ddd, J = 11.5, 9.5, 4.5 Hz, 1H), 2.102.05 (m, 1H), 2.01-1.97 (m, 1H), 1.95-1.88 (m, 2H), 1.36 (qd, J = 11.7, 4.5 Hz, 1H), 1.25
(t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 166.4, 150.3, 136.6, 133.4, 128.9,
128.8, 128.2, 127.9, 121.9, 105.9, 60.0, 58.9, 51.9, 39.4, 24.5, 23.6, 14.8; IR (cm-1) 2925,
1669, 1578, 1139; HRMS (EI) calc’d for C18H21NO2 283.1572, found 283.1558.
Ethyl 1-benzyl-5-methyl-5-(prop-1-en-2-yl)-4,5-dihydro-1H-pyrrole-3-carboxylate 221d

Reagents employed: dihydrofuran (2-14c) (0.048g, 0.24 mmol), benzylamine (0.13ml,
1.2 mmol), Tetrakis(triphenylphosphine)palladium(0) (0.017g, 0.014 mmol), pToluenesulfonic acid monohydrate (0.011g, 0.06 mmol) toluene (2ml): yield 70%
(0.047g, 0.16 mmol) as a yellow oil; Rf = 0.47, 20% EtOAc/hexanes; 1H NMR (600
MHz, CDCl3) δ 7.36-7.33 (m, 3H), 7.30-7.28 (m, 1H), 7.25-7.24 (m, 2H), 7.00 (br s, 1H),
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4.98 (d, J = 8.4 Hz, 2H), 4.12-4.08 (overlapped of quartet with ABq, 3H) 3.99 (ABq, JAB =
14.6 Hz, 1H), 2.94, 2.63 (ABq, JAB = 15.0 Hz, 2H; with each signal split into a doublet
due to 4JCH = 1.3 Hz coupling with the methine proton), 1.79 (s, 3H), 1.40 (s, 3H), 1.22 (t,
J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.7, 148.8, 146.8, 137.8, 128.9, 128.4,
127.8, 112.8, 98.4, 71.6, 58.9, 48.5, 41.6, 23.6, 19.0, 14.8; IR (cm-1) 2977, 1633, 1591,
1145; HRMS (EI) calc’d for C18H23NO2 285.1729, found 285.1716.
Ethyl 1-benzyl-5-methyl-5-vinyl-4,5-dihydro-1H-pyrrole-3-carboxylate 2-21e

Reagents employed: dihydrofuran (2-14d) (0.051g, 0.28 mmol), benzylamine (0.15ml,
1.4 mmol), Tetrakis(triphenylphosphine)palladium(0) (0.019g, 0.017 mmol), pToluenesulfonic acid monohydrate (0.013g, 0.07 mmol), toluene (2.3ml): yield 75%
(0.057g, 0.21 mmol) as a red oil; Rf = 0.39, 20% EtOAc/hexanes; 1H NMR (600 MHz,
CDCl3) δ 7.36-7.33 (m, 2H), 7.30-7.27 (m, 1H), 7.25-7.24 (m, 2H), 6.97 (br s, 1H), 5.98
(dd, J = 17.4, 10.7 Hz, 1H), 5.20 (d, J = 14.7 Hz, 1H), 5.17 (d, J = 7.9 Hz, 1H), 4.14-4.08
(overlapped of quartet with ABq, 3H), 4.05 (ABq, JAB = 14.8 Hz, 1H), 2.85, 2.72 (ABq,
JAB = 14.7 Hz, 2H), 1.36 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ
166.7, 148.8, 141.5, 138.2, 128.8, 128.2, 127.7, 114.5, 98.7, 69.4, 58.9, 48.5, 43.0, 22.1,
14.8; IR (cm-1) 2975, 1671, 1590, 1146, 1075; HRMS (EI) calc’d for C17H21NO2
271.1572, found 271.1571.
(E)-ethyl 1-benzyl-5-styryl-4,5-dihydro-1H-pyrrole-3-carboxylate 2-21f

Reagents employed: dihydrofuran (2-18a) (0.095g, 0.39 mmol), benzylamine (0.21ml,
1.9 mmol), Tetrakis(triphenylphosphine)palladium(0) (0.027g, 0.023 mmol), p-

76

Toluenesulfonic acid monohydrate (0.018g, 0.097 mmol), toluene (3.2ml): yield 70%
(0.091g, 0.27 mmol) as an orange oil; Rf = 0.42, 20% EtOAc/hexanes; 1H NMR (400
MHz, CDCl3) δ 7.38-7.27 (m, 7H), 7.25-7.21 (m, 2H), 7.17 (brs, 1H), 6.43 (d, J = 15.8
Hz, 1H), 6.18 (dd, J = 15.8, 8.7 Hz, 1H), 4.31 (ABq, JAB = 14.9 Hz, 1H), 4.24 (dt, J =
10.8, 9.1 Hz, 1H), 4.17-4.08 (overlapped of quartet with ABq, 3H), 3.07 (ddd, J = 14.9,
11.1, 1.1 Hz, 1H), 2.68 (ddd, J = 14.9, 9.2, 1.3 Hz, 1H), 1.26 (t, J = 7.1 Hz, 1H); 13C
NMR (100 MHz, CDCl3) δ = 166.4, 150.3, 136.8, 136.4, 133.3, 128.9, 128.8, 128.5,
128.3, 128.1, 127.8, 126.6, 100.6, 66.1, 59.1, 51.8, 35.4, 14.8; IR (cm-1) 2977, 1669,
1589, 1167, 1070; HRMS (EI) calc’d for C22H23NO2 333.1729, found 333.1730.
(E)-ethyl 1-benzyl-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrrole-3-carboxylate 2-21g

Reagents employed: dihydrofuran (2-18b) (0.043g, 0.16 mmol), benzylamine (0.08ml,
0.8 mmol), Tetrakis(triphenylphosphine)palladium(0) (0.012g, 0.01 mmol), pToluenesulfonic acid monohydrate (6mg, 0.03 mmol), toluene (1.3ml): yield 72%
(0.042g, 0.11 mmol) as a yellow oil; Rf = 0.38, 30% EtOAc/hexanes; 1H NMR (CDCl3,
600 MHz) δ 7.36-7.33 (m, 2H), 7.31-7.28 (m, 3H), 7.23-7.21 (m, 2H), 7.17 (br s, 1H),
6.88-6.85 (AA’BB’, 2H), 6.37 (d, J = 15.7 Hz, 1H), 6.03 (dd, J = 15.7, 8.8 Hz, 1H), 4.29,
4.10 (ABq, JAB = 14.9 Hz, 2H), 4.21 (dt, J = 11.0, 9.0 Hz, 1H), 4.14 (qd, J = 7.1, 2.3 Hz,
2H), 3.82 (s, 3H), 3.05 (ddd, J = 15.0, 11.1, 1.1 Hz, 1H), 2.66 (ddd, J = 14.9, 9.3, 1.3 Hz,
1H), 1.25 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.5, 159.6, 150.3, 136.9,
132.8, 129.1, 128.8, 128.3, 127.9, 127.8, 126.3, 114.2, 100.5, 66.3, 59.0, 55.4, 51.7, 35.5,
14.8; IR (thin film, cm-1) 2930, 1674, 1592, 1511, 1248, 1178, 1075, 700; HRMS (EI)
calc’d for C23H23NO3 363.1834, found 363.1824.
(E)-ethyl 1-benzyl-5-(3,4-dimethoxystyryl)-4,5-dihydro-1H-pyrrole-3-carboxylate 218h
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Reagents employed: dihydrofuran (2-18c) (0.05g, 0.16 mmol), benzylamine (0.09ml, 0.8
mmol), Tetrakis(triphenylphosphine)palladium(0) (0.011g, 0.0096 mmol), pToluenesulfonic acid monohydrate (8mg, 0.04 mmol), toluene (1.3ml): yield 85%
(0.054g, 0.14 mmol) as a light yellow oil; Rf = 0.24, 30% EtOAc/hexanes; 1H NMR
(CDCl3, 600 MHz) δ 7.36-7.33 (m, 2H), 7.31-7.28 (m, 1H), 7.24-7.22 (m, 2H), 7.18 (brs,
1H), 6.91-6.88 (m, 2H), 6.82 (d, J = 8.2 Hz, 1H), 6.36 (d, J = 15.7 Hz, 1H), 6.03 (dd, J =
15.7, 8.8 Hz, 1H), 4.30 (ABq, JAB = 15.0 Hz, 1H), 4.23 (dt, J = 11.3, 9.0 Hz, 1H), 4.164.10 (overlapped of quartet with ABq, 3H), 3.91 (s, 3H), 3.89 (s, 3H), 3.06 (ddd, J = 15.0,
11.1, 1.1 Hz, 1H), 2.68 (ddd, J = 15.0, 9.1, 1.3 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H); 13C
NMR (150 MHz, CDCl3) δ 166.5, 150.4, 149.3, 149.2, 136.9, 132.9, 129.5, 128.9, 128.3,
127.8, 126.5, 120.0, 111.2, 108.8, 100.5, 66.3, 59.1, 56.1, 56.0, 51.8, 35.5, 14.8; IR (cm) 2933, 1669, 1588, 1512, 1263, 1137, 1071; HRMS (EI) calc’d for C24H27NO4
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393.1940, found 393.1921.
(E)-ethyl 1-benzyl-5-(2-methylstyryl)-4,5-dihydro-1H-pyrrole-3-carboxylate 2-21i

Reagents employed: dihydrofuran (2-18e) (0.05g, 0.19 mmol), benzylamine (0.1ml, 0.95
mmol), Tetrakis(triphenylphosphine)palladium(0) (0.013g, 0.011 mmol), pToluenesulfonic acid monohydrate (9mg, 0.047 mmol), toluene (1.6ml): yield 66%
(0.043g, 0.12 mmol) as a dark yellow oil; Rf = 0.4, 20% EtOAc/hexanes; 1H NMR (400
MHz, CDCl3) δ 7.42-7.29 (m, 4H), 7.26-7.15 (m, 6H), 6.65 (d, J = 15.6 Hz, 1H), 6.07
(dd, J = 15.6, 8.8 Hz, 1H), 4.33 (ABq, JAB = 14.9 Hz, 1H), 4.27 (dt, J = 11.0, 9.3 Hz, 1H),
4.19-4.12 (overlapped of quartet with ABq, 3H), 3.09 (dd, J = 14.8, 11.2 Hz, 1H), 2.70
(ddd, J = 14.9, 9.3, 1.3 Hz, 1H), 2.33 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100
MHz, CDCl3) δ 166.4, 150.4, 136.8, 135.6, 135.5, 131.2, 130.4, 129.8, 128.8, 128.3,
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127.9, 127.8, 126.3, 125.9, 100.5, 66.3, 59.1, 51.8, 35.5, 19.9, 14.8; IR (cm-1) 2977,
1670, 1590, 1168, 1072; HRMS (EI) calc’d for C23H25NO2 347.1885, found 347.1883.
(E)-ethyl 1-benzyl-5-(4-fluorostyryl)-4,5-dihydro-1H-pyrrole-3-carboxylate 2-21j

Reagents employed: dihydrofuran (2-18f) (0.08g, 0.3 mmol), benzylamine (0.16ml, 1.5
mmol), Tetrakis(triphenylphosphine)palladium(0) (0.021g, 0.018 mmol), pToluenesulfonic acid monohydrate (0.014g, 0.075 mmol), toluene (2.5ml): yield 68%
(0.072g, 0.2 mmol) as an orange oil; Rf = 0.34, 20% EtOAc/hexanes; 1H NMR (400
MHz, CDCl3) δ 7.37-7.28 (m, 5H, 7.23-7.21 (m, 2H), 7.17 (t, J = 1.2 Hz, 1H), 7.04-6.99
(m, 2H), 6.39 (d, J = 15.8 Hz, 1H), 6.08 (dd, J = 15.8, 8.7 Hz, 1H), 4.30 (ABq, JAB = 14.9
Hz, 1H), 4.22 (dt, J = 10.8, 9.0 Hz, 1H), 4.17-4.08 (overlapped of quartet with ABq, 3H),
3.06 (ddd, J = 15.0, 11.1, 1.1 Hz, 1H), 2.66 (ddd, J = 15.0, 9.3, 1.3 Hz, 1H), 1.25 (t, J =
7.1 Hz, 3H); 13C NMR 166.4, 162.6 (d, 1JCF = 247.4 Hz), 150.3, 136.8, 132.5 (d, 4JCF =
3.4 Hz), 132.0, 128.8, 128.33, 128.31, 128.26, 128.23, 128.1, 127.8, 115.7 (d, 2JCF = 21.6
Hz), 100.6, 66.1, 59.1, 51.9, 35.4, 14.8 ; 19F{1H} NMR (376 MHz, CDCl3) δ -113.73; IR
(cm-1) 2923, 1671, 1590, 1507, 1226, 1168, 1071; HRMS (EI) calc’d for C22H22FNO2
351.1635, found 351.1629.
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Chapter 3

3

Synthesis of (±)-β-Allokainic Acid

This chapter was adapted from the following manuscript:
Piotrowski, M. L.; Kerr, M. A. Eur. J. Org. Chem. 2019, 3122-3126.

3.1 Introduction
The kainoid amino acids are a family of compounds that have gained considerable
attention due to their biological properties such as neuroexcitatory and excitotoxic
activities.108–111 α-kainic acid (3-1a) and its related structures (Figure 3-1) have been
found to behave as agonists for the glutamate receptors mediating the effects of Lglutamic acid and thus have been extensively used for the elucidation of the
neurophysiological role of glutamic acid.109,113

Figure 3-1. Kainoid family of compounds. Natural and unnatural

It has been shown that when in direct contact with neurons, α-kainic acid can induce
motor hyperactivity and seizures and can destroy neurons in specific regions that contain
high concentrations of the molecule.108,109 This discovery helped to create model
conditions for human diseases such as epilepsy, Huntington’s chorea and stroke.109,111
Through the continuous study of the biological properties of the family of kainoid
compounds, a better understanding of the structure activity relationship was obtained. It
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was found that the stereochemistry around the pyrrolidine ring plays an important part in
the biological activity of the molecule; the 2,3-trans-3,4-cis compounds showed potent
activity whereas in 3-epi (2,3-cis) or 4-epi (3,4-trans) showed a dramatic reduction in
activity.113
We have recently shown the formation of substituted 2,5-dihydrooxepine rings (3-5)
through a vinylogous Cloke-Wilson rearrangement (Scheme 3-1) of donor-acceptor
cyclopropanes such as (3-4) and subsequent transformations that offer ready formation of
dihydropyrroles such as (3-6).133 This compound was deemed a viable synthetic precursor
to target the kainoid family of compounds. Our efforts towards the synthesis of members
of the kainoids, resulting in the successful synthesis of (±)-β-allokainic acid, are
described herein.

Scheme 3-1. Formation of 2,5-dihydrooxepines through a vinylogous Cloke-Wilson rearrangement of
donor-acceptor cyclopropanes and subsequent steps towards dihydropyrrole

3.2 Results and Discussion
Our original target compound was (±)-α-kainic acid (3-1a)134–139 which was envisioned to
be obtained by basic hydrolysis of intermediate (3-7) which could be obtained from (3-8)
through oxidatively cleaving the olefin to the di-acid followed by esterification (Scheme
3-2). The benzyl group in this oxidation step will most likely oxidize to a benzoyl group.
The isopropenyl moiety can be formed via dehydration of the tertiary alcohol. Compound
(3-8) would be obtained from (3-6) through a vinylogous carbamate double bond
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reduction and Grignard addition with methylmagnesium bromide to form the tertiary
alcohol. And finally, compound (3-6) can be obtained as shown in our previous work
(Scheme 3-1).

Scheme 3-2. Retrosynthetic analysis towards kainic acid

The vinylogous carbamate double bond in (3-6) was reduced with sodium borohydride in
acetic acid140 providing the major diastereomer (3-9a) in a 60% yield and minor
diastereomer (3-9b) in a 4% yield. At this time, it was still unclear as to which
diastereomer was obtained. Treatment of (3-9a) with methylmagnesium bromide
furnished the tertiary alcohol (3-8). Subjecting this compound to a variety of oxidative
reactions resulted in extensive decomposition (Scheme 3-3a). Taking compound (3-8)
and subjecting it towards Upjohn dihydroxylation conditions did furnish the desired diol
(3-11); however, attempts at cleaving the diol to the di-aldehyde (3-12) resulted in
decomposition (Scheme 3-3b). Attempts at protecting the tertiary alcohol (3-8) prior to
the oxidation step was also unsuccessful (Scheme 3-3c).
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Scheme 3-3. (a) Synthetic efforts towards the di-acid moiety. Conditions: (a) Oxone, OsO4, DMF; (b)
RuCl3, NaIO4, CCl4, CH3CN, H2O; (c) RuO2, NaIO4, EtOAc, H2O; (d) 1) O3 2) HCO2H, H2O2; (3b)
Attempted Johnson-Lemieux oxidation; (3c). Attempts at tertiary alcohol protection. Conditions: (a)
MOMCl, NaI, DIPEA, DME; (b) Ac2O, DMAP, DCM; (c) Ac2O, NaOAc, 140 °C, MW.

Due to the electron donating ability of the benzyl group, it is believed that under
oxidative conditions, not only can the benzyl group oxidize to a benzoyl, but the C-5
position on the pyrrolidine ring could also potentially oxidize forming a lactam, which
could cause a mixture of products.141 Therefore, the removal of the benzyl group prior to
the oxidative cleavage step would be ideal.
Treatment of (3-9a) under Upjohn dihydroxylation conditions produced diol (3-14)
followed by acetonide protection using 2,2-dimethoxylpropane (2,2-DMP) and PPTS
producing acetonide (3-15). Transformation of the ester into the isopropenyl moiety
began by treating (3-15) with excess methylmagnesium bromide forming tertiary alcohol
(3-16). The use of Burgess reagent, known to be a very strong dehydrating agent for
tertiary alcohols142, provided the isopropenyl compound (3-17a) as the major isomer in a
50 % yield along with minor isopropylidene isomer (3-17b) in a 22% yield. After
chromatographic separation of the two isomers, (3-17a) was treated with ethyl
chloroformate forming carbamate (3-18)143 (Scheme 3-4).
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Scheme 3-4. Synthetic route to carbamate 3-18 and ultimate stereochemical confirmation

The stereochemistry of compound (3-18) was confirmed by comparing it with data
published by the Coldham group during their work towards kainic acid143. The assigned
stereochemistry was a disappointing revelation since the configuration of the isopropenyl
moiety would need to be epimeric to access kainic acid. Epimerization of the ester moiety
in (3-9a) or similar compounds was unsuccessful (Scheme 3-5). With this information in
hand we diverted our task to the synthesis of β-allokainic acid (3-1d).144

Scheme 3-5. Attempted epimerization’s

Starting from compound (3-17a), the benzyl group was replaced with a
benzyloxycarbonyl group, forming carbamate (3-23) (Scheme 3-6). Acetonide removal
yielded diol (3-24) which set the stage for oxidative cleavage. Many conditions involving
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sodium periodate were explored with all leading to decomposition. A switch in oxidant to
PhI(OAc)2 in DCM provided the crude di-aldehyde145 which was subjected to a double
Pinnick oxidation146 followed by derivatization as the methyl esters for ease of
purification. Thus, (3-25) was produced as a 1:1 mixture of rotamers (presumably as a
result of the CBz group) in an overall yield of 64% over the three steps. Finally, basic
hydrolysis provided (±)-β-allokainic acid (3-1d) in 60% yield.118,147

Scheme 3-6. Final synthetic steps towards (±)-β-allokainic acid

3.3 Conclusion
In summary, a synthesis of (±)-β-allokainic acid has been achieved in a linear sequence
of 12 steps with an overall yield of 3.5%. The synthesis of the pyrrolidine core (3-6) can
be achieved in three chemical operations employing our previously reported vinylogous
Cloke-Wilson rearrangement. Further manipulation to the final product is achieved
through simple chemical transformations with minimal purification steps required.
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3.5 Experimental
3.5.1

General Considerations

All reactions were conducted under an atmosphere of argon unless otherwise indicated.
DCM, toluene, DMF, THF, and benzene were dried and deoxygenated by passing the
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nitrogen purged solvents through activated alumina columns. All other solvents and
reagents were used as purchased from Sigma Aldrich, Alfa Aesar, Caledon, VWR or
Oakwood Chemicals and used as received. Reaction progress was monitored by TLC
(EM Science, silica gel 60 F254), visualized with UV light, and the plates developed with
p-anisaldehyde, vanillin, basic potassium permanganate or DMP stains. Column
chromatography was performed using silica gel (230-400 mesh, Silicycle Chemical
Division Inc).
NMR experiments were performed on Varian Mercury 400, Bruker AvIII 400, Inova 400
and Inova 600 MHz instruments with 13C operating frequencies of 100, 100, 100, and 125
MHz respectively. Chemical shifts are reported in ppm relative to the residual solvent
signal (CDCl3, referenced to residual CHCl3 at δ = 7.26 for 1H and δ = 77.1 for 13C; D2O
referenced at δ = 4.79 for 1H). Coupling constants (J) are reported in Hz, and
multiplicities of the signals are described using the following abbreviations: s = singlet, d
= doublet, t = triplet, q = quartet, quin = quintet, m = multiplet, br = broad. High
resolution mass spectra (HRMS) were obtained on a Thermo Scientific DFS mass
spectrometer using electron impact ionization. Melting points were determined using a
Digimelt MPA160 melting point apparatus from Stanford Research Systems (SRS).
Infrared spectra were obtained using a Bruker Alpha II Platinum ATR spectrometer or as
thin films on NaCl plates using a Bruker Vector 33 FT-IR instrument and are reported in
frequency of absorption (cm-1).

3.5.2

Procedures and characterization data

Procedure for vinylogous carbamate double bond reduction (3-9a,b):
A round bottom flask containing 3-6 (1.13g, 4.2 mmol) was dissolved in acetic acid
(35ml) under an open atmosphere. NaBH4 (0.79g, 21 mmol) was added slowly in small
portions at room temperature and the reaction was stirred for one hour. The reaction was
slowly quenched with water and extracted with DCM. The organic layers were washed
twice with saturated NaHCO3, once with brine, dried with MgSO4 and concentrated
under reduced pressure. The major isomer 3-9a was separated by flash chromatography
(EtOAc/hexanes); yield: 60% (0.68g, 2.5 mmol) as an orange oil; Rfmajor = 0.32, 20%
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EtOAc in hexanes; yield minor 3-9b: 4% (0.04g, 0.17 mmol) as an orange oil; Rfminor =
0.18, 20% EtOAc in hexanes.
(±)-(3S,3aS,6aS)-ethyl 1-benzyl-1,2,3,3a,4,6a-hexahydrocyclopenta[b]pyrrole-3carboxylate (3-9a)

H NMR (400 MHz, CDCl3) δ 7.36-7.28 (m, 4H), 7.25-7.23 (m, 1H), 5.70-5.68 (m, 1H),

1

5.42 (dq, J = 6.1, 2.1 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H), 3.84 (br d, J = 8.8 Hz, 1H) 3.75
(ABq, JAB = 12.8 Hz, 2H), 3.10-3.02 (m, 2H), 2.72-2.65 (m, 2H), 2.63-2.55 (m, 1H), 2.28
(dquin, J = 17.4, 2.4 Hz, 1H), 1.25 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ
174.3, 139.2, 131.4, 131.2, 129.2, 128.3, 127.1, 74.8, 60.6, 59.5, 56.6, 51.0, 43.3, 38.6,
14.3; IR (cm-1) 2799, 1729, 1159, 697; HRMS (EI) m/z calc’d for C17H21NO2 271.1572
(M+): found 271.1564.
(±)-(3R,3aS,6aS)-ethyl 1-benzyl-1,2,3,3a,4,6a-hexahydrocyclopenta[b]pyrrole-3carboxylate (3-9b)

H NMR (400 MHz, CDCl3) δ 7.37-7.29 (m, 4H), 7.25-7.22 (m, 1H), 5.91-5.88 (m, 1H),

1

5.68 (dq, J = 5.8, 2.2 Hz, 1H), 4.30 (br s, 1H), 4.14 (ddquin, J = 10.8, 7.2, 3.6 Hz, 2H),
3.79, 3.65 (ABq, JAB = 13.1 Hz, 2H), 3.24-3.15 (m, 2H), 2.89-2.85 (m, 1H), 2.69-2.61
(m, 1H), 2.50-2.43 (m, 1H), 2.14-2.07 (m, 1H), 1.26 (t, 7.1 Hz, 3H); 13C NMR (100
MHz, CDCl3) δ = 173.0, 134.5, 129.2, 128.7, 128.4, 128.1, 127.0, 72.8, 60.3, 56.6, 51.5,
47.5, 41.3, 35.9, 14.4; IR (cm-1) 2956, 1729, 1179, 697; HRMS (EI, source temp 250 °C)
m/z calc’d for C17H21NO2 271.1572 (M+): found 271.1569.
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Procedure for dihydroxylation reaction (3-14)
A round bottom flask containing 3-9a (1.36g, 5.0 mmol) was dissolved in 4:3 mixture of
THF:H2O (29:21ml) under an open atmosphere. A small crystal of OsO4 was added and
the reaction stirred for 10 minutes. NMO (0.7g, 6.0 mmol) was added and the reaction
was stirred overnight. Sodium sulfite (12 equiv.) was added and the reaction was stirred
for one hour. The reaction was diluted with brine and extracted with ethyl acetate. The
organic layer was dried with Na2SO4 and the solvent was removed under reduced
pressure providing the corresponding diol 3-14 as a white solid without the need for
further purification; yield = 90% (1.37g, 4.5 mmol); Rf = 0.15, 50% EtOAc in hexanes;
melting point: 119.8-120.2 °C.
(±)-(3S,3aS,5R,6S,6aR)-ethyl 1-benzyl-5,6dihydroxyoctahydrocyclopenta[b]pyrrole-3-carboxylate (3-14)

H NMR (400 MHz, CDCl3) δ 7.34-7.27 (m, 5H), 4.36 (br s, 1H), 4.11 (qd, J = 7.1, 1.1

1

Hz, 2H), 3.87, 3.52 (ABq, JAB = 13.0 Hz, 2H), 3.78 (br t, J = 3.3 Hz, 1H), 3.10 (dd, J =
8.9, 6.4 Hz, 1H), 3.06-3.01 (m, 2H), 2.66-2.58 (m, 1H), 2.43 (dd, J = 10.9, 8.9 Hz, 1H),
2.06-1.96 (m, 2H), 1.91 (br s, 1H), 2.03-1.98 (m, 2H), 1.83 (ddd, J = 13.5, 6.1, 2.4 Hz,
1H), 1.25 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 173.7, 138.9, 128.9, 128.5,
127.4, 77.3, 77.2, 74.0, 60.7, 59.4, 57.7, 50.1, 42.9, 36.7, 14.3; IR (cm-1) 3404, 3315,
2966, 1734, 1100; HRMS (EI) m/z calc’d for C17H23NO4 305.1627 (M+), found
305.1628.
Procedure for acetonide protection (3-15)
Diol 3-14 (1.46g, 4.8 mmol) was placed in a round bottom flask under an argon gas
atmosphere. DMF (40ml) was added followed by 2,2-dimethoxypropane (40ml). PPTS
(1.20g, 4.8 mmol) was added and the reaction was warmed to 50 ˚C overnight. The
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reaction was cooled to room temperature, diluted with water and extracted with ether.
The organic extracts were washed with saturated NaHCO3, water, brine, dried with
Na2SO4 and concentrated. Column chromatography eluting with EtOAc/hexanes
provided the final product as a yellow oil; yield 92% (1.51g, 4.4 mmol); Rf = 0.31, 20%
EtOAc in hexanes.
(±)-(3aS,3bR,6S,6aS,7aR)-ethyl 4-benzyl-2,2-dimethyloctahydro[1,3]dioxolo[4',5':4,5]cyclopenta[1,2-b]pyrrole-6-carboxylate (3-15)

H NMR (600 MHz, CDCl3) δ 7.32-7.27 (m, 4H), 7.25-7.22 (m, 1H), 4.81 (t, J = 5.3 Hz,

1

1H), 4.46 (d, J = 5.3 Hz, 1H), 4.13-4.09 (q, J = 7.1 Hz, overlapped with ABq, J = 13.3 Hz,
3H), 3.27 (ABq, J = 13.4 Hz, 1H), 3.20 (dd, J = 9.6, 7.9 Hz, 1H), 3.10-3.06 (m, 1H), 3.01
(d, J = 7.2 Hz, 1H), 2.68 (td, J = 8.2, 3.5 Hz, 1H), 2.42 (dd, J = 9.7, 8.5 Hz, 1H), 2.30 (dd,
J = 13.9, 7.8 Hz, 1H), 1.81 (ddd, J = 14.4, 10.1, 4.8 Hz, 1H), 1.46 (s, 3H), 1.31 (s, 3H),
1.23 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 174.6, 138.9, 128.7, 128.4,
127.1, 110.0, 83.9, 83.0, 76.2, 60.8, 58.1, 57.4, 47.6, 45.3, 39.3, 26.9, 24.6, 14.3; IR (cm) 2981, 1730, 1370, 1158, 1048, 700; HRMS (EI) m/z calc’d for C20H27NO4 345.1940

1

(M+), found 345.1938.
Procedure for Grignard addition (3-16)
Starting material 3-15 (1.51g, 4.4 mmol) was placed in round bottom flask under an
argon gas atmosphere. THF (37ml) was added and the reaction was cooled to 0 ˚C in an
ice/water bath. MeMgBr (3.0M in diethyl ether, 7.2 ml, 21.8 mmol) was added dropwise
over five minutes. The ice/water bath was removed, and the reaction was stirred at room
temperature for 1.5 hours. The reaction was cooled back to 0 ˚C and slowly quenched
with saturated ammonium chloride. The aqueous layer was extracted with ethyl acetate.
The combined organic layers were washed with brine, dried with Na 2SO4, and
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concentrated to give 3-16 as a yellow oil without the need of any further purification;
yield = 99% (1.43g, 4.3 mmol); Rf = 0.07, 30% EtOAc in hexanes.
(±)-2-((3aS,3bR,6S,6aS,7aR)-4-benzyl-2,2-dimethyloctahydro[1,3]dioxolo[4',5':4,5]cyclopenta[1,2-b]pyrrol-6-yl)propan-2-ol (3-16)

H NMR (400 MHz, CDCl3) δ 7.20-7.25 (m, 4H), 7.23-7.18 (m, 1H), 4.77 (t, J = 5.1 Hz,

1

1H), 4.42 (d, J = 5.1 Hz, 1H), 4.07, 3.14 (ABq, J = 13.3 Hz, 2H), 2.97 (dd, J = 9.4, 7.8
Hz, 1H), 2.80 (d, J = 7.4 Hz, 1H), 2.74-2.67 (m, 1H), 2.22 (dd, J = 14.1, 8.2 Hz, 1H), 2.07
(t, J = 9.4 Hz, 1H), 1.87-1.74 (m, 2H), 1.43 (s, 3H), 1.28 (s, 3H), 1.13 (s, 3H), 1.08 (s,
3H); 13C NMR (100 MHz, CDCl3) δ 139.2, 128.7, 128.3, 126.9, 109.7, 84.1, 83.4, 77.2,
71.4, 58.4, 56.8, 54.9, 43.1, 40.8, 28.4, 27.9, 26.9, 24.6; IR (cm-1) 3493, 2973, 2928,
1370, 1049; HRMS (EI) m/z calc’d for C20H29NO3 331.2147 (M+), found 331.2145.
Procedure for dehydration reaction (3-17a,b)
Tertiary alcohol 3-16 (0.73g, 2.2 mmol) was placed in round bottom flask under an argon
gas atmosphere. Benzene was added (31ml) followed by Burgess reagent (1.04g, 4.4
mmol) and the reaction was stirred at 50 ˚C for two hours. The reaction was cooled to
room temperature and the solvent was removed under reduced pressure. The product was
purified by column chromatography eluting with EtOAc/hexanes providing (3-17a,b) as
yellow oils; yield 3-17a = 50% (0.34g, 1.1 mmol), yield 3-17b = 22% (0.15g, 0.48
mmol); Rf 3-17a = 0.53, Rf 3-17b = 0.66, 30% EtOAc in hexanes.
(±)-(3aS,3bR,6R,6aS,7aR)-4-benzyl-2,2-dimethyl-6-(prop-1-en-2-yl)octahydro[1,3]dioxolo[4',5':4,5]cyclopenta[1,2-b]pyrrole (3-17a)
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H NMR (400 MHz, CDCl3) δ 7.31-7.28 (m, 4H), 7.25-7.22 (m, 1H), 4.81 (td, J = 5.1,

1

1.2 Hz, 1H), 4.68-4.66 (m, 2H), 4.45 (d, J = 5.1 Hz, 1H), 4.09, 3.24 (ABq, J = 13.3 Hz,
2H), 3.06 (dd, J = 9.4, 7.4 Hz, 1H), 2.95 (d, J = 7.8 Hz, 1H), 2.77-2.70 (m, 1H), 2.47-2.42
(m, 1H), 2.25 (ddd, J = 14.1, 8.2, 1.2 Hz, 1H), 2.13 (t, J = 9.3 Hz, 1H), 1.84 (ddd, J =
14.1, 9.4, 5.1 Hz, 1H), 1.69 (br s, 3H), 1.46 (s, 3H), 1.31 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 146.5, 139.2, 128.8, 128.3, 127.0, 109.9, 109.6, 84.6, 83.3, 76.6, 59.6, 58.5,
51.0, 46.3, 39.9, 27.1, 24.8, 21.3; IR (cm-1) 3027, 2984, 1645, 1370, 1056; HRMS (EI)
m/z calc’d for C20H27NO2 313.2042 (M+), found 313. 2036.
(±)-(3aS,3bR,6aS,7aR)-4-benzyl-2,2-dimethyl-6-(propan-2-ylidene)octahydro[1,3]dioxolo[4',5':4,5]cyclopenta[1,2-b]pyrrole (3-17b)

H NMR (600 MHz, CDCl3) δ 7.33-7.29 (m, 4H), 7.25-7.22 (m, 1H), 4.84 (t, J = 5.0 Hz,

1

1H), 4.50 (d, J = 5.4 Hz, 1H), 4.14, 3.25 (ABq, J = 13.6 Hz, 2H), 3.54, 2.79 (ABq, J =
13.4 Hz, 2H), 3.35-3.29 (m, 1H), 3.01 (d, J = 6.2 Hz, 1H), 2.55 (dd, J = 14.0, 7.7 Hz, 1H),
1.78 (ddd, J = 14.2, 10.9, 4.7 Hz, 1H), 1.64 (s, 3H), 1.48 (s, 3H), 1.47 (s, 3H), 1.32 (s,
3H); 13C NMR (100 MHz, CDCl3) δ 139.4, 133.6, 128.5, 128.3, 126.9, 122.0, 109.6,
83.9, 83.4, 76.9, 58.4, 58.0, 44.9, 37.9, 26.8, 24.4, 21.0, 20.8; IR (cm-1) 2979, 2931,
1741, 1370, 1047; HRMS (EI) m/z calc’d for C20H27NO2 313.2042 (M+), found
313.2041.
Procedure for the conversion of a benzyl group to a carbamate (3-18 and 3-23)
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To a round bottom flask containing acetonide 3-17a (1 equiv.) under argon gas was
added DCM (0.1M). The corresponding chloroformate (6 equiv.) was added and reaction
was heated to 40 ˚C for 19 hours with ethyl chloroformate and 24 hours with benzyl
chloroformate. The reaction was cooled to room temperature and the solvent was
removed under reduced pressure. The product was purified by flash chromatography
eluting with EtOAc/hexanes.
(±)-(3aS,3bR,6R,6aS,7aR)-ethyl 2,2-dimethyl-6-(prop-1-en-2-yl)hexahydro[1,3]dioxolo[4',5':4,5]cyclopenta[1,2-b]pyrrole-4(3aH)-carboxylate (3-18)

Reagents employed: Acetonide 3-17a (0.093g, 0.3 mmol), ethyl chloroformate (0.17ml,
1.8 mmol), DCM (3ml): yield 92% (0.081g, 0.27 mmol) as an oil; Rf = 0.32, 30% EtOAc
in hexanes; Full characterization can be found in the following published article 143.
(±)-(3aS,3bR,6R,6aS,7aR)-benzyl 2,2-dimethyl-6-(prop-1-en-2-yl)hexahydro[1,3]dioxolo[4',5':4,5]cyclopenta[1,2-b]pyrrole-4(3aH)-carboxylate (3-23)

Reagents employed: Acetonide 3-17a (0.4964g, 1.6 mmol), benzyl chloroformate (1.4
ml, 9.6 mmol), DCM (16ml): yield 89% (0.5108g, 1.4 mmol) as a white solid; Rf = 0.27,
20% EtOAc in hexanes; melting point: 86.5-87.1 °C; 1H NMR (600 MHz, CDCl3) δ
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7.44-7.29 (m, 5H), 5.30 (br d, J = 12.8 Hz, 1H), 5.15 (br s, 1H), 4.76 (br s, 1H), 4.69-4.58
(m, 3H), 4.07 (d, J = 7.0 Hz, 1H), 3.64 (br d, J = 11.7 Hz, 1H), 3.57-3.52 (m, 1H), 2.932.88 (m, 1H), 2.42 (br s, 1H), 2.16 (dt, J = 14.3, 7.5 Hz, 1H), 1.72 (br s, 3H), 1.68-1.60
(m, 1H), 1.47 (br s, 3H), 1.29 (s, 3H); 13C NMR (100 MHz, CDCl3) mixture of rotamers;
δ 155.0, 154.9, 145.8, 145.5, 137.1, 136.9, 128.6, 128.5, 128.2, 128.1, 127.8, 127.6,
110.6, 110.5, 110.4, 86.4, 85.4, 81.2, 69.1, 68.4, 67.0, 66.9, 50.4, 50.0, 48.1, 47.4, 46.8,
46.0, 36.6, 36.5, 26.9, 24.5, 21.5; IR (cm-1) 2937, 1696, 1648, 1411, 1357, 1205, 1059;
HRMS (EI) m/z calc’d for C21H27NO4 357.1940, found 357.1935.
Procedure for acetonide deprotection (3-24)
Acetonide 3-23 (0.49g, 1.4 mmol) was dissolved in THF (7 ml) under an open
atmosphere. Aqueous 1M HCl (7 ml) was added and the reaction was stirred at room
temperature for 24 hours. The reaction was diluted with water and extracted with ethyl
acetate, washed with saturated NaHCO3, brine and dried with Na2SO4. The solvent was
removed under reduced pressure providing diol 3-24 as a white solid without the need for
further purification; Yield = 97% (0.43g, 0.63 mmol); Rf = 0.19, 30% EtOAc in hexanes;
melting point: 85.0-85.4 °C.
(±)-(3R,3aS,5R,6S,6aR)-benzyl 5,6-dihydroxy-3-(prop-1-en-2yl)hexahydrocyclopenta[b]pyrrole-1(2H)-carboxylate (3-24)

H NMR (600 MHz, CDCl3) δ 7.40-7.32 (m, 5H), 5.15 (ABq, JAB = 12.3 Hz, 2H, ΔδAB =

1

0.01), 4.92 (s, 1H), 4.79 (br s, 1H), 4.74 (br s, 1H), 4.27 (t, J = 3.9 Hz, 1H), 4.22 (dd, J =
10.2, 7.2 Hz, 1H), 3.97 (dd, J = 7.2, 3.7 Hz, 1H), 3.81 (dd, J = 10.8, 7.3 Hz, 1H), 3.30 (t, J
= 10.7 Hz, 1H), 2.92-2.87 (m, 1H), 2.85 (br s, 1H), 2.49 (td, J = 10.1, 7.3 Hz, 1H), 2.15
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(dd, J = 14.6, 9.1 Hz, 1H), 1.70 (s, 3H), 1.62 (dt, J = 14.7, 5.2 Hz, 1H); 13C NMR (100
MHz, CDCl3) δ 156.8, 142.9, 136.3, 128.7, 128.3, 128.1, 111.8, 80.6, 75.9, 69.0, 67.5,
53.4, 52.9, 43.4, 36.0, 20.7; IR (cm-1) 3433, 3344, 2932, 2891, 1678, 1424, 1355, 1149;
HRMS (EI) m/z calc’d for C18H23NO4 317.1627 (M+), found 317.1619.
Procedure for the synthesis of protected β-allokainic acid dimethylester (3-25)
Diol 3-24 (0.42g, 1.3 mmol) placed in a round bottom flask was dissolved in reagent
grade DCM (13 ml) under an open atmosphere. Iodobenzene diacetate (0.50g, 1.6 mmol)
was added in a single portion and stirred at room temperature for two hours. Solvent was
removed under reduced pressure and the crude material was taken to the next step.
Assuming full conversion, the crude di-aldehyde (0.41g, 1.3 mmol) was dissolved in tertbutanol (93 ml) under an open atmosphere. 2-methyl-2-butene (0.55 ml, 5.2 mmol) was
added followed by an aqueous mixture of sodium chlorite (0.30g, 3.4 mmol) and sodium
phosphate monobasic monohydrate (0.43g, 3.1 mmol) in 14 ml of water using a glass
pipette. The reaction was stirred at room temperature for 18 hours. Solvent was removed
under reduced pressure and the residue was dissolved in 20 ml of 0.1M NaOH and
extracted with DCM. The aqueous layer was acidified to pH 1 with concentrated HCl and
extracted with ethyl acetate collecting in a different flask. The combined ethyl acetate
layers were washed with brine and dried with Na2SO4. The solvent was removed
providing the crude di-acid as a foamy white solid. The crude material was taken to the
next step.
The crude di-acid (0.36g, 1.0 mmol) was dissolved in a 2:5 mixture of methanol: toluene
(6.2: 15.6 ml) under an atmosphere of argon. Trimethylsilyl diazomethane (2.0M in
diethyl ether, 1.6 ml, 3.1 mmol) was added dropwise at room temperature. The reaction
was stirred for 30 minutes and few drops of acetic acid was added until the bright yellow
colour disappeared. Solvent was removed under reduced pressure. Residue was dissolved
in methanol and washed with a small amount of HPLC grade hexanes. Methanol was
removed under reduced pressure providing the product 3-25 (1:1 mixture of rotamers) as
a pale-yellow oil. Yield 63% over three steps (0.29g, 0.78 mmol); Rf = 0.42, 30% EtOAc
in hexanes.
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(±)-(2R,3S,4R)-1-benzyl 2-methyl 3-(2-methoxy-2-oxoethyl)-4-(prop-1-en-2yl)pyrrolidine-1,2-dicarboxylate (3-25)

H NMR (600 MHz, CDCl3) 1:1 mixture of rotamers; δ 7.37-7.27 (m, 10H), 5.19-5.02

1

(overlapped ABq, JAB = 12.4 Hz, 4H), 4.19 (dt, J = 7.9, 1.3 Hz, 2H), 4.85 (br d, J = 3.9
Hz, 2H), 4.65 (d, J = 8.1 Hz, 1H), 4.61 (d, J = 8.3 Hz, 1H), 3.86-3.78 (m, 2H), 3.72 (s,
3H), 3.69 (s, 3H), 3.68 (s, 3H), 3.58 (s, 3H), 3.36-3.26 (m, 2H), 2.92-2.82 (m, 2H), 2.792.67 (m, 2H), 2.47 (t, J = 3.5 Hz, 1H), 2.43 (t, J = 3.5 Hz, 1H), 2.08-1.98 (m, 2H), 1.70 (s,
3H), 1.68 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.88, 171.72, 171.66, 171.58,
154.60, 153.99, 140.82, 140.76, 136.44, 136.40, 128.45, 128.37, 128.03, 127.93, 127.77,
114.94, 114.90, 67.17, 67.05, 61.76, 61.49, 51.91, 51.86, 51.78, 51.77, 49.87, 49.54,
49.20, 48.26, 40.73, 39.95, 33.34, 33.26, 18.51; IR (cm-1) 2952, 1738, 1702, 1412;
HRMS (EI) m/z calc’d for C20H25NO6 375.1682 (M+), found 375.1682.
Procedure for the synthesis of β-allokainic acid (3-1d)
Compound 3-25 (0.025g, 0.066 mmol) was dissolved in methanol (0.35ml) and 10M
NaOH (0.6ml) and was heated to 100 °C for 14 hours. The reaction mixture was cooled
to room temperature and washed with DCM. The aqueous layer was collected and
Amberlite CG-50 (H+ form) was periodically added with stirring until the aqueous layer
was neutralized. The mixture was filtered and concentrated. The resulting compound was
then purified using Dowex 50WX8 resin (100-200 mesh, H+ form) eluting with 5%
aqueous ammonia providing the final compound 3-1d in a 60% yield (8mg, 0.04 mmol)
as an off-white solid with characterization matching the following references 113,144.
(±)-β-allokainic acid (3-1d)
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H NMR (600 MHz, D2O) δ 5.13 (s, 1H), 5.06 (s, 1H), 4.72 (d, J = 8.8 Hz, 1H), 3.78 (dd,

1

J = 11.9, 8.2 Hz, 1H), 3.39 (dd, J = 11.9, 10.5 Hz, 1H), 3.04 (dtd, J = 11.4, 9.2, 4.9 Hz,
1H), 2.88 (td), J = 10.9, 8.3 Hz, 1H), 2.77 (dd, J = 17.7, 5.1 Hz, 1H), 2.55 (dd, J = 17.7,
9.7 Hz, 1H), 1.82 (s, 3H); 13C NMR (D2O, 100MHz) δ 175.7, 170.4, 139.7, 115.9, 61.5,
48.5, 47.9, 39.6, 33.1, 17.6; HRMS (ESI) m/z calc’d for C10H15NO4 213.1001 (M+),
found 214.1079 (M+ + 1).
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Chapter 4

4

Lewis Acid Assisted Rearrangement of Dihydrofurans to
Cyclopentenes

This chapter is part of a manuscript that is in preparation:
Piotrowski, M. L.; Kerr, M. A. Org Lett.

4.1 Introduction
Five-membered carbocycles are commonly found within a variety of bioactive
molecules.47–51 Natural products (4-1a-c) and pharmaceuticals (4-2a-c) exemplify both
the prevalence and importance of these scaffolds (Figure 4-1). Synthesizing these fivemembered rings has attracted the attention of the chemical community for many years.

Figure 4-1. Bioactive natural products and pharmaceuticals containing a five-membered carbocycle

Although the prevalence of cyclopentene scaffolds in bioactive molecules is limited
compared to examples containing cyclopentanes, cyclopentenes serve as key
intermediates towards saturated counterparts. The most common ways of synthesizing
functionalized cyclopentenes are cycloaddition/annulation reactions148–151 and
rearrangements.92,152–156 Rearrangement reactions constitute an important class of
reactivity since they provide easy access to cyclopentenes in an atom-economic fashion.
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There are only a few examples in the literature where heterocycles were rearranged to
five-membered carbocycles. Funk et al. showcased a Ireland-Claisen rearrangement of
lactones (4-3) forming carbocyclic compounds of various ring sizes.157 One example was
the formation of a cyclopentane ring (4-4) (Scheme 4-1a). The Piancatelli rearrangement
is a useful reaction for the conversion of 2-furylcarbinols (4-5) to 4hydroxycyclopentanones (4-6) under aqueous acid conditions (Scheme 4-1b).158,159 More
recently, the work by Rovis showed a Lewis acid mediated [1,3]-ring contraction of 2,5dihydrooxepines (4-7) towards substituted cyclopentenes (4-8) (Scheme 4-1c).160

Scheme 4-1. Rearrangements of heterocycles to five-membered carbocycles

We recently reported the synthesis of a variety of dihydrofurans (4-12a) and 2,5dihydrooxepines (4-13) through the tandem cyclopropanation/Cloke-Wilson
rearrangement or vinylogous variant respectively.133 Each of these heterocycles are easily
manipulated to other useful compounds (4-12a,b), (4-14a,b) in a single transformation
via Lewis acid or transition metal catalyzed reactions. We showcased these
transformations in the synthesis of (±)-β-allokainic acid (see chapter 3) (4-15) (Scheme 42).161

99

Scheme 4-2. Tandem cyclopropanation/(vinylogous)Cloke-Wilson rearrangement and subsequent
transformations

We were interested to see whether we could continue to find ways of forming other
heterocyclic, or even carbocyclic compounds, through single step manipulations of the
heterocycles obtained via our previous methodologies. After examining the various
heterocycles synthesized, we noticed that dihydrofurans (4-12a) contain a 1,5-diene
system which could potentially be utilized in a Claisen rearrangement or through an allyl
cation intermediate to generate cyclopentenes. Herein, we report the rearrangement of
dihydrofurans (4-16) to cyclopentenes (4-17) under Lewis acid catalysis and propose a
mechanism for the transformation (Scheme 4-3).

Scheme 4-3. Rearrangement of dihydrofurans to cyclopentenes

4.2 Results and Discussion
The dihydrofurans used in this study (Figure 4-2) were synthesized using our previously
reported procedures. Dihydrofurans (4-16a, d-f, h) required an additional treatment with
a Lewis acid to induce complete cyclization followed by filtration through a silica plug.
Dihydrofuran (4-16k) was produced via a cross-metathesis reaction (see Experimental).
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Figure 4-2. Dihydrofurans synthesized for cyclopentene formation. [a] additional treatment with a
Lewis acid; overall yields as shown [b] formed via cross-metathesis

Our study commenced by treating dihydrofuran (4-16b) with Sc(OTf)3 in DCM at 40 °C
and to our delight we obtained cyclopentene (4-17b) in a quantitative yield with a 5:1 dr.
However, when treating dihydrofuran (4-16a) under the exact same reaction conditions, a
poor yield of cyclopentene (4-17a) was obtained due to a high amount of decomposition.
Our optimization studies therefore commenced with dihydrofuran (4-16a) (Table 2).
Table 2. Conditions tested for the rearrangement of dihydrofurans to cyclopentenes

Entry

Catalyst

Solvent

Temp (° C)

Yield %

1

Sc(OTf)3

DCM

40

Trace

2

Sc(OTf)3

DCM

25

No reaction

3

Sc(OTf)3

DCE

60

Trace

4

Sc(OTf)3

toluene

60

Trace

5

Sc(OTf)3

toluene

110

Decomp.

6

Sc(OTf)3

MeCN

60

Trace
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7

Yb(OTf)3

DCM

40

Trace

8

Yb(OTf)3

DCE

60

Trace

9

Yb(OTf)3

toluene

60

Trace

10

TiCl4

DCM

40

Decomp.

11

BF3OEt2

DCM

40

Trace

12

BF3OEt2

toluene

60

Trace

13

Cu(OTf)2

DCM

40

Decomp.

14

Al(OTf)3

DCM

40

Trace

15

Sn(OTf)2

DCM

40

Trace

16

Sc(OTf)3

HFIP

65

50% (2:1 dr)

17

Sc(OTf)3

EtOH

65

No reaction

18

BF3OEt2

HFIP

65

Decomp.

19

BF3OEt2

HFIP

25

39% (2:1 dr)

20

Yb(OTf)3
(20mol%)

HFIP

65

50% (2:1 dr)

21

In(OTf)3

HFIP

65

69% (2:1 dr)

22

In(OTf)3

HFIP

25

55% (2:1 dr)

23

Sn(OTf)2

HFIP

65

72% (2:1 dr)

24

Al(OTf)3

HFIP

65

83% (2:1 dr)

25

Zn(OTf)2

HFIP

65

trace

26

N/A

HFIP

80

No reaction

After screening a great deal of Lewis acids, solvents, and temperatures, the best
conditions obtained in our hands was with the use of 10 mol% of Al(OTf)3 in refluxing
hexafluoroisopropanol (HFIP) (entry 24) (Figure 4-3). Some key notes to mention: (1)
except for the two electron rich examples (4-17b,c), the reaction gave poor results in any
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solvent other than HFIP. (2) Cyclopentenes (4-17b,c) required milder conditions as
mentioned in the experimental. (3) The mixture of cyclopropane/dihydrofuran that was
obtained during the formation of (4-16a, d-f, h) can be treated under these optimized
conditions to provide cyclopentenes (4-17a,d,f,h) with no change in yield. (4)
Dihydrofuran (4-16l) was never isolated cleanly since both steps resulted in a mixture of
inseparable products (note (3) was applied to cleanly obtain cyclopentene (4-17l)). (5)
With the exception of cyclopentene (4-17k) the products are not stable to column
chromatography as indications of regenerated starting material was seen implying that the
reaction may be reversible.

Figure 4-3. Formation of cyclopentenes. [a] the cyclopentenes can also be obtained from the
cyclopropane/dihydrofuran mixture without going through pure dihydrofuran. [b] required milder
conditions: DCM, 40 °C

Interestingly, in (Figure 4-3), (4-17j) was not formed, however, extending the carbon
chain resulted in cyclopentene (4-17k) albeit in low yield. Due to these reasons, we
hypothesized that the rearrangement may be going through a step-wise mechanism
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instead of a concerted [3+3] sigmatropic rearrangement (Scheme 4-4). Upon treatment
with a Lewis acid, an allyl cation intermediate (4-18) may be generated. The allyl cation
would undergo resonance (4-19) followed by an enolate-type cyclization generating the
final cyclopentene products. Based on the proposed mechanism, cyclopentene (4-17j)
was not formed because the rearrangement would require going from a tertiary to a
primary carbocation. This mechanism also explains why the cyclopentenes containing
aromatic groups worked so well since benzylic carbocations would be generated. HFIP is
known to stabilize carbocations and could have positively impacted the transition state
energy of the intermediates of this reaction162.

Scheme 4-4. Proposed mechanism for cyclopentene formation. [a] Ruled out concerted mechanism.
[b] Proposed step-wise mechanism involving an allyl cation intermediate followed by enolate-type
cyclization

With the completion of the rearrangements, we attempted improving the
diastereoselectivity of the reaction and possibly provide kinetic resolution of the
products. Both catalysts (Figure 4-4) have been reported in a variety of enolate addition
reactions.163–167 Following literature procedures168,169, we synthesized [Sn(pybox)](OTf)2
(4-20), since Sn(OTf)2 gave good results during the optimization process (see Table 2).
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Figure 4-4. Chiral catalysts

We tested this chiral catalyst under a variety of conditions and unfortunately, only
starting material was isolated (Table 3). When using commercially available chiral
phosphoric acid (R)-(-)-BDHP (4-21), we were excited to see the diastereoselectivity for
cyclopentenes (4-17b,g) increase from 5:1 and 2.5:1 to 7:1 dr, but with a significant dropin yield. Treating the less electron-rich dihydrofuran (4-16a) resulted in no change in dr
with a decrease in yield. We tested this rearrangement with chiral catalyst (4-21) using a
variety of solvents and solvent mixtures containing HFIP, all of which resulted in no
improvement in dr and poor yields.
Table 3. Attempts at improving diastereoselectivity

Catalyst (30 mol%)

Solvent

Temp (°C)

Product

Results

[Sn(pybox)](OTf)2

HFIP

65

B

No rxn

[Sn(pybox)](OTf)2

DCM

40

B

No rxn

[Sn(pybox)](OTf)2

DCM/HFIP

65

B

No rxn

(R)-(-)-BDHP

HFIP

65

B

50% (7:1dr)

(R)-(-)-BDHP

HFIP

65

C

50% (7:1dr)

(R)-(-)-BDHP

HFIP

65

A

35% (2:1dr)

(R)-(-)-BDHP

MeCN

65

A

Trace
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(R)-(-)-BDHP

DCM

40

A

Trace

(R)-(-)-BDHP

DCM/HFIP

65

A

Trace

To determine the relative stereochemistry of the major and minor diastereomers, we
attempted to hydrogenate the sensitive cyclopentenes in the hopes of separating the
diastereomers via column chromatography. Cyclopentenes (4-17b,c,f,k) were inseparable
after hydrogenation and cyclopentene (4-17h) underwent dehalogenation under these
conditions. However, a collection of separated diastereomers (4-22a-j) were isolated
(Scheme 4-5).

Scheme 4-5. Hydrogenation of cyclopentenes to cyclopentanes

To determine the relative structural configuration of these products, experiments with 1H
NMR such as NOE failed to yield conclusive results. However, reacting cyclopentane (422b) with 2,4-DNPH (4-23) formed hydrazone (4-24) that was isolated as a crystal for Xray analysis (Scheme 4-6).
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Scheme 4-6. Hydrazone formation

Due to the similarities in 1H NMR of each major diastereomer, the resulting
stereochemistry is tentatively assigned to each cyclopentene product (Figure 4-5).

Figure 4-5. Determined stereochemistry for major diastereomer

4.3 Conclusion
In summary, we have synthesized functionalized cyclopentenes through the
rearrangement of dihydrofurans in high yields and moderate diastereoselectivities. Based
on the reaction yields and solvent studies, our proposed mechanism involves the
formation of an ionic intermediate that undergoes an enolate type ring closure generating
the desired cyclopentenes. The products obtained have useful functional handles that can
provide access to more complex frameworks.
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4.5 Experimental
4.5.1

General Considerations

All reactions were conducted under an atmosphere of argon unless otherwise indicated.
DCM, toluene, and acetonitrile were dried and deoxygenated by passing the nitrogen
purged solvents through activated alumina columns. All other solvents and reagents were
used as purchased from Sigma Aldrich, Alfa Aesar, Caledon, VWR or Oakwood
Chemicals and used as received. Reaction progress was followed by thin layer
chromatography (TLC) (Merck, TLC silica gel 60 F254) visualized with UV light, and
the plates developed with p-anisaldehyde, vanillin, basic potassium permanganate or
DMP stains. Column chromatography was performed using silica gel (230-400 mesh,
Silicycle Chemical Division Inc).
NMR experiments were performed on Varian Mercury 400, Bruker AvIII 400, Inova 400
and Inova 600 MHz instruments with 13C operating frequencies of 100, 100, 100, and
150 MHz respectively. Chemical shifts are reported in ppm relative to the residual
solvent signal; CDCl3, referenced to residual CHCl3 at δ = 7.26 for 1H and δ = 77.1 for
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C; d6-DMSO referenced at δ = 2.50 for 1H and δ = 39.5 for 13C. Coupling constants (J)

13

are reported in Hz, and multiplicities of the signals are described using the following
abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, m =
multiplet, br = broad. High resolution mass spectra (HRMS) were obtained on a Thermo
Scientific DFS mass spectrometer using electron impact ionization. Melting points were
determined using a Digimelt MPA160 melting point apparatus from Stanford Research
Systems (SRS). Infrared spectra were obtained using a Bruker Alpha II Platinum ATR
spectrometer or as thin films on NaCl plates using a Bruker Vector 33 FT-IR instrument
and are reported in frequency of absorption (cm-1). The synthetic procedures for
dihydrofurans can be found in our previous published work133 along with the following
changes: 0.1 mol% of Rh2(esp)2 was used and a filtration through a silica plug eluting
with EtOAc/Hexanes was required for the dihydrofurans (4-16a, d-f, h) that needed to be
treated with Sc(OTf)3 to complete the cyclization in order to obtain good results for
cyclopentene rearrangement.

4.5.2

Experimental procedures and characterization data

Synthesis of dihydrofuran (4-17k)
Dihydrofuran (4-16j) (1 equiv.) was placed in flask with stir bar under an atmosphere of
argon. Deoxygenated DCM (0.088M) was added followed by deoxygenated 1-hexene (5
equiv.) that was distilled prior to use over CaH2. Grubbs second generation catalyst (4
mol%) was added and the reaction was refluxed for 24 hours. The reaction was
concentrated under reduced pressure and purified by column chromatography using 5 %
EtOAc/Hexanes as the eluent providing dihydrofuran (4-16k) as an oil; yield 42% (0.12g,
0.5 mmol); Rf = 0.27, 5% EtOAc/Hexanes.
(E)-ethyl 5-(hex-1-en-1-yl)-5-methyl-4,5-dihydrofuran-3-carboxylate (4-16k)
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H NMR (400 MHz, CDCl3) δ 7.17 (t, J = 1.9 Hz, 1H), 5.69-5.57 (m, 2H), 4.15 (q, J =

1

7.1 Hz, 2H), 2.80, 2.63 (ABq, JAB = 14.6 Hz, 2H); with each signal split into a doublet
due to 4JCH = 1.9 Hz coupling with the methine proton), 2.03 (br q, J = 6.6 Hz, 2H), 1.45
(s, 3H), 1.39-1.28 (m, 4H), 1.25 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ
165.6, 155.4, 132.8, 129.9, 107.8, 90.9, 59.7, 40.2, 31.9, 31.3, 26.7, 22.2, 14.5, 14.0; IR
(cm-1) 2928, 1702, 1623, 1155, 1100, 1053; HRMS (EI) m/z calc’d for C14H22O3
238.1569 (M+), found 238.1571.
(E)-ethyl 5-(4-((tert-butyldimethylsilyl)oxy)styryl)-4,5-dihydrofuran-3-carboxylate
(4-16g)

Reagents employed: (E)-(4-(buta-1,3-dien-1-yl)phenoxy)(tert-butyl)dimethylsilane
(0.32g, 1.24 mmol), formyldiazoacetate (0.35g, 2.48 mmol), Bis[rhodium(α,α,α′,α′tetramethyl-1,3-benzenedipropionic acid)] (1mg, 0.00124 mmol), DCM (10.5ml): yield
51% (0.24g, 0.64 mmol) as a yellow oil; Rf = 0.37, 10% EtOAc/Hexanes; 1H NMR (400
MHz, CDCl3) δ 7.28-7.26 (m, 3H), 6.81-6.78 (AA’BB’, 2H), 6.57 (d, J = 15.7 Hz, 1H),
6.14 (dd, J = 15.8, 7.5 Hz, 1H), 5.35 (dt, J = 11.1, 8.1 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H),
3.08 (ddd, J = 14.7, 10.5, 1.9 Hz, 1H), 2.72 (ddd, J = 14.7, 8.0, 1.8 Hz, 1H), 1.28 (t, J =
7.1 Hz, 3H), 0.98 (s, 9H), 0.20 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 165.3, 156.4,
156.1, 132.5, 129.3, 128.0, 125.3, 120.4, 108.9, 86.2, 59.9, 34.2, 25.8, 18.3, 14.5, -4.2; IR
(cm-1) 2930, 1702, 1624, 1508, 1252, 1098; HRMS (EI) m/z calc’d for C21H30O4Si
374.1913 (M+), found 374.1909.
(E)-ethyl 5-(4-bromostyryl)-4,5-dihydrofuran-3-carboxylate (4-16h)
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Reagents employed: (E)-1-bromo-4-(buta-1,3-dien-1-yl)benzene (0.27g, 1.29 mmol),
formyldiazoacetate (0.36g, 2.58 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3benzenedipropionic acid)] (1mg, 0.00129 mmol), DCM (10.5ml): yield 45% (0.19g, 0.59
mmol) as an oil; Rf = 0.34, 10% EtOAc/Hexanes; Reagents employed:
cyclopropane/dihydrofuran mixture (0.19g, 0.59 mmol), Sc(OTf)3 (0.014g, 0.029 mmol),
DCM (5ml): yield 87% (0.16g, 0.51 mmol) as a white solid; Melting point: 38.5-39.8
°C; Rf = 0.34, 10% EtOAc/Hexanes; 1H NMR (400 MHz, DMSO-d6) δ 7.55-7.52 (m,
2H), 7.49-7.45 (m, 3H), 6.65 (d, J = 15.9 Hz, 1H), 6.48 (dd, J = 15.9, 6.9 Hz, 1H), 5.44
(dt, J = 9.9, 7.3 Hz, 1H), 4.10 (q, J = 7.1Hz, 2H), 3.02 (ddd, J = 14.6, 10.6, 1.9 Hz, 1H),
2.62 (ddd, J = 14.6, 7.9, 1.9 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz,
DMSO-d6) δ 164.2, 156.6, 135.1, 131.5, 130.3, 128.9, 128.7, 121.1, 108.1, 84.8, 59.2,
33.3, 14.3; IR (cm-1) 2979, 1699, 1618, 1127, 1097, 1071; HRMS (EI) m/z calc’d for
C15H15BrO3 322.0205 (M+), found 322.0192.
(E)-ethyl 5-(2-(benzo[d][1,3]dioxol-5-yl)vinyl)-4,5-dihydrofuran-3-carboxylate (416i)

Note: compound may be light sensitive
Reagents employed: (E)-5-(buta-1,3-dien-1-yl)benzo[d][1,3]dioxole (0.4g, 2.29 mmol),
formyldiazoacetate (0.65g, 4.58 mmol), Bis[rhodium(α,α,α′,α′-tetramethyl-1,3benzenedipropionic acid)] (2mg, 0.00229 mmol), DCM (19.5ml): yield 47% (0.31g, 1.07
mmol) as a yellow solid; Melting point 56.4-57.8 °C; Rf = 0.25, 25% EtOAc/Hexanes;
H NMR (600 MHz, CDCl3) δ 7.27 (t, J = 1.9 Hz, 1H), 6.93 (d, J = 1.8 Hz, 1H), 6.84-

1

6.82 (m, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.54 (d, J = 15.7 Hz, 1H), 6.10 (dd, J = 15.7, 7.4
Hz, 1H), 5.96 (s, 2H), 5.34 (dddd, J = 10.5, 8.2, 7.4, 1.0 Hz, 1H), 4.19 (q, J = 7.1 Hz,
2H), 3.08 (ddd, J = 14.7, 10.5, 1.9 Hz, 1H), 2.71 (ddd, J = 14.7, 8.0, 1.9 Hz, 1H), 1.28 (t,
J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 165.2, 156.3, 148.2, 147.9, 132.5, 130.4,
125.6, 121.8, 108.9, 108.4, 106.0, 101.3, 86.0, 59.9, 34.2, 14.5; IR (cm-1) 2985, 1690,
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1626, 1442, 1243, 1097, 1036; HRMS (EI) m/z calc’d for C16H16O5 288.0998 (M+),
found 288.1002.
General procedure for the synthesis of cyclopentenes
The starting dihydrofuran (1 equiv.) was placed in a round bottom flask under an
atmosphere of argon. Hexafluoroisopropanol (0.12M) was added followed by Al(OTf)3
(10 mol%) and the reaction was heated to 65 °C under reflux; (For dihydrofurans (416b,c) mild conditions were required, DCM (0.12M) was used and heated to 40 °C for 30
minutes). Once the dihydrofuran was fully consumed, the reaction was cooled to room
temperature and concentrated under reduced pressure. The crude material was filtered
through a silica plug eluting with the indicated mixture of EtOAc/Hexanes and
concentrated under reduced pressure.
(±)-Ethyl 1-formyl-2-phenylcyclopent-3-enecarboxylate (4-17a)

Reagents employed: (E)-ethyl 5-styryl-4,5-dihydrofuran-3-carboxylate (4-16a) (0.32g,
1.34 mmol), Al(OTf)3 (0.063g, 0.134 mmol), HFIP (11ml): yield 84% (0.28, 1.1 mmol)
as a colourless oil; Rf = 0.52 and 0.44 for minor and major diastereomer respectively;
filtered through silica plug using 10% EtOAc/Hexanes; 1H NMR (400 MHz, CDCl3)
major diastereomer δ 9.78 (s, 1H), 7.33-7.27 overlap (m, 3H), 7.25-7.20 overlap (m, 3H),
7.19-7.16 overlap (m, 3H), 5.93-5.90 (m, 1H), 5.70-5.64 overlap (m, 2H), 4.50-4.49 (m,
1H), 3.71 (dq, J = 10.7, 7.1 Hz, 1H), 3.60 (dq, J = 10.8, 7.1 Hz, 1H), 3.28-3.20 overlap
(m, 2H), 2.88-2.85 overlap (m, 1H), 2.84-2.82 overlap (m, 1H), 0.86 (t, J = 7.1 Hz, 3H);
minor diastereomer δ 9.02 (s, 1H), 5.97-5.94 (m, 1H), 4.82-4.80 (m, 1H), 4.32-4.26 (m,
2H), 1.32 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) mixture of diastereomers δ
197.0, 196.8, 172.1, 169.2, 138.5, 137.3, 131.2, 131.0, 130.3, 129.7, 129.1, 129.0, 128.9,
128.3, 127.8, 127.6, 69.4, 66.8, 62.1, 61.5, 58.6, 55.9, 36.1, 35.4, 14.3, 13.7; IR (cm-1)
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2982, 1742, 1715, 1231, 698; HRMS (EI) m/z calc’d for C15H16O3 244.1099 (M+), found
244.1095.
(±)-Ethyl 1-formyl-2-(4-methoxyphenyl)cyclopent-3-enecarboxylate (4-17b)

Reagents employed: Dihydrofuran (4-16b) (0.1g, 0.36 mmol), Al(OTf)3 (0.017g, 0.036
mmol), DCM (3ml): yield 100% (0.1g, 0.36 mmol) as a yellow oil; Rf = 0.48, 30%
EtOAc/Hexanes; filtered through Celite plug; 1H NMR (600 MHz, CDCl3) major
diastereomer δ 9.78 (s, 1H), 7.09-7.07 overlap (AA’BB’, 2H), 6.82-6.79 (AA’BB’, 2H),
5.89-5.87 (m, 1H), 5.64-6.61 overlap (m, 1H), 4.45-4.44 (m, 1H), 3.77 (s, 3H), 3.74 (dq, J
= 10.7, 7.1 Hz, 1H), 3.64 (dq, J = 10.7, 7.1 Hz, 1H), 3.22-3.17 overlap (m, 1H), 2.85-2.80
overlap (m, 1H), 0.91 (t, J = 7.1 Hz, 3H); minor diastereomer δ 9.04 (s, 1H), 6.84-6.83
(AA’BB’, 2H), 5.93-5.91 (m, 1H), 4.76-4.75 (m, 1H), 4.33-4.25 (m, 2H), 3.78 (s, 3H),
1.31 (t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) mixture of diastereomers δ 197.2,
196.0, 172.2, 169.2, 159.2, 159.1, 131.3, 131.2, 130.3, 130.1, 130.0, 129.9, 129.4, 129.1,
114.3, 113.6, 69.3, 66.6, 62.0, 61.4, 58.0, 55.38, 55.36, 55.31, 35.9, 35.1, 14.2, 13.7; IR
(cm-1) 2957, 1741, 1716, 1510, 1241, 1032; HRMS (EI) m/z calc’d for C16H18O4
274.1205 (M+), found 274.1200.
(±)-Ethyl 2-(3,4-dimethoxyphenyl)-1-formylcyclopent-3-enecarboxylate (4-17c)

Reagents employed: Dihydrofuran (4-16c) (0.1g, 0.33 mmol), Al(OTf)3 (0.015g, 0.033
mmol), DCM (2.8ml): yield 100% (0.1g, 0.33 mmol) as a yellow oil; Rf = 0.35, 20%
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EtOAc/Hexanes; filtered through a Celite plug; 1H NMR (400 MHz, CDCl3) δ 9.77 (s,
1H), 6.78-6.66 (m, 3H), 5.88 (ddt, J = 5.8, 2.6, 1.9 Hz, 1H), 5.63 (dtd, J = 5.8, 2.5, 1.8
Hz, 1H), 4.45 (apparent q, J = 2.4 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.76 (dq, J = 10.8,
7.2 Hz, 1H), 3.66 (dq, J = 10.8, 7.1 Hz, 1H), 3.24-3.18 (m, 1H), 2.85-2.80 (m, 1H), 0.90
(t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 195.8, 169.2, 148.6, 148.4, 131.4,
130.9, 129.3, 121.3, 112.3, 110.8, 69.3, 61.4, 56.0, 55.9, 55.5, 35.3, 13.8; IR (cm-1) 2935,
1742, 1715, 1590, 1232; HRMS (EI) m/z calc’d for C17H20O5 304.1311 (M+), found
304.1314.
(±)-Ethyl 2-(4-fluorophenyl)-1-formylcyclopent-3-enecarboxylate (4-17d)

Reagents employed: (E)-ethyl 5-(4-fluorostyryl)-4,5-dihydrofuran-3-carboxylate (4-16d)
(0.1g, 0.38 mmol), Al(OTf)3 (0.018g, 0.038 mmol), HFIP (3.2ml): yield 79% (0.079g,
0.30 mmol) as a oil; Rf = 0.4, 0.33, 10% EtOAc/Hexanes; filtered through a silica plug
eluting with 10% EtOAc/Hexanes; 1H NMR (600 MHz, CDCl3) major diastereomer δ
9.74 (s, 1H), 7.16-7.12 overlap (m, 4H), 6.97-6.94 (m, 2H), 5.90 (ddt, J = 5.7, 2.6, 1.9
Hz, 1H), 5.64-5.61 overlap (m, 2H), 4.50 (apparent q, J = 2.4 Hz, 1H), 3.74 (dq, J = 10.7,
7.2 Hz, 1H), 3.65 (dq, J = 10.8, 7.1 Hz, 1H), 3.24-3.18 overlap (m, 2H), 2.85-2.81
overlap (m, 2H), 0.90 (t, J = 7.1 Hz, 3H); minor diastereomer δ 9.02 (s, 1H), 7.00-6.97
(m, 2H), 5.95-5.93 (m, 1H), 4.79 (apparent quin, J = 2.3 Hz, 1H), 4.28 (qd, J = 7.1, 4.8
Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H); 13C NMR mixture of diastereomers (150 MHz, CDCl3)
δ 196.8, 195.4, 171.9, 169.0, 163.2, 163.1, 161.5, 161.4, 134.25, 134.23, 133.1, 133.0,
131.1, 130.8, 130.7, 130.6, 130.52, 130.50, 130.4, 129.7, 115.8, 115.7, 115.1, 115.0, 69.2,
66.7, 62.1, 61.5, 57.7, 54.8, 36.0, 35.4, 14.2, 13.7; 19F NMR mixture of diastereomers
(564 MHz, CDCl3) δ -114.6, -115.0; IR (cm-1) 2983, 1742, 1717, 1508, 1225; HRMS
(EI) m/z calc’d for C15H15FO3 262.1005 (M+), found 262.0998.

115

(±)-Ethyl 1-formyl-2-(o-tolyl)cyclopent-3-enecarboxylate (4-17f)

Reagents employed: (E)-ethyl 5-(2-methylstyryl)-4,5-dihydrofuran-3-carboxylate (416f) (0.03g, 0.12 mmol), Al(OTf)3 (6mg, 0.012 mmol), HFIP (1ml): yield 94% (0.028g,
0.11 mmol) as a colourless oil; Rf = 0.52, 0.44 for minor and major diastereomer
respectively; filtered through silica plug using 10% EtOAc/Hexanes; 1H NMR (600
MHz, CDCl3) major diastereomer δ 9.81 (s, 1H), 7.18-7.10 overlap (m, 5H), 7.07-7.04
(m, 1H), 5.89 (ddt, J = 5.8, 2.7, 2.0 Hz, 1H), 5.89 (dtd, J = 5.7, 2.5, 1.8 Hz, 1H), 4.85
(apparent q, J = 2.3 Hz, 1H), 3.68 (dq, J = 10.7, 7.1 Hz, 1H), 3.55 (dq, J = 10.8, 7.2 Hz,
1H), 3.32-3.26 overlap (m, 2H), 2.85-2.84 overlap (m, 1H), 2.82-2.81 overlap (m, 1H),
2.41 (s, 3H), 0.84 (t, J = 7.1 Hz, 3H); minor diastereomer δ 8.97 (s, 1H), 5.99-5.97 (m,
1H), 5.62-5.60 (m, 1H), 5.04-5.03 (m, 1H), 4.29 (qd, J = 7.1, 1.8 Hz, 2H), 2.43 (s, 3H),
1.31 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) mixture of diastereomers δ 197.0,
196.6, 172.7, 169.4, 137.0, 136.9, 136.7, 135.4, 131.8, 131.5, 130.9, 130.3, 130.0, 129.0,
128.8, 128.6, 127.7, 127.4, 126.6, 126.0, 69.2, 66.1, 62.5, 61.5, 54.6, 51.0, 36.2, 36.1,
20.3, 20.1, 14.2, 13.5; IR (cm-1) 2981, 1742, 1715, 1231; HRMS (EI) m/z calc’d for
C16H18O3 258.1256 (M+), found 258.1246.
(±)-Ethyl 2-(4-((tert-butyldimethylsilyl)oxy)phenyl)-1-formylcyclopent-3enecarboxylate (4-17g)
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Reagents employed: dihydrofuran (4-16g) (0.055g, 0.14 mmol), Al(OTf)3 (7mg, 0.014
mmol), HFIP (1.2ml): yield 89% (0.049g, 0.13 mmol) as an oil; Rf = 0.45, 0.34 for minor
and major diastereomer respectively, 10% EtOAc/Hexanes; filtered through silica plug
eluting with 10% EtOAc/Hexanes; 1H NMR (600 MHz, CDCl3) major diastereomer δ
9.78 (s, 1H), 7.03-7.00 overlap (m, 3H), 6.75-6.72 (AA’BB’, 2H), 5.87 (ddt, J = 5.7, 2.5,
1.9 Hz, 1H), 5.64-5.61 overlap (m, 1H), 4.42 (apparent q, J = 2.4 Hz, 1H), 3.74 (dq, J =
10.8, 7.2 Hz, 1H), 3.64 (dq, J = 10.7, 7.2 Hz, 1H), 3.24-3.17 overlap (m, 2H), 2.85-2.79
overlap (m, 2H), 0.97 (s, 9H), 0.92 (t, J = 7.2 Hz, 3H), 0.16 (s, 6H); minor diastereomer δ
9.03 (s, 1H), 6.78-6.76 (AA’BB’, 2H), 5.93-5.90 (m, 1H), 4.74 (apparent quin, J = 2.2
Hz, 1H), 4.32-4.24 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H), 0.97 (s, 9H), 0.18 (s, 6H); 13C NMR
(100 MHz, CDCl3) mixture of diastereomers δ 197.2, 196.0, 172.3, 169.2, 155.3, 155.2,
131.3, 131.2, 131.0, 130.1, 130.0, 129.9, 129.8, 129.3, 120.5, 119.8, 69.3, 66.6, 62.0,
61.4, 58.1, 55.4, 35.9, 35.1, 25.8, 25.7, 18.4, 18.3, 14.3, 13.8, -4.2, -4.3; IR (cm-1) 2930,
1746, 1718, 1508, 1235; HRMS (EI) m/z calc’d for C21H30O4Si 374.1913 (M+), found
374.1910.
(±)-Ethyl 2-(4-bromophenyl)-1-formylcyclopent-3-enecarboxylate (4-17h)

Reagents employed: dihydrofuran (4-16h) (0.19g, 0.59 mmol) Al(OTf)3 (0.028g, 0.059
mmol), HFIP (5ml): yield 77% (0.14g, 0.43 mmol) as a clear oil; Rf = 0.44, 0.37, 10%
EtOAc/Hexanes, for minor and major diastereomer respectively; filtered through silica
plug eluting with 10% EtOAc/Hexanes; 1H NMR (600 MHz, CDCl3) major diastereomer
δ 9.73 (s, 1H), 7.40-7.37 (AA’BB’, 2H), 7.07-7.03 overlap (m, 3H), 5.90 (ddt, J = 5.8,
2.6, 1.9 Hz, 1H), 5.62-5.60 overlap (m, 2H), 4.48 (apparent q, J = 2.3 Hz, 1H), 3.76 (dq, J
= 10.8, 7.1 Hz, 1H), 3.66 (dq, J = 10.8, 7.1 Hz, 1H), 3.24-3.18 overlap (m, 2H), 2.85-2.81
overlap (m, 2H), 0.90 (t, J = 7.1 Hz, 3H); minor diastereomer δ 9.02 (s, 1H), 7.43-7.41
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(AA’BB’, 2H), 5.96-5.94 (m, 1H), 4.76 (apparent quin, J = 2.3 Hz, 1H), 4.28 (qd, J = 7.1,
4.9 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H); 13C NMR mixture of diastereomers δ 196.5, 195.2,
171.8, 168.9, 137.6, 136.4, 132.0, 131.3, 130.9, 130.83, 130.81, 130.6, 130.5, 130.0,
121.8, 121.5, 69.2, 66.7, 62.1, 61.6, 57.8, 54.9, 36.1, 35.5, 14.2, 13.7; IR (cm-1) 2981,
1742, 1715, 1487, 1230; HRMS (EI) m/z calc’d for C15H15BrO3 322.0205 (M+), found
322.0200.
(±)-Ethyl 2-(benzo[d][1,3]dioxol-5-yl)-1-formylcyclopent-3-enecarboxylate (4-17i)

Reagents employed: dihydrofuran (4-16i) (0.21g, 0.71 mmol), Al(OTf)3 (0.034g, 0.071
mmol), HFIP (6ml): yield 87% (0.18g, 0.62 mmol) as a dark yellow oil; Rf = 0.27, 0.2
for minor and major diastereomer respectively, 10% EtOAc/Hexanes; filtered through a
silica plug eluting with 15% EtOAc/Hexanes; 1H NMR (400 MHz, CDCl3) major
diastereomer δ 9.75 (s, 1H), 6.76-6.70 overlap (m, 2H), 6.67-6.63 overlap (m, 3H), 5.92
(s, 2H), 5.90-5.87 (m, 1H), 5.63-5.60 overlap (m, 1H), 4.43 (apparent q, J = 2.4 Hz, 1H),
3.82 (dq, J = 10.7, 7.2 Hz, 1H), 3.74 (dq, J = 10.8, 7.1 Hz, 1H), 3.25-3.15 overlap (m,
2H), 2.85-2.79 overlap (m, 2H), 0.97 (t, J = 7.1 Hz, 3H); minor diastereomer δ 9.08 (s,
1H), 5.94 (s, 2H), 4.73 (apparent quin, J = 2.1 Hz, 1H), 4.32-4.24 (m, 2H), 1.31 (t, J = 7.2
Hz, 3H); 13C NMR (100 MHz, CDCl3) mixture of diastereomers δ 197.0, 195.8, 172.1,
169.1, 148.2, 147.6, 147.2, 147.0, 132.1, 131.8, 131.3, 131.0, 130.3, 129.6, 122.4, 122.1,
109.5, 109.1, 108.6, 108.0, 101.2, 101.1, 69.3, 66.6, 62.1, 61.5, 58.3, 55.5, 36.0, 35.2,
14.3, 13.8; IR (cm-1) 2982, 1739, 1715, 1484, 1227, 1035; HRMS (EI) m/z calc’d for
C16H16O5 288.0998 (M+), found 288.0998.
(±)-Ethyl 2-butyl-1-formyl-4-methylcyclopent-3-enecarboxylate (4-17k)
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Reagents employed: dihydrofuran (4-16k) (0.03g, 0.12 mmol) Al(OTf)3 (5mg, 0.012
mmol), HFIP (1ml): yield 37% (0.011g, 0.04 mmol) as an oil; Rf = 0.25, 5%
EtOAc/Hexanes; required column purification eluting with 5% EtOAc/Hexanes; 1H
NMR (400 MHz, CDCl3) major diastereomer δ 9.73 (s, 1H), 5.25-5.22 overlap (m, 1H),
4.27-4.16 overlap (m, 3H), 3.38-3.33 (m, 1H), 2.95-2.84 overlap (m, 2H), 2.73-2.59
overlap (m, 2H), 1.74 (s, 3H), 1.74-1.55 overlap (m, 1H), 1.40-1.23 overlap (m, 14H),
0.93-0.86 overlap (m, 6H); minor diastereomer δ 9.67 (s, 1H), 3.09-3.05 (m, 1H), 1.72 (s,
3H); 13C NMR (100 MHz, CDCl3) mixture of diastereomers δ 199.0, 197.4, 172.5, 170.4,
138.7, 137.9, 125.5, 124.6, 67.8, 66.6, 61.6, 61.4, 53.8, 49.7, 40.2, 38.5, 31.4, 30.8, 29.8,
22.9, 22.8, 16.5, 16.4, 14.3, 14.2, 14.1, 14.0; IR (cm-1) 2930, 1744, 1716, 1445, 1230;
HRMS (EI) m/z calc’d for C14H22O3 238.1569 (M+), found 238.1575.
(±)-Ethyl 1-formyl-2-(naphthalen-2-yl)cyclopent-3-enecarboxylate (4-17l)

Reagents employed: dihydrofuran/cyclopropane mixture (0.13g, 0.44 mmol), Al(OTf)3
(0.021g, 0.044 mmol), HFIP (3.6ml): yield 75% (0.098g, 0.33 mmol) as an oil; Rf = 0.45,
0.41 for minor and major diastereomer respectively, 10% EtOAc/Hexanes; filtered
through a plug of silica eluting with 5% EtOAc/Hexanes; 1H NMR (400 MHz, CDCl3)
major diastereomer δ 9.83 (s, 1H), 7.80-7.74 overlap (m, 4H), 7.65-7.7.64 overlap (m,
1H), 7.48-7.42 overlap (m, 2H), 7.30-7.27 overlap (m, 1H), 5.98 (ddt, J = 5.7, 2.6, 1.9
Hz, 1H), 5.77-5.71 overlap (m, 1H), 4.68 (apparent q, J = 2.4 Hz, 1H), 3.61 (dq, J = 10.8,
7.1 Hz, 1H), 3.48 (dq, J = 10.8, 7.1 Hz, 1H), 3.35-3.28 overlap (m, 1H), 2.93-2.86
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overlap (m, 1H), 0.70 (t, J = 7.1 Hz, 3H); minor diastereomer δ 6.03-6.01 (m, 1H), 4.98
(apparent quin, J = 1.9 Hz, 1H), 4.36-4.26 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H); 13C NMR
(100 MHz, CDCl3) mixture of diastereomers δ 196.9, 195.7, 172.2, 169.1, 136.0, 134.9,
133.5, 133.3, 132.97, 132.90, 131.2, 131.0, 130.5, 129.9, 128.7, 128.0, 127.9, 127.88,
127.85, 127.81, 127.78, 127.70, 127.1, 126.8, 126.4, 126.2, 126.0, 125.7, 69.5, 66.9, 62.1,
61.5, 58.7, 55.9, 36.2, 35.5, 14.3, 13.5; IR (cm-1) 2981, 1740, 1715, 1231; HRMS (EI)
m/z calc’d for C19H18O3 294.1256 (M+), found 294.1254.
General procedure for hydrogenation of cyclopentene
Palladium on carbon (1 equiv.) was placed in round bottom flask with stir bar under
house vacuum. Methanol (0.12M) was added and the flask was purged with hydrogen
gas. The starting cyclopentene (1 equiv.) was dissolved in methanol (0.12M) under an
atmosphere of argon and was added to the Pd/C mixture. The reaction was stirred for
three hours, filtered through Celite and concentrated under reduced pressure. The crude
material was purified by column chromatography eluting with the indicated
EtOAc/Hexanes mixture.
(±)-Ethyl 1-formyl-2-phenylcyclopentanecarboxylate (4-22a,b)

Reagents employed: Cyclopentene (4-17a) (0.1g, 0.41 mmol), Pd/C (0.044g, 0.41
mmol), methanol (7ml): crude yield (mixture of diastereomers) 95% (0.095g, 0.38
mmol), isolated yield minor 16% (0.016g, 0.06 mmol) as an oil; Rf = 0.52, 10%
EtOAc/Hexanes; isolated yield major 40% (0.04g, 0.16 mmol) as an oil; Rf = 0.44, 10%
EtOAc/Hexanes; purified by column chromatography eluting with 2.5% to 5%
EtOAc/Hexanes.
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Data analysis for minor diastereomer (4-22a): 1H NMR (600 MHz, CDCl3) δ 9.27 (s,
1H), 7.31-7.28 (m, 2H), 7.25-7.20 (m, 3H), 4.25 (qd, J = 7.1, 1.8 Hz, 2H), 3.88 (dd, J =
11.5, 6.5 Hz, 1H), 2.58-2.53 (m, 1H), 2.10-2.05 (m, 1H), 2.01-1.94 (m, 3H), 1.87-1.81
(m, 1H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 200.0, 173.2, 137.5,
128.7, 128.5, 127.4, 66.3, 61.7, 53.8, 31.3, 30.5, 24.0, 14.3; IR (cm-1) 2958, 1739, 1712,
1248; HRMS (EI) m/z calc’d for C15H18O3 246.1256 (M+), found 246.1257.
Data analysis for major diastereomer (4-22b): 1H NMR (600 MHz, CDCl3) δ 9.83 (s,
1H), 7.27-7.23 (m, 2H), 7.22-7.18 (m, 3H), 3.86 (dd, J = 10.7, 7.0 Hz, 1H), 3.76 (dq, J =
10.7, 7.1 Hz, 1H), 3.64 (dq, J = 10.7, 7.2 Hz, 1H), 2.43 (ddd, J = 13.7, 10.6, 7.9 Hz, 1H),
2.19-2.12 (m, 3H), 2.05-2.00 (m, 1H), 1.65-1.56 (m, 1H), 0.82 (t, J = 7.1 Hz, 3H); 13C
NMR (100 MHz, CDCl3) δ 197.9, 171.1, 140.1, 128.6, 128.2, 127.0, 69.2, 61.2, 49.9,
32.6, 31.4, 24.6, 13.6; IR (cm-1) 2959, 1711, 1223; HRMS (EI) m/z calc’d for C15H18O3
246.1256 (M+), found 246.1249.
(±)-Ethyl 2-(4-fluorophenyl)-1-formylcyclopentanecarboxylate (4-22c,d)

Reagents employed: Cyclopentene (4-17d) (0.14g, 0.54 mmol), Pd/C (0.057g, 0.54
mmol), methanol (9ml): crude yield (mixture of diastereomers) 94% (0.13g, 0.49 mmol),
isolated yield minor 13% (0.019g, 0.07 mmol) as an oil; Rf = 0.44, 10% EtOAc/Hexanes;
isolated yield major 24% (0.035g, 0.13 mmol) as an oil; Rf = 0.37, 10% EtOAc/Hexanes;
purified by column chromatography eluting with 5% EtOAc/Hexanes.
Data analysis for minor diastereomer (4-22c): 1H NMR (400 MHz, CDCl3) δ 9.27 (s,
1H), 7.21-7.15 (m, 2H), 7.01-6.95 (m, 2H), 4.25 (q, J = 7.2 Hz, 2H), 3.85 (dd, J = 11.4,
6.5 Hz, 1H), 2.54 (dt, J = 14.0, 8.0 Hz, 1H), 2.10-1.77 (m, 5H), 1.27 (t, J = 7.1 Hz, 3H);
C NMR (100 MHz, CDCl3) δ 199.9, 173.0, 162.1 (d, 1JCF = 246.1 Hz), 133.2 (d, 4JCF =
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3.4 Hz), 130.0 (d, 3JCF = 7.9 Hz), 115.5 (d, 2JCF = 21.1 Hz), 66.3, 61.8, 52.9, 31.5, 30.6,
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23.9, 14.3; 19F{1H} (376 MHz, CDCl3) δ -115.2; IR (cm-1) 2960, 1740, 1712, 1510,
1224; HRMS (EI) m/z calc’d for C15H17FO3 264.1162 (M+), found 264.1149.
Data analysis for major diastereomer (4-22d): 1H NMR (400 MHz, CDCl3) δ 9.80, 7.207.15 (m, 2H), 6.97-6.91 (m, 2H), 3.87 (dd, J = 10.3, 7.5 Hz, 1H), 3.79 (dq, J = 10.7, 7.1
Hz, 1H), 3.68 (dq, J = 10.7, 7.1 Hz, 1H), 2.42 (ddd, J = 13.8, 10.7, 7.7 Hz, 1H), 2.17-2.08
(m, 3H), 2.05-1.97 (m, 1H), 1.65-1.52 (m, 1H), 0.86 (t, J = 7.2 Hz, 3H); 13C NMR (100
MHz, CDCl3) δ 197.5, 171.1, 161.9 (d, 1JCF = 245.2 Hz), 135.7 (d, 4JCF = 3.3 Hz), 130.1
(d, 3JCF = 7.9 Hz), 114.9 (d, 2JCF = 21.2 Hz), 69.1, 61.3, 48.7, 32.7, 31.6, 24.5, 13.7;
F{1H} (376 MHz, CDCl3) δ -115.9; IR (cm-1) 2960, 1712, 1510, 1220; HRMS (EI) m/z
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calc’d for C15H17FO3 264.1162 (M+), found 264.1152.
(±)-Ethyl 2-(benzo[d][1,3]dioxol-5-yl)-1-formylcyclopentanecarboxylate (4-22e,f)

Reagents employed: cyclopentene (4-17i) (0.071g, 0.24 mmol), Pd/C (0.025g, 0.24
mmol), methanol (4ml): crude yield (mixture of diastereomers) 90% (0.064g, 0.22
mmol); isolated yield minor 15% (0.011g, 0.04 mmol) as an oil; Rf = 0.37, 5%
EtOAc/Hexanes; isolated yield major 42% (0.03g, 0.1 mmol) as an oil; Rf = 0. 31, 5%
EtOAc/Hexanes; purified by column chromatography eluting with 5% EtOAc/Hexanes.
Data analysis for minor diastereomer (4-22e): 1H NMR (400 MHz, CDCl3) δ 9.31 (s,
1H), 6.75-6.66 (m, 3H), 5.93 (s, 2H), 4.25 (qd, J = 7.1, 0.8 Hz, 2H), 3.81 (dd, J = 11.3,
6.5 Hz, 1H), 2.53 (dt, J = 13.9, 8.0 Hz, 1H), 2.07-1.76 (m, 5H), 1.28 (t, J = 7.1 Hz, 3H);
C NMR (100 MHz, CDCl3) δ 200.1, 173.2, 147.9, 146.8, 131.2, 121.5, 108.8, 108.3,
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101.9, 66.2, 61.7, 53.5, 31.5, 30.4, 23.9, 14.3; IR (cm-1) 2958, 1737, 1711, 1488, 1233;
HRMS (EI) m/z calc’d for C16H18O5 290.1154 (M+), found 290.1147.
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Data analysis for major diastereomer (4-22f): 1H NMR (400 MHz, CDCl3) δ 9.81 (s,
1H), 6.71-6.67 (m, 3H), 5.89 (s, 2H), 3.89-3.74 (m, 3H), 2.39 (ddd, J = 13.7, 10.4, 7.8
Hz, 1H), 2.15-2.05 (m, 3H), 2.03-1.95 (m, 1H), 1.63-1.51 (m, 1H), 0.93 (t, J = 7.2 Hz,
3H); 13C NMR (100 MHz, CDCl3) δ 197.9, 171.2, 147.4, 146.5, 133.7, 121.7, 109.1,
107.9, 101.0, 69.0, 61.3, 49.7, 32.7, 31.3, 24.3, 13.8; IR (cm-1) 2959, 1711, 1487, 1225;
HRMS (EI) m/z calc’d for C16H18O5 290.1154 (M+), found 290.1150.
(±)-Ethyl 2-(4-((tert-butyldimethylsilyl)oxy)phenyl)-1formylcyclopentanecarboxylate (4-22g,h)

Reagents employed: cyclopentene (4-17g) (0.093g, 0.25 mmol), Pd/C (0.027g, 0.25
mmol), methanol (4ml): crude yield (mixture of diastereomers) 96% (0.09g, 0.24 mmol);
isolated yield minor 19% (0.018g, 0.05 mmol) as an oil; Rf = 0.34, 5% EtOAc/Hexanes;
isolated yield major 24% (0.023g, 0.06 mmol) as an oil; Rf = 0.28, 5% EtOAc/Hexanes;
purified by column chromatography eluting with 5% EtOAc/Hexanes.
Data analysis for minor diastereomer (4-22g): 1H NMR (600 MHz, CDCl3) δ 9.26 (s,
1H), 7.06-7.04 (AA’BB’, 2H), 6.77-6.74 (AA’BB’, 2H), 4.24 (qd, J = 7.2, 5.9 Hz, 2H),
3.81 (dd, J = 11.7, 6.6 Hz, 1H), 2.53 (dt, J = 13.8, 8.2 Hz, 1H), 2.06-2.01 (m, 1H), 2.001.78 (m, 4H), 1.26 (t, J = 7.1 Hz, 3H), 0.97 (s, 9H), 0.18 (s, 6H); 13C NMR (100 MHz,
CDCl3) δ 200.4, 173.3, 154.9, 129.9, 129.4, 120.1, 66.2, 61.6, 53.3, 31.4, 30.3, 25.7, 23.9,
18.3, 14.3, -4.2; IR (cm-1) 2955, 1741, 1715, 1509, 1226; HRMS (EI) m/z calc’d for
C21H32O4Si 376.2070 (M+), found 376.2061.
Data analysis for major diastereomer (4-22h): 1H NMR (600 MHz, CDCl3) δ 9.83, 7.077.04 (AA’BB’, 2H), 6.73-6.71 (AA’BB’, 2H), 3.81-3.77 (m, 2H), 3.66 (dq, J = 10.7, 7.2
Hz, 1H), 2.39 (ddd, J = 13.7, 10.6, 7.9 Hz, 1H), 2.16-2.07 (m, 3H), 2.03-1.98 (m, 1H),
1.62-1.53 (m, 1H), 0.96 (s, 9H), 0.89 (t, J = 7.2 Hz, 3H), 0.16 (s, 6H); 13C NMR (150
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MHz, CDCl3) δ 198.1, 171.3, 154.7, 132.6, 129.5, 119.7, 69.1, 61.2, 49.5, 32.8, 31.3,
25.8, 24.5, 18.3, 13.8, -4.3; IR (cm-1) 2931, 1741, 1714, 1510, 1252; HRMS (EI) m/z
calc’d for C21H32O4Si 376.2070 (M+), found 376.2063.
(±)-Ethyl 1-formyl-2-(naphthalen-2-yl)cyclopentanecarboxylate (4-22i,j)

Reagents employed: cyclopentene (4-17l) (0.09g, 0.31 mmol), Pd/C (0.032g, 0.31
mmol), methanol (5ml): crude yield (mixture of diastereomers) 93% (0.085g, 0.28
mmol); isolated yield minor 12% (0.011g, 0.04 mmol) as an oil; Rf = 0.45, 10%
EtOAc/Hexanes; isolated yield major 45% (0.041g, 0.14 mmol) as an oil; Rf = 0.41, 10%
EtOAc/Hexanes; purified by column chromatography eluting with 5% EtOAc/Hexanes.
Data analysis for minor diastereomer (4-22i): 1H NMR (600 MHz, CDCl3) δ 9.27 (s,
1H), 7.82-7.77 (m, 3H), 7.67 (br s, 1H), 7.49-7.44 (m, 2H), 7.34 (dd, J = 8.5, 1.9 Hz, 1H),
4.27 (qd, J = 7.1, 1.9 Hz, 2H), 4.06 (dd, J = 11.6, 6.6 Hz, 1H), 2.62 (dt, J = 14.1, 8.4 Hz,
1H), 2.19-2.13 (m, 1H), 2.11-2.02 (m, 3H), 1.93-1.85 (m, 1H), 1.27 (t, J = 7.1 Hz, 3H);
C NMR (150 MHz, CDCl3) δ 199.9, 173.2, 135.1, 133.4, 132.7, 128.3, 127.9, 127.7,
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127.2, 126.6, 126.4, 126.0, 66.5, 61.8, 53.9, 31.4, 30.7, 24.1, 14.3 IR (cm-1) 2957, 1738,
1717, 1245; HRMS (EI) m/z calc’d for C19H20O3 296.1412 (M+), found 296.1411.
Data analysis for major diastereomer (4-22j) 1H NMR (600 MHz, CDCl3) δ 9.89 (s, 1H),
7.79-7.77 (m, 2H), 7.74 (d, J = 8.5 Hz, 1H), 7.67 (br s, 1H), 7.46-7.41 (m, 2H), 7.34 (dd,
J = 8.5, 1.8 Hz, 1H), 4.04 (dd, J = 10.8, 6.8 Hz, 1H), 3.68 (dq, J = 10.7, 7.1 Hz, 1H), 3.54
(dq, J = 10.8, 7.2 Hz, 1H), 2.50 (ddd, J = 13.9, 10.5, 7.9 Hz, 1H), 2.33 (dtd, J = 12.5,
10.8, 7.2 Hz, 1H), 2.23-2.18 (m, 2H), 2.10 (dddt, J = 12.7, 7.6, 5.3, 2.4 Hz, 1H), 0.64 (t, J
= 7.1 Hz, 3H); 13C NMR (600 MHz, CDCl3) δ 197.9, 171.1, 137.5, 133.3, 132.6, 127.8,
127.7, 127.6, 127.1, 127.0, 126.1, 125.7, 69.3, 61.2, 50.0 32.7, 31.65, 31.64, 24.6, 13.5;
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IR (cm-1) 2958, 1711, 1225; HRMS (EI) m/z calc’d for C19H20O3 296.1412 (M+), found
296.1409.
Procedure for the formation of hydrazone derivative
Cyclopentane (4-22b) (0.11g, 0.45 mmol) was placed in a round bottom flask under an
argon gas atmosphere. Absolute ethanol (7ml) was added followed by MgSO 4 (0.13g, 1.1
mmol) and the mixture was stirred. To the mixture was added 2,4-dinitophenylhydrazine
(0.13g, 0.58 mmol) and the reaction was stirred for five hours. The reaction was
concentrated under reduced pressure, re-dissolved in DCM, pre-absorbed onto silica and
purified by column chromatography eluting with 10% EtOAc/Hexanes providing
hydrazone (4-24) as a bright yellow solid; yield = 78% (0.15g, 0.35 mmol); Rf = 0.32,
10% EtOAc/Hexanes; melting point = 133.5-134.8 °C.
(±)-(1R,2R)-ethyl 1-((E)-(2-(2,4-dinitrophenyl)hydrazono)methyl)-2phenylcyclopentanecarboxylate (4-24)

H NMR (600 MHz, CDCl3) δ 11.15 (s, 1H), 9.15 (d, J = 2.5 Hz, 1H), 8.35 (dd, J = 9.6,

1

2.6, 0.7 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.89 (br s, 1H), 7.30-7.27 (m, 2H), 7.25-7.22
(m, 3H), 3.82-3.72 (m, 3H), 2.55 (ddd, J = 13.5, 9.3, 8.3 Hz, 1H), 2.41-2.35 (m, 1H),
2.34-2.29 (m, 1H), 2.22-2.12 (m, 2H), 1.90-1.82 (m, 1H), 0.91 (t, J = 7.2 Hz, 3H); 13C
NMR (100 MHz, CDCl3) δ 172.5, 153.1, 145.3, 139.9, 138.3, 130.2, 129.3, 128.4, 128.3,
127.3, 123.6, 116.6, 61.6, 61.3, 54.5, 34.1, 32.0, 24.3, 13.8; IR (cm-1) 3277, 2954, 1716,
1615, 1585, 1496, 1136; HRMS (EI) m/z calc’d for C21H22N4O6 426.1539 (M+), found
426.1544.
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4.5.3

X-ray analysis data

Experimental for C21H22N4O6 (b20024)
Data Collection and Processing. The sample (b20024) was submitted by Mathew
Piotrowski of the Kerr research group at the University of Western Ontario. The sample
was mounted on a Mitegen polyimide micromount with a small amount of Paratone N
oil. All X-ray measurements were made on a Bruker Kappa Axis Apex2 diffractometer at
a temperature of 110 K. The unit cell dimensions were determined from a symmetry
constrained fit of 9904 reflections with 4.96° < 2θ < 59.34°. The data collection strategy
was a number of ω and φ scans which collected data up to 64.12° (2θ). The frame
integration was performed using SAINT. The resulting raw data was scaled and
absorption corrected using a multi-scan averaging of symmetry equivalent data using
SADABS.
Structure Solution and Refinement. The structure was solved by using a dual space
methodology using the SHELXT program. All non-hydrogen atoms were obtained from
the initial solution. The hydrogen atoms were introduced at idealized positions. The
carbon bound hydrogen atoms were allowed to ride on their parent carbon while the
nitrogen bound hydrogen atoms were allowed to refine isotropically.
Pseudo-symmetry. The structure exhibits a high degree of pseudo-symmetry. The
structure was solved and refined as primitive monoclinic with a space group of P 21
containing two symmetry independent molecules in the asymmetric unit (designated as A
and B). The structure can also be reasonably refined as primitive orthorhombic with a
space group assignment of P na21 with one molecule in the asymmetric unit. However,
the systematic absences for the n and a glide planes exhibit numerous and significant
violations. There were 253 out of 1715 and 117 out of 416 reflections which had
intensities above 3σ(I)/I for the n and a glide planes absences respectively. For this
reason, the lower symmetry structure was chosen. It is necessary to note that the
ADDSYM (missing symmetry) routine in PLATON gives a 100% match for a P na21
structure.
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The structural model was fit to the data using full matrix least-squares based on F2. The
refinement model included twinning by pseudo-merohedry. The twin law, a mirror plane
across the (100), was derived by the COSET program. One of the nitro groups on each
of the symmetry independent molecules exhibits a disorder which leads to two distinct
positions for one of the oxygen atoms. For the A molecule the occupancy of the
predominant conformer was 0.62(8) while for the B molecule the predominant conformer
had an occupancy of 0.532(15). The calculated structure factors included corrections for
anomalous dispersion from the usual tabulation. The structure was refined using the
SHELXL program from the SHELX suite of crystallographic software. Graphic plots
were produced using the Mercury program suite. Additional information and other
relevant literature references can be found in the reference section of this website
(http://xray.chem.uwo.ca).
1

. Bruker-AXS, SAINT version 2013.8, 2013, Bruker-AXS, Madison, WI 53711, USA

2
3
4
5
6

. Bruker-AXS, SADABS version 2012.1, 2012, Bruker-AXS, Madison, WI 53711, USA

7

. Sheldrick, G. M., Acta Cryst. 2015, A71, 3-8
. Spek, A. L., J. Appl. Cryst., 2003, 36, 7-13
Boyle, P. D. J. Appl. Cryst., 2014, 47, 467-470
. Sheldrick, G. M., Acta Cryst. 2015, C71, 3-8

. Macrae, C. F.; Bruno, I. J.; Chisholm, J. A.; Edington, P. R.; McCabe, P.; Pidcock, E.;
Rodriguez-Monge, L.; Taylor, R.; van de Streek, J. and Wood, P. A. J. Appl. Cryst., 2008, 41, 466-470
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Figure 4-6. ORTEP drawing of b20024 molecule B showing naming and numbering scheme.
Ellipsoids are at the 50% probability level and hydrogen atoms were drawn with arbitrary radii for
clarity. The disordered oxygen position is designated as O4B’.

Table 4. Summary of crystal data for b20024
Formula

C21H22N4O6

Formula Weight (g/mol)

426.42

Crystal Dimensions (mm )

0.423 × 0.268 × 0.043

Crystal Color and Habit

yellow plate

Crystal System

monoclinic

Space Group

P 21

Temperature, K

110

a, Å

9.2001(19)

b, Å

6.1392(14)

c, Å

36.280(9)

a,°

90

128

b,°

90.137(11)

g,°

90

V, Å3

2049.1(8)

Number of reflections to determine final unit cell

9904

Min and Max 2q for cell determination, °

4.96, 59.34

Z

4

F(000)

896

r (g/cm)

1.382

l, Å, (MoKa)

0.71073

m, (cm-1)

0.103

Diffractometer Type

Bruker Kappa Axis Apex2

Scan Type(s)

phi and omega scans

Max 2q for data collection, °

64.12

Measured fraction of data

0.999

Number of reflections measured

55522

Unique reflections measured

12633

Rmerge

0.0566

Number of reflections included in refinement

12633

Cut off Threshold Expression

I > 2sigma(I)

Structure refined using

full matrix least-squares using F2

Weighting Scheme

w=1/[sigma2(Fo2)+(0.0471P)2+0.85
26P] where P=(Fo2+2Fc2)/3

Number of parameters in least-squares

582

R1

0.0548

wR2

0.1154
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R1 (all data)

0.0722

wR2 (all data)

0.1239

GOF

1.034

Maximum shift/error

0.000

Min & Max peak heights on final DF Map (e-/Å)

-0.325, 0.278

Where:
R1 =

( |Fo| - |Fc| ) /

Fo

wR2 = [

( w( Fo2 - Fc2 )2 ) /

(w Fo4 ) ]½

GOF = [

( w( Fo2 - Fc2 )2 ) / (No. of reflns. - No. of params. ) ]½

130

Chapter 5

5

Future Work and Summary

5.1 Future work
The use of formyldiazoacetate (5-1) towards the synthesis of DA cyclopropane (5-2) can
offer novel and underexplored reactivity that can generate compounds of high synthetic
interest. DA cyclopropane (5-2) can be obtained in modest yields under metal carbenoid
conditions. Azomethine ylides could be formed via condensation between the aldehyde
on the cyclopropane (5-2) and an amine (5-3). Upon heating, this would result in a
decarboxylation generating the desired ylide (5-4) followed by ring-opening of the
cyclopropane forming various tetrahydropyridine derivatives (5-5) (Scheme 5-1)170.

Scheme 5-1. Generation of aldehyde/ester DA cyclopropane and subjecting it to azomethine ylide
formation/ring-opening forming tetrahydropyridine derivatives

Anionic oxy-Cope rearrangements could also be explored with DA cyclopropane (5-2).
Reacting cyclopropane (5-2) with allylmagnesium bromide would generate allyl alcohol
(5-6). Deprotonating the alcohol with KH in the presence of 18-crown-6, an oxy-Cope
rearrangement would occur, resulting in ring-opened products such as (5-7). A one-pot
procedure to functionalized cyclopentanes could be possible as well. Instead of isolating
the ring-opened product (5-8), a palladium mediated cyclization (5-9) in the presence of
aryl or alkenyl halides followed by a reductive elimination (5-10) would furnish
cyclopentane compounds (5-11) (Scheme 5-2)171,172.
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Scheme 5-2. Anionic oxy-Cope rearrangement of DA cyclopropane and possible one-pot procedure to
functionalized cyclopentanes

Recently, treatment of DA cyclopropane (5-2) with phenylhydrazine (5-12) forming
hydrazone derivatives (5-13) has been shown to provide tetrahydropyridazines (5-14) in
moderate to good yields173,174 (Scheme 5-3). The conditions that provided the best results
thus far is with the use of 10 mol% of Al(OTf)3 in refluxing DCM. Further conditions
need to be tested in order to improve the yields, more examples need to be synthesized,
and the stereochemistry around the tetrahydropyridazine ring needs to be determined.

Scheme 5-3. Intramolecular ring-opening of hydrazone derived cyclopropanes to
tetrahydropyridazines

5.2 Summary
The work presented within this thesis describes new ways of synthesizing sought after
heterocycles and carbocycles such as pyrrolidines, dihydropyrroles, dihydrofurans,
cyclopentenes, and dihydrooxepines. Beginning with the (vinylogous) Cloke-Wilson
rearrangement, the required vinylcyclopropyl aldehyde (5-16) was obtained in a single
step which underwent spontaneous rearrangement in situ to either dihydrofurans (5-17) or
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2,5-dihydrooxepines (5-18) depending on the 1,3-diene system used (5-15). Each of the
heterocycles synthesized were capable of being transformed to other dihydrofuran
derivatives (5-17, 5-19), dihydropyrroles (5-20, 5-21) or cyclopentenes (5-22) with
careful choice of solvent, temperature, and catalyst (Figure 5-1).

Figure 5-1. Synthesis of dihydrofurans and 2,5-dihydrooxepines via (vinylogous)-Cloke-Wilson
rearrangement and subsequent transformations to dihydrofurans, dihydropyrroles and
cyclopentenes

With the successful formation of dihydropyrroles, one of the scaffolds (5-23) caught our
attention as it was deemed a viable synthetic precursor to target kainic acid. This natural
molecule possesses important biological properties such as neuroexcitatory and
excitotoxic activities that were used to create model conditions for the better
understanding of common human neurological disorders. However, due to
stereochemical constraints, one of the less active isomers of kainic acid, β-allokainic acid
(5-27) was synthesized instead (Figure 5-2).
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Figure 5-2. Synthetic route towards (±)-β-allokainic acid

The synthesis of cyclic systems will always dominate organic chemistry literature.
Numerous bioactive natural products and pharmaceuticals contain the abovementioned
cyclic systems as well as many others not mentioned within this dissertation. Therefore,
discovering new methodologies towards carbocycles and heterocycles is of value in the
synthetic community. The reader may ask themselves who cares about this “random”
heterocyclic or carbocyclic compound and why is it important? The ability to easily
synthesize sought after structural motifs, such as pyrrolidines and cyclopentenes, but also
new and underexplored heterocycles or carbocycles can have great potential in
pharmaceutical industries. Unknowingly, these types of academic discoveries can
potentially result in new lead compounds to combat various diseases.
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